Ligand source activities (1 row/activity)





Ligands (move mouse cursor over ligand name to see structure) Receptor Activity Chemical information
Sel. page Common
name
GPCRdb
ID
Reference
ligand
Vendors

Species

Assay
Type

Activity
Type
Activity
Relation
Activity
Value
p-value
(-log)
Fold
selectivity
Tested
GPCRs
Assay
Description
Source

Mol
weight
Rot
Bonds
H don

H acc

LogP

Smiles

DOI

11372270 67525 None 26 Human Functional pIC50 = 9.2 9.2 -2 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 375 5 1 6 1.1 C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1 10.1016/j.ejmech.2023.115175
11372270.0 67525 None 26 Human Functional pIC50 = 9.2 9.2 -2 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 375 5 1 6 1.1 C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1 10.1016/j.ejmech.2023.115175
CHEMBL189475 67525 None 26 Human Functional pIC50 = 9.2 9.2 -2 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 375 5 1 6 1.1 C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1 10.1016/j.ejmech.2023.115175
CHEMBL4442431 67525 None 26 Human Functional pIC50 = 9.2 9.2 -2 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 375 5 1 6 1.1 C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1 10.1016/j.ejmech.2023.115175
12073810 171655 None 18 Human Functional pIC50 = 9 9.0 - 1
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.ejmech.2023.115175
CHEMBL446458 171655 None 18 Human Functional pIC50 = 9 9.0 - 1
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.ejmech.2023.115175
8498 3315 None 44 Human Functional pIC50 = 9 9.0 -33 2
Antagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxisAntagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxis
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
9838712 3315 None 44 Human Functional pIC50 = 9 9.0 -33 2
Antagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxisAntagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxis
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
9838712.0 3315 None 44 Human Functional pIC50 = 9 9.0 -33 2
Antagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxisAntagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxis
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
CHEMBL191413 3315 None 44 Human Functional pIC50 = 9 9.0 -33 2
Antagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxisAntagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxis
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
DB12614 3315 None 44 Human Functional pIC50 = 9 9.0 -33 2
Antagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxisAntagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxis
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
135907804 113023 None 0 Human Functional pIC50 = 8 8.0 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 363 5 2 6 2.8 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1[C@H]1C[C@@H]1C(=O)O 10.1016/j.bmcl.2014.06.011
CHEMBL3310786 113023 None 0 Human Functional pIC50 = 8 8.0 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 363 5 2 6 2.8 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1[C@H]1C[C@@H]1C(=O)O 10.1016/j.bmcl.2014.06.011
8497 2737 None 41 Human Functional pIC50 = 8 8.0 1 4
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acsmedchemlett.1c00113
9865554 2737 None 41 Human Functional pIC50 = 8 8.0 1 4
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acsmedchemlett.1c00113
CHEMBL216981 2737 None 41 Human Functional pIC50 = 8 8.0 1 4
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acsmedchemlett.1c00113
162646828 179716 None 0 Human Functional pIC50 = 8 8.0 912 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 413 4 3 6 3.1 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@@H](C3CCCCC3)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4742368 179716 None 0 Human Functional pIC50 = 8 8.0 912 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 413 4 3 6 3.1 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@@H](C3CCCCC3)N2)c1O 10.1021/acsmedchemlett.1c00113
45485775 200141 None 0 Human Functional pIC50 = 7 7.0 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 424 8 3 8 2.3 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(OC)cc1 10.1016/j.bmcl.2009.08.014
CHEMBL571141 200141 None 0 Human Functional pIC50 = 7 7.0 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 424 8 3 8 2.3 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(OC)cc1 10.1016/j.bmcl.2009.08.014
163322282 191744 None 3 Human Functional pIC50 = 7 7.0 478 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 352 6 2 7 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2oncc12 10.1016/j.ejmech.2023.115240
CHEMBL5195797 191744 None 3 Human Functional pIC50 = 7 7.0 478 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 352 6 2 7 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2oncc12 10.1016/j.ejmech.2023.115240
24970094 126879 None 0 Human Functional pIC50 = 6 6.0 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 397 8 2 4 3.6 CC(C)(NC(=O)c1ccc2c(c1OCCOc1ccccc1)CCCC2)C(=O)O nan
CHEMBL3654434 126879 None 0 Human Functional pIC50 = 6 6.0 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 397 8 2 4 3.6 CC(C)(NC(=O)c1ccc2c(c1OCCOc1ccccc1)CCCC2)C(=O)O nan
136074345 113029 None 0 Human Functional pIC50 = 5 5.0 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 319 4 1 5 3.5 N#Cc1c(O)nc(CSc2cccc(F)c2F)nc1C1CC1 10.1016/j.bmcl.2014.06.011
CHEMBL3310793 113029 None 0 Human Functional pIC50 = 5 5.0 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 319 4 1 5 3.5 N#Cc1c(O)nc(CSc2cccc(F)c2F)nc1C1CC1 10.1016/j.bmcl.2014.06.011
CHEMBL5083610 217363 None 0 Human Functional pIC50 = 6.0 6.0 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccccc1F)Nc1ccc2c(c1O)S(=O)(=O)CCC2 10.1021/acs.jmedchem.1c01219
1485055 35431 None 19 Human Functional pIC50 = 5.0 5.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 271 3 1 5 3.0 Cc1cc2nc(CSc3ccccc3)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
CHEMBL1437942 35431 None 19 Human Functional pIC50 = 5.0 5.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 271 3 1 5 3.0 Cc1cc2nc(CSc3ccccc3)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
91937331 114993 None 0 Human Functional pIC50 = 7.0 7.0 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 380 6 4 6 2.0 O=C(Nc1ccc(O)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 10.1021/jm500827t
CHEMBL3342318 114993 None 0 Human Functional pIC50 = 7.0 7.0 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 380 6 4 6 2.0 O=C(Nc1ccc(O)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 10.1021/jm500827t
CHEMBL5076384 216922 None 0 Human Functional pIC50 = 6.0 6.0 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=c1c(Nc2ccccc2Cl)c(Nc2ccc3c(c2O)S(=O)(=O)CCC3)c1=O 10.1021/acs.jmedchem.1c01219
72948072 104688 None 0 Human Functional pIC50 = 5.0 5.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 319 5 1 5 2.3 COc1cc(CCc2cccc(F)c2F)nc2cc(CO)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104898 104688 None 0 Human Functional pIC50 = 5.0 5.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 319 5 1 5 2.3 COc1cc(CCc2cccc(F)c2F)nc2cc(CO)nn12 10.1016/j.bmcl.2013.11.074
172458912 196325 None 0 Human Functional pIC50 = 7.9 7.9 - 1
Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assayInhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay
ChEMBL 526 10 4 9 3.8 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)OC(C)(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5421394 196325 None 0 Human Functional pIC50 = 7.9 7.9 - 1
Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assayInhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay
ChEMBL 526 10 4 9 3.8 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)OC(C)(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
163322283 190918 None 3 Human Functional pIC50 = 7.0 7.0 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 362 6 2 6 3.4 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cnccc12 10.1016/j.ejmech.2023.115240
CHEMBL5183834 190918 None 3 Human Functional pIC50 = 7.0 7.0 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 362 6 2 6 3.4 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cnccc12 10.1016/j.ejmech.2023.115240
56839294 123073 None 0 Human Functional pIC50 = 6.0 6.0 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 379 6 3 5 1.8 CN(Cc1ccc(B(O)O)cc1)c1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
CHEMBL3609005 123073 None 0 Human Functional pIC50 = 6.0 6.0 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 379 6 3 5 1.8 CN(Cc1ccc(B(O)O)cc1)c1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
11222420 86765 None 0 Human Functional pIC50 = 6.0 6.0 40 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 368 2 3 7 2.5 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Cl)N2 10.1016/j.bmcl.2007.05.011
CHEMBL231924 86765 None 0 Human Functional pIC50 = 6.0 6.0 40 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 368 2 3 7 2.5 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Cl)N2 10.1016/j.bmcl.2007.05.011
66856548 104689 None 0 Human Functional pIC50 = 6.0 6.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 305 4 2 5 2.0 OCc1cc2nc(CCc3cccc(F)c3F)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
CHEMBL3104899 104689 None 0 Human Functional pIC50 = 6.0 6.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 305 4 2 5 2.0 OCc1cc2nc(CCc3cccc(F)c3F)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
72947877 104692 None 0 Human Functional pIC50 = 5.0 5.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 431 6 1 8 4.8 Oc1cc(CSc2nc(-c3ccccc3)cs2)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104904 104692 None 0 Human Functional pIC50 = 5.0 5.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 431 6 1 8 4.8 Oc1cc(CSc2nc(-c3ccccc3)cs2)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
72948068 104694 None 0 Human Functional pIC50 = 5.0 5.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 408 7 1 8 3.7 COc1ccc(SCc2cc(O)n3nc(Cc4ccccc4)nc3n2)c(OC)c1 10.1016/j.bmcl.2013.11.074
CHEMBL3104906 104694 None 0 Human Functional pIC50 = 5.0 5.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 408 7 1 8 3.7 COc1ccc(SCc2cc(O)n3nc(Cc4ccccc4)nc3n2)c(OC)c1 10.1016/j.bmcl.2013.11.074
170901566 197174 None 1 Human Functional pIC50 = 5.0 5.0 -12 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 310 9 3 7 2.2 CCCCCCSc1nc(N[C@H](C)CO)c2nn[nH]c2n1 10.1016/j.ejmech.2023.115240
CHEMBL5440411 197174 None 1 Human Functional pIC50 = 5.0 5.0 -12 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 310 9 3 7 2.2 CCCCCCSc1nc(N[C@H](C)CO)c2nn[nH]c2n1 10.1016/j.ejmech.2023.115240
172445949 195207 None 0 Human Functional pIC50 = 6.0 6.0 - 1
Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assayInhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay
ChEMBL 691 14 6 10 4.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CNC(=O)OCC3c4ccccc4-c4ccccc43)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5398802 195207 None 0 Human Functional pIC50 = 6.0 6.0 - 1
Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assayInhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay
ChEMBL 691 14 6 10 4.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CNC(=O)OCC3c4ccccc4-c4ccccc43)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
172461006 196523 None 0 Human Functional pIC50 = 4.9 4.9 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 463 4 1 8 3.4 CC(C)(C)OC(=O)N1CCN(c2nc(SCc3cccc(F)c3F)nc3[nH]nnc23)CC1 10.1016/j.ejmech.2023.115240
CHEMBL5425847 196523 None 0 Human Functional pIC50 = 4.9 4.9 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 463 4 1 8 3.4 CC(C)(C)OC(=O)N1CCN(c2nc(SCc3cccc(F)c3F)nc3[nH]nnc23)CC1 10.1016/j.ejmech.2023.115240
56839499 123078 None 0 Human Functional pIC50 = 6.9 6.9 5 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 380 6 3 6 1.2 CN(Cc1ccc(B(O)O)cc1)c1ncc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
CHEMBL3609011 123078 None 0 Human Functional pIC50 = 6.9 6.9 5 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 380 6 3 6 1.2 CN(Cc1ccc(B(O)O)cc1)c1ncc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
172450974 195735 None 0 Human Functional pIC50 = 4.9 4.9 -2 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 324 9 3 7 2.5 CC(C)CCCCSc1nc(N[C@H](C)CO)c2nn[nH]c2n1 10.1016/j.ejmech.2023.115240
CHEMBL5409816 195735 None 0 Human Functional pIC50 = 4.9 4.9 -2 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 324 9 3 7 2.5 CC(C)CCCCSc1nc(N[C@H](C)CO)c2nn[nH]c2n1 10.1016/j.ejmech.2023.115240
172441979 195080 None 0 Human Functional pIC50 = 4.9 4.9 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 282 7 3 7 1.4 CCCCSc1nc(N[C@H](C)CO)c2nn[nH]c2n1 10.1016/j.ejmech.2023.115240
CHEMBL5396369 195080 None 0 Human Functional pIC50 = 4.9 4.9 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 282 7 3 7 1.4 CCCCSc1nc(N[C@H](C)CO)c2nn[nH]c2n1 10.1016/j.ejmech.2023.115240
45485756 200857 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 360 6 3 7 0.6 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(C)=O 10.1016/j.bmcl.2009.08.014
CHEMBL576886 200857 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 360 6 3 7 0.6 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(C)=O 10.1016/j.bmcl.2009.08.014
24769501 125243 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 445 8 2 4 4.7 CC(C)(NC(=O)c1ccc2ccccc2c1OCCOc1ccc(F)c(Cl)c1)C(=O)O nan
CHEMBL3645133 125243 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 445 8 2 4 4.7 CC(C)(NC(=O)c1ccc2ccccc2c1OCCOc1ccc(F)c(Cl)c1)C(=O)O nan
9887803 140924 None 26 Human Functional pIC50 = 7.9 7.9 19 2
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL 409 3 4 4 3.6 NS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acs.jmedchem.1c01219
CHEMBL3819292 140924 None 26 Human Functional pIC50 = 7.9 7.9 19 2
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL 409 3 4 4 3.6 NS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acs.jmedchem.1c01219
CHEMBL5089441 217698 None 0 Human Functional pIC50 = 6.9 6.9 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccc2c(c1O)S(=O)(=O)CC=C2)Nc1cccc(Cl)c1Cl 10.1021/acs.jmedchem.1c01219
136074340 113022 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 391 6 1 7 3.3 CCOC(=O)[C@H]1C[C@@H]1c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
CHEMBL3310785 113022 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 391 6 1 7 3.3 CCOC(=O)[C@H]1C[C@@H]1c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
44447928 95666 None 0 Rabbit Functional pIC50 = 5.9 5.9 -30 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL257829 95666 None 0 Rabbit Functional pIC50 = 5.9 5.9 -30 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
72947878 104693 None 0 Human Functional pIC50 = 4.9 4.9 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 374 5 1 8 3.0 N#Cc1cccnc1SCc1cc(O)n2nc(Cc3ccccc3)nc2n1 10.1016/j.bmcl.2013.11.074
CHEMBL3104905 104693 None 0 Human Functional pIC50 = 4.9 4.9 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 374 5 1 8 3.0 N#Cc1cccnc1SCc1cc(O)n2nc(Cc3ccccc3)nc2n1 10.1016/j.bmcl.2013.11.074
CHEMBL5078087 217024 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None Cc1ccc(NC(=O)Nc2ccc3c(c2O)S(=O)(=O)CCC3)cc1 10.1021/acs.jmedchem.1c01219
CHEMBL5083848 217377 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None Cc1c(F)cccc1Nc1c(Nc2ccc3c(c2O)S(=O)(=O)CCC3)c(=O)c1=O 10.1021/acs.jmedchem.1c01219
72948073 104687 None 0 Human Functional pIC50 = 4.9 4.9 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 461 7 1 7 3.7 CS(=O)(=O)Nc1cc(CSc2cccc(F)c2F)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104897 104687 None 0 Human Functional pIC50 = 4.9 4.9 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 461 7 1 7 3.7 CS(=O)(=O)Nc1cc(CSc2cccc(F)c2F)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
44447928 95666 None 0 Human Functional pIC50 = 7.9 7.9 30 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL257829 95666 None 0 Human Functional pIC50 = 7.9 7.9 30 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
135907764 113020 None 15 Human Functional pIC50 = 6.9 6.9 18 2
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 319 4 1 5 3.5 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CC1 10.1016/j.bmcl.2014.06.011
CHEMBL3310783 113020 None 15 Human Functional pIC50 = 6.9 6.9 18 2
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 319 4 1 5 3.5 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CC1 10.1016/j.bmcl.2014.06.011
CHEMBL5088825 217670 None 0 Human Functional pIC50 = 6.9 6.9 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccccc1Br)Nc1ccc2c(c1O)S(=O)(=O)CCC2 10.1021/acs.jmedchem.1c01219
162652088 180367 None 0 Human Functional pIC50 = 6.9 6.9 707 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 359 4 3 6 1.9 CCC1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
CHEMBL4750465 180367 None 0 Human Functional pIC50 = 6.9 6.9 707 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 359 4 3 6 1.9 CCC1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
135907767 113009 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 369 4 1 5 4.6 Cc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1 10.1016/j.bmcl.2014.06.011
CHEMBL3310773 113009 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 369 4 1 5 4.6 Cc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1 10.1016/j.bmcl.2014.06.011
136986993 113117 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 372 4 1 4 4.4 Oc1nc(SCc2cccc(F)c2F)nc(C2CC2)c1Br 10.1016/j.bmcl.2014.06.011
CHEMBL3311396 113117 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 372 4 1 4 4.4 Oc1nc(SCc2cccc(F)c2F)nc(C2CC2)c1Br 10.1016/j.bmcl.2014.06.011
24970093 126878 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 387 7 2 3 4.5 CC(C)(NC(=O)c1ccc2c(c1OCCC1CCCCC1)CCCC2)C(=O)O nan
CHEMBL3654433 126878 None 0 Human Functional pIC50 = 5.9 5.9 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 387 7 2 3 4.5 CC(C)(NC(=O)c1ccc2c(c1OCCC1CCCCC1)CCCC2)C(=O)O nan
10268984 80345 None 0 Human Functional pIC50 = 6.8 6.8 - 1
Inhibition of chemotaxis of CHO cells expressing human CXCR2Inhibition of chemotaxis of CHO cells expressing human CXCR2
ChEMBL 343 3 3 6 1.5 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C2CCCC2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL214162 80345 None 0 Human Functional pIC50 = 6.8 6.8 - 1
Inhibition of chemotaxis of CHO cells expressing human CXCR2Inhibition of chemotaxis of CHO cells expressing human CXCR2
ChEMBL 343 3 3 6 1.5 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C2CCCC2)c1O 10.1016/j.bmcl.2006.04.082
46897449 114988 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2C(=O)O)nc1 10.1021/jm500827t
CHEMBL3342311 114988 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2C(=O)O)nc1 10.1021/jm500827t
CHEMBL5076418 216927 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccc(Br)cc1)Nc1ccc2c(c1O)S(=O)(=O)CC=C2 10.1021/acs.jmedchem.1c01219
151755055 173842 None 0 Human Functional pIC50 = 4.8 4.8 - 1
Antagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 392 5 3 6 3.8 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nnc(-c3ccccc3)[nH]2)c1O 10.1016/j.ejmech.2019.111853
CHEMBL4536494 173842 None 0 Human Functional pIC50 = 4.8 4.8 - 1
Antagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 392 5 3 6 3.8 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nnc(-c3ccccc3)[nH]2)c1O 10.1016/j.ejmech.2019.111853
162657065 181007 None 0 Human Functional pIC50 = 7.8 7.8 1548 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 522 7 4 8 3.4 CC(C)(C)OC(=O)NCCCS(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccccc3)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4757674 181007 None 0 Human Functional pIC50 = 7.8 7.8 1548 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 522 7 4 8 3.4 CC(C)(C)OC(=O)NCCCS(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccccc3)N2)c1O 10.1021/acsmedchemlett.1c00113
11625425 140551 None 0 Human Functional pIC50 = 7.8 7.8 - 1
Antagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPRAntagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPR
ChEMBL 397 6 3 8 3.4 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL380947 140551 None 0 Human Functional pIC50 = 7.8 7.8 - 1
Antagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPRAntagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPR
ChEMBL 397 6 3 8 3.4 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL5090244 217741 None 0 Human Functional pIC50 = 6.8 6.8 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=c1c(Nc2ccccc2Br)c(Nc2ccc3c(c2O)S(=O)(=O)CCC3)c1=O 10.1021/acs.jmedchem.1c01219
24953463 104709 None 0 Human Functional pIC50 = 6.8 6.8 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 359 4 1 6 4.3 Oc1cc(CSc2cccc(F)c2F)nc2cc(-c3ccco3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3105080 104709 None 0 Human Functional pIC50 = 6.8 6.8 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 359 4 1 6 4.3 Oc1cc(CSc2cccc(F)c2F)nc2cc(-c3ccco3)nn12 10.1016/j.bmcl.2013.11.074
136074340 113022 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 391 6 1 7 3.3 CCOC(=O)[C@H]1C[C@@H]1c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
CHEMBL3310785 113022 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 391 6 1 7 3.3 CCOC(=O)[C@H]1C[C@@H]1c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
24958572 104443 None 2 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 308 3 1 6 2.7 Cc1nc2nc(CSc3cccc(F)c3F)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
CHEMBL3102879 104443 None 2 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 308 3 1 6 2.7 Cc1nc2nc(CSc3cccc(F)c3F)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
151755055 173842 None 0 Human Functional pIC50 = 4.8 4.8 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 392 5 3 6 3.8 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nnc(-c3ccccc3)[nH]2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4536494 173842 None 0 Human Functional pIC50 = 4.8 4.8 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 392 5 3 6 3.8 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nnc(-c3ccccc3)[nH]2)c1O 10.1021/acsmedchemlett.1c00113
168279497 190860 None 0 Human Functional pIC50 = 4.8 4.8 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cc[nH]c12 10.1016/j.ejmech.2023.115240
CHEMBL5182926 190860 None 0 Human Functional pIC50 = 4.8 4.8 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cc[nH]c12 10.1016/j.ejmech.2023.115240
135907774 113011 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 413 6 1 6 5.1 CC(C)Oc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1 10.1016/j.bmcl.2014.06.011
CHEMBL3310775 113011 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 413 6 1 6 5.1 CC(C)Oc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1 10.1016/j.bmcl.2014.06.011
CHEMBL5081113 217211 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccccc1C(F)(F)F)Nc1ccc2c(c1O)S(=O)(=O)CC=C2 10.1021/acs.jmedchem.1c01219
46897452 114984 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 406 5 1 3 6.1 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc(Cl)c(Cl)c2)nc1 10.1021/jm500827t
CHEMBL3342303 114984 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 406 5 1 3 6.1 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc(Cl)c(Cl)c2)nc1 10.1021/jm500827t
172465276 196906 None 0 Human Functional pIC50 = 5.8 5.8 -3 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 322 6 3 7 2.2 C[C@H](CO)Nc1nc(SCC2CCCCC2)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5434552 196906 None 0 Human Functional pIC50 = 5.8 5.8 -3 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 322 6 3 7 2.2 C[C@H](CO)Nc1nc(SCC2CCCCC2)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5086977 217549 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None Cc1c(Cl)cccc1NC(=O)Nc1ccc2c(c1O)S(=O)(=O)CC=C2 10.1021/acs.jmedchem.1c01219
57864041 125245 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 399 6 2 2 4.8 CC(C)(NC(=O)c1ccc2ccccc2c1C#CCCCc1ccccc1)C(=O)O nan
CHEMBL3645135 125245 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 399 6 2 2 4.8 CC(C)(NC(=O)c1ccc2ccccc2c1C#CCCCc1ccccc1)C(=O)O nan
172470403 197050 None 0 Human Functional pIC50 = 4.8 4.8 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 369 7 2 7 2.8 OCCCSc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5437555 197050 None 0 Human Functional pIC50 = 4.8 4.8 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 369 7 2 7 2.8 OCCCSc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
46897451 114989 None 0 Human Functional pIC50 = 6.8 6.8 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 406 6 2 6 3.9 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2-c2nn[nH]n2)nc1 10.1021/jm500827t
CHEMBL3342312 114989 None 0 Human Functional pIC50 = 6.8 6.8 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 406 6 2 6 3.9 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2-c2nn[nH]n2)nc1 10.1021/jm500827t
135907781 113019 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 333 4 1 5 3.9 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CCC1 10.1016/j.bmcl.2014.06.011
CHEMBL3310782 113019 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 333 4 1 5 3.9 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CCC1 10.1016/j.bmcl.2014.06.011
24959296 104699 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 416 5 1 6 5.0 Oc1cc(CSc2cccc(Cl)c2Cl)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104911 104699 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 416 5 1 6 5.0 Oc1cc(CSc2cccc(Cl)c2Cl)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
24958938 104701 None 2 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 384 5 1 6 4.0 Oc1cc(CSc2ccc(F)c(F)c2)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104913 104701 None 2 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 384 5 1 6 4.0 Oc1cc(CSc2ccc(F)c(F)c2)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
68603807 104712 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 347 3 1 5 3.9 Oc1cc(CSc2cccc(F)c2F)nc2c3c(nn12)CCCC3 10.1016/j.bmcl.2013.11.074
CHEMBL3105083 104712 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 347 3 1 5 3.9 Oc1cc(CSc2cccc(F)c2F)nc2c3c(nn12)CCCC3 10.1016/j.bmcl.2013.11.074
44447946 95047 None 0 Rabbit Functional pIC50 = 5.8 5.8 -77 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 515 6 3 3 5.0 O=C(NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12)NS(=O)(=O)c1ccccc1 10.1016/j.bmcl.2008.01.127
CHEMBL254773 95047 None 0 Rabbit Functional pIC50 = 5.8 5.8 -77 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 515 6 3 3 5.0 O=C(NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12)NS(=O)(=O)c1ccccc1 10.1016/j.bmcl.2008.01.127
24970255 126884 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 399 8 2 5 4.0 CC(C)(NC(=O)c1ccc2sccc2c1OCCOc1ccccc1)C(=O)O nan
CHEMBL3654439 126884 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 399 8 2 5 4.0 CC(C)(NC(=O)c1ccc2sccc2c1OCCOc1ccccc1)C(=O)O nan
172461550 196824 None 0 Human Functional pIC50 = 5.8 5.8 3 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 352 6 3 7 2.1 C[C@@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5432877 196824 None 0 Human Functional pIC50 = 5.8 5.8 3 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 352 6 3 7 2.1 C[C@@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
57864038 125240 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 399 8 2 5 4.0 CC(C)(NC(=O)c1sc2ccccc2c1OCCOc1ccccc1)C(=O)O nan
CHEMBL3645130 125240 None 0 Human Functional pIC50 = 5.8 5.8 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 399 8 2 5 4.0 CC(C)(NC(=O)c1sc2ccccc2c1OCCOc1ccccc1)C(=O)O nan
9968028 80326 None 0 Human Functional pIC50 = 7.7 7.7 - 1
Inhibition of chemotaxis of CHO cells expressing human CXCR2Inhibition of chemotaxis of CHO cells expressing human CXCR2
ChEMBL 345 5 3 6 1.7 CCC(CC)/N=c1\c(O)c(O)\c1=N/c1cccc(C(=O)N(C)C)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL214047 80326 None 0 Human Functional pIC50 = 7.7 7.7 - 1
Inhibition of chemotaxis of CHO cells expressing human CXCR2Inhibition of chemotaxis of CHO cells expressing human CXCR2
ChEMBL 345 5 3 6 1.7 CCC(CC)/N=c1\c(O)c(O)\c1=N/c1cccc(C(=O)N(C)C)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL5090422 217753 None 0 Human Functional pIC50 = 6.7 6.7 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None Cc1ccc(NC(=O)Nc2ccc3c(c2O)S(=O)(=O)CC=C3)cc1 10.1021/acs.jmedchem.1c01219
CHEMBL5078246 217034 None 0 Human Functional pIC50 = 4.7 4.7 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccc2c(c1O)S(=O)(=O)CC=C2)Nc1cccc(F)c1Cl 10.1021/acs.jmedchem.1c01219
3854666 3501 None 58 Human Functional pIC50 = 6.7 6.7 -1 2
Antagonist activity against CXCR2 (unknown origin) by calcium flux assayAntagonist activity against CXCR2 (unknown origin) by calcium flux assay
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1016/j.ejmech.2021.113812
833 3501 None 58 Human Functional pIC50 = 6.7 6.7 -1 2
Antagonist activity against CXCR2 (unknown origin) by calcium flux assayAntagonist activity against CXCR2 (unknown origin) by calcium flux assay
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1016/j.ejmech.2021.113812
CHEMBL239767 3501 None 58 Human Functional pIC50 = 6.7 6.7 -1 2
Antagonist activity against CXCR2 (unknown origin) by calcium flux assayAntagonist activity against CXCR2 (unknown origin) by calcium flux assay
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1016/j.ejmech.2021.113812
59446380 114997 None 0 Human Functional pIC50 = 5.7 5.7 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 440 8 3 6 1.9 O=C(O)CN(C(=O)c1ccc(SCc2ccccc2B(O)O)nc1)c1ccc(F)cc1 10.1021/jm500827t
CHEMBL3342323 114997 None 0 Human Functional pIC50 = 5.7 5.7 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 440 8 3 6 1.9 O=C(O)CN(C(=O)c1ccc(SCc2ccccc2B(O)O)nc1)c1ccc(F)cc1 10.1021/jm500827t
44610601 171711 None 0 Human Functional pIC50 = 8.7 8.7 - 1
Antagonist activity at CXCR2 (unknown origin) by [35S]-GTPgammaS binding assayAntagonist activity at CXCR2 (unknown origin) by [35S]-GTPgammaS binding assay
ChEMBL 483 9 3 9 3.0 CC[C@@H](Nc1c(Nc2ccc(Cl)c(S(=O)(=O)N(C)OC)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.ejmech.2019.111853
CHEMBL4465379 171711 None 0 Human Functional pIC50 = 8.7 8.7 - 1
Antagonist activity at CXCR2 (unknown origin) by [35S]-GTPgammaS binding assayAntagonist activity at CXCR2 (unknown origin) by [35S]-GTPgammaS binding assay
ChEMBL 483 9 3 9 3.0 CC[C@@H](Nc1c(Nc2ccc(Cl)c(S(=O)(=O)N(C)OC)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.ejmech.2019.111853
16098481 82143 None 0 Human Functional pIC50 = 8.6 8.6 218 2
Inhibition of CXCL1-induced human neutrophil chemotaxisInhibition of CXCL1-induced human neutrophil chemotaxis
ChEMBL 383 6 3 7 2.5 Cc1ccc([C@@H](C)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)o1 10.1021/jm0609622
CHEMBL216602 82143 None 0 Human Functional pIC50 = 8.6 8.6 218 2
Inhibition of CXCL1-induced human neutrophil chemotaxisInhibition of CXCL1-induced human neutrophil chemotaxis
ChEMBL 383 6 3 7 2.5 Cc1ccc([C@@H](C)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)o1 10.1021/jm0609622
8497 2737 None 41 Human Functional pIC50 = 8.5 8.5 1 4
Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assayInhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
9865554 2737 None 41 Human Functional pIC50 = 8.5 8.5 1 4
Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assayInhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
CHEMBL216981 2737 None 41 Human Functional pIC50 = 8.5 8.5 1 4
Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assayInhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
172446176 195522 None 0 Human Functional pIC50 = 6.7 6.7 28 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 366 7 3 7 2.5 CC[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5405321 195522 None 0 Human Functional pIC50 = 6.7 6.7 28 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 366 7 3 7 2.5 CC[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5078730 217070 None 0 Human Functional pIC50 = 6.7 6.7 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=c1c(Nc2ccccc2Cl)c(Nc2ccc3c(c2O)S(=O)(=O)CC=C3)c1=O 10.1021/acs.jmedchem.1c01219
24970171 126880 None 0 Human Functional pIC50 = 5.7 5.7 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 409 9 2 3 4.6 CC(C)(NC(=O)c1ccc2c(c1OCCCCc1ccccc1)CCCC2)C(=O)O nan
CHEMBL3654435 126880 None 0 Human Functional pIC50 = 5.7 5.7 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 409 9 2 3 4.6 CC(C)(NC(=O)c1ccc2c(c1OCCCCc1ccccc1)CCCC2)C(=O)O nan
72948071 104716 None 0 Human Functional pIC50 = 4.7 4.7 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 321 4 1 5 3.6 CCc1cnn2c(O)cc(CSc3cccc(F)c3F)nc12 10.1016/j.bmcl.2013.11.074
CHEMBL3105087 104716 None 0 Human Functional pIC50 = 4.7 4.7 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 321 4 1 5 3.6 CCc1cnn2c(O)cc(CSc3cccc(F)c3F)nc12 10.1016/j.bmcl.2013.11.074
172455714 196121 None 0 Human Functional pIC50 = 5.7 5.7 3 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 366 7 3 7 2.5 C[C@H](CCO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5417284 196121 None 0 Human Functional pIC50 = 5.7 5.7 3 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 366 7 3 7 2.5 C[C@H](CCO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
46897163 119147 None 5 Human Functional pIC50 = 7.7 7.7 -1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 466 7 3 6 3.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3426944 119147 None 5 Human Functional pIC50 = 7.7 7.7 -1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 466 7 3 6 3.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 10.1016/j.bmcl.2015.07.090
122187266 123083 None 0 Human Functional pIC50 = 7.7 7.7 -6 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 446 8 3 7 2.3 O=C(Nc1ccc(F)cc1)c1ccc(N(Cc2ccc(B(O)O)cn2)Cc2ccco2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3609016 123083 None 0 Human Functional pIC50 = 7.7 7.7 -6 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 446 8 3 7 2.3 O=C(Nc1ccc(F)cc1)c1ccc(N(Cc2ccc(B(O)O)cn2)Cc2ccco2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL5083131 217333 None 0 Human Functional pIC50 = 6.7 6.7 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccc2c(c1O)S(=O)(=O)CCC2)Nc1cccc(Cl)c1Cl 10.1021/acs.jmedchem.1c01219
CHEMBL5087256 217571 None 0 Human Functional pIC50 = 6.7 6.7 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccccc1Cl)Nc1ccc2c(c1O)S(=O)(=O)CCC2 10.1021/acs.jmedchem.1c01219
46897162 3716 None 15 Human Functional pIC50 = 6.7 6.7 6 2
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1021/jm500827t
8501 3716 None 15 Human Functional pIC50 = 6.7 6.7 6 2
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1021/jm500827t
CHEMBL3342269 3716 None 15 Human Functional pIC50 = 6.7 6.7 6 2
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1021/jm500827t
44447915 169254 None 0 Rabbit Functional pIC50 = 5.7 5.7 -43 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 399 6 2 4 3.2 CS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL440405 169254 None 0 Rabbit Functional pIC50 = 5.7 5.7 -43 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 399 6 2 4 3.2 CS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
24970173 126881 None 0 Human Functional pIC50 = 5.7 5.7 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 411 9 2 4 4.0 CC(C)(NC(=O)c1ccc2c(c1OCCCOc1ccccc1)CCCC2)C(=O)O nan
CHEMBL3654436 126881 None 0 Human Functional pIC50 = 5.7 5.7 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 411 9 2 4 4.0 CC(C)(NC(=O)c1ccc2c(c1OCCCOc1ccccc1)CCCC2)C(=O)O nan
46897450 114986 None 0 Human Functional pIC50 = 5.7 5.7 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 2 4 4.5 O=C(O)c1cccc(CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)c1 10.1021/jm500827t
CHEMBL3342309 114986 None 0 Human Functional pIC50 = 5.7 5.7 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 2 4 4.5 O=C(O)c1cccc(CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)c1 10.1021/jm500827t
172455676 196431 None 0 Human Functional pIC50 = 6.7 6.7 - 1
Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assayInhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay
ChEMBL 634 12 5 9 5.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)OCC3c4ccccc4-c4ccccc43)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5423846 196431 None 0 Human Functional pIC50 = 6.7 6.7 - 1
Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assayInhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay
ChEMBL 634 12 5 9 5.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)OCC3c4ccccc4-c4ccccc43)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
162675855 183417 None 0 Human Functional pIC50 = 5.7 5.7 45 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 425 4 3 6 3.0 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccc(F)cc3)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4797191 183417 None 0 Human Functional pIC50 = 5.7 5.7 45 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 425 4 3 6 3.0 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccc(F)cc3)N2)c1O 10.1021/acsmedchemlett.1c00113
90467234 167537 None 40 Human Functional pIC50 = 7.7 7.7 - 1
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 467 7 3 7 2.7 O=C(Nc1ccc(F)cc1)c1cnc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 10.1016/j.ejmech.2023.115175
90467234.0 167537 None 40 Human Functional pIC50 = 7.7 7.7 - 1
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 467 7 3 7 2.7 O=C(Nc1ccc(F)cc1)c1cnc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 10.1016/j.ejmech.2023.115175
CHEMBL4297480 167537 None 40 Human Functional pIC50 = 7.7 7.7 - 1
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 467 7 3 7 2.7 O=C(Nc1ccc(F)cc1)c1cnc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 10.1016/j.ejmech.2023.115175
122187256 123072 None 0 Human Functional pIC50 = 5.7 5.7 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 365 6 4 5 1.8 O=C(Nc1ccc(F)cc1)c1ccc(NCc2ccc(B(O)O)cc2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3609004 123072 None 0 Human Functional pIC50 = 5.7 5.7 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 365 6 4 5 1.8 O=C(Nc1ccc(F)cc1)c1ccc(NCc2ccc(B(O)O)cc2)nc1 10.1016/j.bmcl.2015.07.090
23642281 125908 None 0 Human Functional pIC50 = 5.7 5.7 - 1
Calicum Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes).Calicum Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes).
ChEMBL 507 8 2 3 6.6 CCC(NC(=O)c1ccc2ccccc2c1OCc1ccc(C(F)(F)F)cc1)(C(=O)O)c1ccccc1 nan
CHEMBL3648347 125908 None 0 Human Functional pIC50 = 5.7 5.7 - 1
Calicum Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes).Calicum Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes).
ChEMBL 507 8 2 3 6.6 CCC(NC(=O)c1ccc2ccccc2c1OCc1ccc(C(F)(F)F)cc1)(C(=O)O)c1ccccc1 nan
122187265 123082 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 464 8 3 7 2.0 O=C(Nc1ccc(F)cc1)c1ccc(N(Cc2ccc(B(O)O)cn2)CC2CCOCC2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3609015 123082 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 464 8 3 7 2.0 O=C(Nc1ccc(F)cc1)c1ccc(N(Cc2ccc(B(O)O)cn2)CC2CCOCC2)nc1 10.1016/j.bmcl.2015.07.090
162644015 181871 None 0 Human Functional pIC50 = 4.6 4.6 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 292 2 3 5 1.9 N#Cc1ccc(NC2=NC(=O)C(c3ccccc3)N2)c(O)c1 10.1021/acsmedchemlett.1c00113
CHEMBL4777637 181871 None 0 Human Functional pIC50 = 4.6 4.6 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 292 2 3 5 1.9 N#Cc1ccc(NC2=NC(=O)C(c3ccccc3)N2)c(O)c1 10.1021/acsmedchemlett.1c00113
172450116 195812 None 0 Human Functional pIC50 = 5.6 5.6 2 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 308 6 3 7 1.8 C[C@H](CO)Nc1nc(SCC2CCCC2)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5411165 195812 None 0 Human Functional pIC50 = 5.6 5.6 2 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 308 6 3 7 1.8 C[C@H](CO)Nc1nc(SCC2CCCC2)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5075434 216862 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None Cc1c(Cl)cccc1NC(=O)Nc1ccc2c(c1O)S(=O)(=O)CCC2 10.1021/acs.jmedchem.1c01219
168275518 190615 None 0 Human Functional pIC50 = 4.6 4.6 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 367 6 2 6 4.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ccsc12 10.1016/j.ejmech.2023.115240
CHEMBL5179345 190615 None 0 Human Functional pIC50 = 4.6 4.6 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 367 6 2 6 4.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ccsc12 10.1016/j.ejmech.2023.115240
168293276 192252 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 351 6 3 6 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]cnc12 10.1016/j.ejmech.2023.115240
CHEMBL5203743 192252 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 351 6 3 6 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]cnc12 10.1016/j.ejmech.2023.115240
122187260 123076 None 0 Human Functional pIC50 = 5.6 5.6 -1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 380 6 3 6 1.2 CN(Cc1cccc(B(O)O)c1)c1ncc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
CHEMBL3609009 123076 None 0 Human Functional pIC50 = 5.6 5.6 -1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 380 6 3 6 1.2 CN(Cc1cccc(B(O)O)c1)c1ncc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
CHEMBL5092474 217861 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=c1c(Nc2ccc3c(c2O)S(=O)(=O)CC=C3)c(Nc2cccc(Cl)c2Cl)c1=O 10.1021/acs.jmedchem.1c01219
162657640 181273 None 0 Human Functional pIC50 = 4.6 4.6 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 421 5 3 6 2.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@H](Cc3ccccc3)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4760919 181273 None 0 Human Functional pIC50 = 4.6 4.6 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 421 5 3 6 2.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@H](Cc3ccccc3)N2)c1O 10.1021/acsmedchemlett.1c00113
24769071 125242 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 435 10 2 4 4.9 CC(C)CC(C)(NC(=O)c1ccc2ccccc2c1OCCOc1ccccc1)C(=O)O nan
CHEMBL3645132 125242 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 435 10 2 4 4.9 CC(C)CC(C)(NC(=O)c1ccc2ccccc2c1OCCOc1ccccc1)C(=O)O nan
172454055 195717 None 0 Human Functional pIC50 = 5.6 5.6 3 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 310 8 3 7 2.1 CCCC(C)CSc1nc(N[C@H](C)CO)c2nn[nH]c2n1 10.1016/j.ejmech.2023.115240
CHEMBL5409489 195717 None 0 Human Functional pIC50 = 5.6 5.6 3 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 310 8 3 7 2.1 CCCC(C)CSc1nc(N[C@H](C)CO)c2nn[nH]c2n1 10.1016/j.ejmech.2023.115240
9928389 79640 None 0 Human Functional pIC50 = 7.6 7.6 - 1
Inhibition of chemotaxis of CHO cells expressing human CXCR2Inhibition of chemotaxis of CHO cells expressing human CXCR2
ChEMBL 351 3 3 6 1.8 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL211468 79640 None 0 Human Functional pIC50 = 7.6 7.6 - 1
Inhibition of chemotaxis of CHO cells expressing human CXCR2Inhibition of chemotaxis of CHO cells expressing human CXCR2
ChEMBL 351 3 3 6 1.8 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
24953464 104713 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 343 3 1 5 4.2 Oc1cc(CSc2cccc(F)c2F)nc2c3ccccc3nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3105084 104713 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 343 3 1 5 4.2 Oc1cc(CSc2cccc(F)c2F)nc2c3ccccc3nn12 10.1016/j.bmcl.2013.11.074
10479502 1548 None 26 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 assessed as inhibition of neutrophil CD11b up-regulationAntagonist activity at CXCR2 assessed as inhibition of neutrophil CD11b up-regulation
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
8499 1548 None 26 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 assessed as inhibition of neutrophil CD11b up-regulationAntagonist activity at CXCR2 assessed as inhibition of neutrophil CD11b up-regulation
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
CHEMBL2178579 1548 None 26 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 assessed as inhibition of neutrophil CD11b up-regulationAntagonist activity at CXCR2 assessed as inhibition of neutrophil CD11b up-regulation
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
DB12135 1548 None 26 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 assessed as inhibition of neutrophil CD11b up-regulationAntagonist activity at CXCR2 assessed as inhibition of neutrophil CD11b up-regulation
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
122187261 123077 None 0 Human Functional pIC50 = 5.6 5.6 -1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 366 6 4 6 1.2 O=C(Nc1ccc(F)cc1)c1cnc(NCc2ccc(B(O)O)cc2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3609010 123077 None 0 Human Functional pIC50 = 5.6 5.6 -1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 366 6 4 6 1.2 O=C(Nc1ccc(F)cc1)c1cnc(NCc2ccc(B(O)O)cc2)nc1 10.1016/j.bmcl.2015.07.090
162677254 183667 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 345 3 3 6 1.5 CC1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
CHEMBL4800297 183667 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 345 3 3 6 1.5 CC1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
153842018 191136 None 3 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 368 6 2 7 3.5 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ncsc12 10.1016/j.ejmech.2023.115240
CHEMBL5186932 191136 None 3 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 368 6 2 7 3.5 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ncsc12 10.1016/j.ejmech.2023.115240
172449764 195900 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 334 5 2 6 2.9 Fc1cccc(CSc2nc(NC3CC3)c3nn[nH]c3n2)c1F 10.1016/j.ejmech.2023.115240
CHEMBL5412948 195900 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 334 5 2 6 2.9 Fc1cccc(CSc2nc(NC3CC3)c3nn[nH]c3n2)c1F 10.1016/j.ejmech.2023.115240
46897352 114990 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 464 6 1 5 5.1 CC1(C)OB(c2ccccc2CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C 10.1021/jm500827t
CHEMBL3342313 114990 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 464 6 1 5 5.1 CC1(C)OB(c2ccccc2CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C 10.1021/jm500827t
46897256 114985 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 354 5 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2O)nc1 10.1021/jm500827t
CHEMBL3342304 114985 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 354 5 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2O)nc1 10.1021/jm500827t
59446381 114991 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 448 7 3 6 3.2 O=C(Nc1ccc(OC(F)(F)F)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 10.1021/jm500827t
CHEMBL3342314 114991 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 448 7 3 6 3.2 O=C(Nc1ccc(OC(F)(F)F)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 10.1021/jm500827t
172441815 195487 None 0 Human Functional pIC50 = 7.5 7.5 - 1
Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assayInhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay
ChEMBL 512 10 5 9 3.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)OC(C)(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5404638 195487 None 0 Human Functional pIC50 = 7.5 7.5 - 1
Inhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assayInhibition of CXCR2 (unknown origin) expressed in HEK293 coexpressing snap-CXCR2-LGBit and beta-arrestin2-SMBit using furimazine as substrate preincubated for 1 hr followed by substrate addition and measured after 5 mins by bioluminescence based NanoBiT assay
ChEMBL 512 10 5 9 3.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)OC(C)(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
9841667 140836 None 41 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1016/j.ejmech.2023.115175
CHEMBL38182 140836 None 41 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1016/j.ejmech.2023.115175
24953110 104710 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 370 4 1 6 4.1 Oc1cc(CSc2cccc(F)c2F)nc2cc(-c3ccccn3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3105081 104710 None 0 Human Functional pIC50 = 6.6 6.6 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 370 4 1 6 4.1 Oc1cc(CSc2cccc(F)c2F)nc2cc(-c3ccccn3)nn12 10.1016/j.bmcl.2013.11.074
162655442 180799 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 373 5 3 6 2.3 CCC[C@@H]1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
CHEMBL4755486 180799 None 0 Human Functional pIC50 = 5.6 5.6 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 373 5 3 6 2.3 CCC[C@@H]1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
162648477 180068 None 0 Human Functional pIC50 = 7.5 7.5 707 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 373 5 3 6 2.3 CCC[C@H]1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
CHEMBL4746698 180068 None 0 Human Functional pIC50 = 7.5 7.5 707 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 373 5 3 6 2.3 CCC[C@H]1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
91937332 114994 None 0 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 383 6 3 6 1.8 O=C(Nc1ccc(F)cn1)c1ccc(SCc2ccccc2B(O)O)nc1 10.1021/jm500827t
CHEMBL3342319 114994 None 0 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 383 6 3 6 1.8 O=C(Nc1ccc(F)cn1)c1ccc(SCc2ccccc2B(O)O)nc1 10.1021/jm500827t
162662122 181626 None 0 Human Functional pIC50 = 4.5 4.5 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 331 3 3 6 1.1 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)CN2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4765070 181626 None 0 Human Functional pIC50 = 4.5 4.5 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 331 3 3 6 1.1 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)CN2)c1O 10.1021/acsmedchemlett.1c00113
122187263 123080 None 0 Human Functional pIC50 = 6.5 6.5 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 456 8 3 6 2.8 O=C(Nc1ccc(F)cc1)c1ccc(N(Cc2ccccc2)Cc2ccc(B(O)O)cn2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3609013 123080 None 0 Human Functional pIC50 = 6.5 6.5 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 456 8 3 6 2.8 O=C(Nc1ccc(F)cc1)c1ccc(N(Cc2ccccc2)Cc2ccc(B(O)O)cn2)nc1 10.1016/j.bmcl.2015.07.090
172444714 194969 None 0 Human Functional pIC50 = 5.5 5.5 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 348 6 2 6 3.1 Fc1cccc(CSc2nc(NCC3CC3)c3nn[nH]c3n2)c1F 10.1016/j.ejmech.2023.115240
CHEMBL5394281 194969 None 0 Human Functional pIC50 = 5.5 5.5 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 348 6 2 6 3.1 Fc1cccc(CSc2nc(NCC3CC3)c3nn[nH]c3n2)c1F 10.1016/j.ejmech.2023.115240
56645576 548 None 40 Human Functional pIC50 = 8.5 8.5 77 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 476 10 3 8 1.5 OC[C@@H]([C@H](Oc1nc(SCc2cccc(c2F)F)nc(c1)NS(=O)(=O)N1CCC1)C)O 10.1016/j.ejmech.2023.115175
8948 548 None 40 Human Functional pIC50 = 8.5 8.5 77 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 476 10 3 8 1.5 OC[C@@H]([C@H](Oc1nc(SCc2cccc(c2F)F)nc(c1)NS(=O)(=O)N1CCC1)C)O 10.1016/j.ejmech.2023.115175
CHEMBL4562140 548 None 40 Human Functional pIC50 = 8.5 8.5 77 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 476 10 3 8 1.5 OC[C@@H]([C@H](Oc1nc(SCc2cccc(c2F)F)nc(c1)NS(=O)(=O)N1CCC1)C)O 10.1016/j.ejmech.2023.115175
3854666 3501 None 58 Human Functional pIC50 = 7.5 7.5 -1 2
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1021/jm500827t
833 3501 None 58 Human Functional pIC50 = 7.5 7.5 -1 2
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1021/jm500827t
CHEMBL239767 3501 None 58 Human Functional pIC50 = 7.5 7.5 -1 2
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1021/jm500827t
44447923 95520 None 0 Rabbit Functional pIC50 = 5.5 5.5 -38 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 453 6 2 4 4.1 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)C(F)(F)F)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL257178 95520 None 0 Rabbit Functional pIC50 = 5.5 5.5 -38 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 453 6 2 4 4.1 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)C(F)(F)F)c2c1 10.1016/j.bmcl.2008.01.127
162648010 180077 None 0 Human Functional pIC50 = 6.5 6.5 138 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 387 5 3 6 2.5 CC(C)CC1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
CHEMBL4746803 180077 None 0 Human Functional pIC50 = 6.5 6.5 138 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 387 5 3 6 2.5 CC(C)CC1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
162676913 183627 None 0 Human Functional pIC50 = 6.5 6.5 158 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 441 4 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3cccc(Cl)c3)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4799848 183627 None 0 Human Functional pIC50 = 6.5 6.5 158 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 441 4 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3cccc(Cl)c3)N2)c1O 10.1021/acsmedchemlett.1c00113
10479502 1548 None 26 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity at CXCR2 assessed as inhibition of neutrophil shape changeAntagonist activity at CXCR2 assessed as inhibition of neutrophil shape change
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
8499 1548 None 26 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity at CXCR2 assessed as inhibition of neutrophil shape changeAntagonist activity at CXCR2 assessed as inhibition of neutrophil shape change
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
CHEMBL2178579 1548 None 26 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity at CXCR2 assessed as inhibition of neutrophil shape changeAntagonist activity at CXCR2 assessed as inhibition of neutrophil shape change
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
DB12135 1548 None 26 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity at CXCR2 assessed as inhibition of neutrophil shape changeAntagonist activity at CXCR2 assessed as inhibition of neutrophil shape change
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
162660441 181418 None 0 Human Functional pIC50 = 5.5 5.5 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 345 3 3 6 1.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@H](C)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4762597 181418 None 0 Human Functional pIC50 = 5.5 5.5 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 345 3 3 6 1.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@H](C)N2)c1O 10.1021/acsmedchemlett.1c00113
44447915 169254 None 0 Human Functional pIC50 = 7.5 7.5 43 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 399 6 2 4 3.2 CS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL440405 169254 None 0 Human Functional pIC50 = 7.5 7.5 43 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 399 6 2 4 3.2 CS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
136074340 113022 None 0 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 391 6 1 7 3.3 CCOC(=O)[C@H]1C[C@@H]1c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
CHEMBL3310785 113022 None 0 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 391 6 1 7 3.3 CCOC(=O)[C@H]1C[C@@H]1c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
136986968 113030 None 1 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 294 4 1 4 3.6 Oc1cc(C2CC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2014.06.011
CHEMBL3310794 113030 None 1 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 294 4 1 4 3.6 Oc1cc(C2CC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2014.06.011
44432416 87422 None 0 Human Functional pIC50 = 6.5 6.5 151 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 415 3 3 6 4.4 O=S1(=O)N=C(Nc2ccccc2Oc2ccccc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL233346 87422 None 0 Human Functional pIC50 = 6.5 6.5 151 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 415 3 3 6 4.4 O=S1(=O)N=C(Nc2ccccc2Oc2ccccc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL5071577 216750 None 0 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccccc1F)Nc1ccc2c(c1O)S(=O)(=O)CC=C2 10.1021/acs.jmedchem.1c01219
136986994 113118 None 0 Human Functional pIC50 = 5.5 5.5 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 420 4 1 4 4.2 Oc1nc(SCc2cccc(F)c2F)nc(C2CC2)c1I 10.1016/j.bmcl.2014.06.011
CHEMBL3311397 113118 None 0 Human Functional pIC50 = 5.5 5.5 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 420 4 1 4 4.2 Oc1nc(SCc2cccc(F)c2F)nc(C2CC2)c1I 10.1016/j.bmcl.2014.06.011
24769330 125244 None 0 Human Functional pIC50 = 5.5 5.5 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 423 8 2 4 4.2 O=C(NC1(C(=O)O)CCC1)c1ccc2ccccc2c1OCCOc1ccc(F)cc1 nan
CHEMBL3645134 125244 None 0 Human Functional pIC50 = 5.5 5.5 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 423 8 2 4 4.2 O=C(NC1(C(=O)O)CCC1)c1ccc2ccccc2c1OCCOc1ccc(F)cc1 nan
CHEMBL5088269 217638 None 5 Human Functional pIC50 = 7.5 7.5 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None Cc1c(F)cccc1NC(=O)Nc1ccc2c(c1O)S(=O)(=O)CC=C2 10.1021/acs.jmedchem.1c01219
172450141 195840 None 0 Human Functional pIC50 = 5.5 5.5 1 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 355 6 2 7 2.4 OCCSc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5411713 195840 None 0 Human Functional pIC50 = 5.5 5.5 1 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 355 6 2 7 2.4 OCCSc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5087298 217573 None 0 Human Functional pIC50 = 5.5 5.5 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=c1c(Nc2ccc3c(c2O)S(=O)(=O)CCC3)c(Nc2cccc(F)c2Cl)c1=O 10.1021/acs.jmedchem.1c01219
24804051 104700 None 2 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 384 5 1 6 4.0 Oc1cc(CSc2cccc(F)c2F)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104912 104700 None 2 Human Functional pIC50 = 6.5 6.5 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 384 5 1 6 4.0 Oc1cc(CSc2cccc(F)c2F)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
1098331 195550 None 8 Human Functional pIC50 = 6.4 6.4 1 2
Antagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assayAntagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assay
ChEMBL 372 4 1 7 3.0 COc1cc(NS(=O)(=O)c2cccc3nsnc23)c2ncccc2c1 10.1016/j.ejmech.2023.115175
CHEMBL5405836 195550 None 8 Human Functional pIC50 = 6.4 6.4 1 2
Antagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assayAntagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assay
ChEMBL 372 4 1 7 3.0 COc1cc(NS(=O)(=O)c2cccc3nsnc23)c2ncccc2c1 10.1016/j.ejmech.2023.115175
CHEMBL5089049 217684 None 0 Human Functional pIC50 = 6.4 6.4 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None Cc1c(F)cccc1Nc1c(Nc2ccc3c(c2O)S(=O)(=O)CC=C3)c(=O)c1=O 10.1021/acs.jmedchem.1c01219
135907765 113006 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 355 4 1 5 4.3 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1-c1ccccc1 10.1016/j.bmcl.2014.06.011
CHEMBL3310769 113006 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 355 4 1 5 4.3 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1-c1ccccc1 10.1016/j.bmcl.2014.06.011
135907789 113021 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 335 3 1 5 3.9 CC(C)(C)c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
CHEMBL3310784 113021 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 335 3 1 5 3.9 CC(C)(C)c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
46897162 3716 None 15 Human Functional pIC50 = 7.4 7.4 6 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1016/j.ejmech.2023.115175
8501 3716 None 15 Human Functional pIC50 = 7.4 7.4 6 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1016/j.ejmech.2023.115175
CHEMBL3342269 3716 None 15 Human Functional pIC50 = 7.4 7.4 6 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1016/j.ejmech.2023.115175
46897162 3716 None 15 Human Functional pIC50 = 7.4 7.4 6 2
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1021/jm500827t
8501 3716 None 15 Human Functional pIC50 = 7.4 7.4 6 2
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1021/jm500827t
CHEMBL3342269 3716 None 15 Human Functional pIC50 = 7.4 7.4 6 2
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1021/jm500827t
44775716 114983 None 0 Human Functional pIC50 = 6.4 6.4 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 338 5 1 3 4.8 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2)nc1 10.1021/jm500827t
CHEMBL3342291 114983 None 0 Human Functional pIC50 = 6.4 6.4 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 338 5 1 3 4.8 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2)nc1 10.1021/jm500827t
59446412 114980 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 330 5 2 6 2.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2nn[nH]n2)nc1 10.1021/jm500827t
CHEMBL3342270 114980 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 330 5 2 6 2.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2nn[nH]n2)nc1 10.1021/jm500827t
71209600 189165 None 14 Human Functional pIC50 = 8.4 8.4 - 1
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 472 10 3 8 1.6 CC1CN(S(=O)(=O)Nc2cc(O[C@H](C)[C@@H](O)CO)nc(SCc3ccc(F)cc3)n2)C1 10.1016/j.ejmech.2023.115175
CHEMBL5095217 189165 None 14 Human Functional pIC50 = 8.4 8.4 - 1
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 472 10 3 8 1.6 CC1CN(S(=O)(=O)Nc2cc(O[C@H](C)[C@@H](O)CO)nc(SCc3ccc(F)cc3)n2)C1 10.1016/j.ejmech.2023.115175
122187268 123084 None 0 Human Functional pIC50 = 8.4 8.4 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 457 8 3 7 2.2 O=C(Nc1ccc(F)cc1)c1cnc(N(Cc2ccccc2)Cc2ccc(B(O)O)cn2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3609018 123084 None 0 Human Functional pIC50 = 8.4 8.4 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 457 8 3 7 2.2 O=C(Nc1ccc(F)cc1)c1cnc(N(Cc2ccccc2)Cc2ccc(B(O)O)cn2)nc1 10.1016/j.bmcl.2015.07.090
44447946 95047 None 0 Human Functional pIC50 = 8.4 8.4 77 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 515 6 3 3 5.0 O=C(NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12)NS(=O)(=O)c1ccccc1 10.1016/j.bmcl.2008.01.127
CHEMBL254773 95047 None 0 Human Functional pIC50 = 8.4 8.4 77 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 515 6 3 3 5.0 O=C(NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12)NS(=O)(=O)c1ccccc1 10.1016/j.bmcl.2008.01.127
3854666 3501 None 58 Human Functional pIC50 = 7.4 7.4 -1 2
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1021/jm500827t
833 3501 None 58 Human Functional pIC50 = 7.4 7.4 -1 2
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1021/jm500827t
CHEMBL239767 3501 None 58 Human Functional pIC50 = 7.4 7.4 -1 2
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1021/jm500827t
130606 36280 None 44 Human Functional pIC50 = 6.4 6.4 9 4
Antagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assayAntagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assay
ChEMBL 328 4 1 4 3.4 COc1cc(NS(=O)(=O)c2ccc(C)cc2)c2ncccc2c1 10.1016/j.ejmech.2023.115175
CHEMBL1445650 36280 None 44 Human Functional pIC50 = 6.4 6.4 9 4
Antagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assayAntagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assay
ChEMBL 328 4 1 4 3.4 COc1cc(NS(=O)(=O)c2ccc(C)cc2)c2ncccc2c1 10.1016/j.ejmech.2023.115175
44432386 147583 None 0 Human Functional pIC50 = 6.4 6.4 79 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 401 1 3 5 3.4 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL393047 147583 None 0 Human Functional pIC50 = 6.4 6.4 79 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 401 1 3 5 3.4 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL5079979 217144 None 0 Human Functional pIC50 = 6.4 6.4 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccc2c(c1O)S(=O)(=O)CCC2=O)Nc1cccc(Cl)c1Cl 10.1021/acs.jmedchem.1c01219
162647583 180005 None 0 Human Functional pIC50 = 5.4 5.4 25 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 413 4 3 6 3.1 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@H](C3CCCCC3)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4745933 180005 None 0 Human Functional pIC50 = 5.4 5.4 25 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 413 4 3 6 3.1 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@H](C3CCCCC3)N2)c1O 10.1021/acsmedchemlett.1c00113
172465121 196772 None 0 Human Functional pIC50 = 5.4 5.4 4 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 352 7 3 7 2.1 OCCCNc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5431899 196772 None 0 Human Functional pIC50 = 5.4 5.4 4 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 352 7 3 7 2.1 OCCCNc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
172445880 195146 None 0 Human Functional pIC50 = 5.4 5.4 5 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 336 6 3 7 1.4 C[C@H](CO)Nc1nc(OCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5397416 195146 None 0 Human Functional pIC50 = 5.4 5.4 5 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 336 6 3 7 1.4 C[C@H](CO)Nc1nc(OCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
122187255 123071 None 0 Human Functional pIC50 = 6.4 6.4 10 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 379 6 3 5 1.8 CN(Cc1cccc(B(O)O)c1)c1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
CHEMBL3609003 123071 None 0 Human Functional pIC50 = 6.4 6.4 10 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 379 6 3 5 1.8 CN(Cc1cccc(B(O)O)c1)c1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
24960030 104691 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 366 5 1 7 3.9 Cc1cc(SCc2cc(O)n3nc(Cc4ccccc4)nc3n2)c(C)o1 10.1016/j.bmcl.2013.11.074
CHEMBL3104903 104691 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 366 5 1 7 3.9 Cc1cc(SCc2cc(O)n3nc(Cc4ccccc4)nc3n2)c(C)o1 10.1016/j.bmcl.2013.11.074
24959669 104697 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 438 6 1 6 5.7 Cc1ccc(-c2cccc(SCc3cc(O)n4nc(Cc5ccccc5)nc4n3)c2)cc1 10.1016/j.bmcl.2013.11.074
CHEMBL3104909 104697 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 438 6 1 6 5.7 Cc1ccc(-c2cccc(SCc3cc(O)n4nc(Cc5ccccc5)nc4n3)c2)cc1 10.1016/j.bmcl.2013.11.074
24952761 104715 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 318 3 1 6 2.9 N#Cc1cnn2c(O)cc(CSc3cccc(F)c3F)nc12 10.1016/j.bmcl.2013.11.074
CHEMBL3105086 104715 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 318 3 1 6 2.9 N#Cc1cnn2c(O)cc(CSc3cccc(F)c3F)nc12 10.1016/j.bmcl.2013.11.074
172447063 195472 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 294 6 3 7 1.4 C[C@H](CO)Nc1nc(SCC2CCC2)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5404366 195472 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 294 6 3 7 1.4 C[C@H](CO)Nc1nc(SCC2CCC2)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5080880 217198 None 0 Human Functional pIC50 = 6.4 6.4 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None Cc1c(F)cccc1NC(=O)Nc1ccc2c(c1O)S(=O)(=O)CCC2=O 10.1021/acs.jmedchem.1c01219
172449877 196054 None 0 Human Functional pIC50 = 5.4 5.4 2 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 338 6 3 7 1.7 OCCNc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5415857 196054 None 0 Human Functional pIC50 = 5.4 5.4 2 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 338 6 3 7 1.7 OCCNc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5081049 217204 None 0 Human Functional pIC50 = 7.4 7.4 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccc2c(c1O)S(=O)(=O)CCC2)Nc1cccc(F)c1Cl 10.1021/acs.jmedchem.1c01219
162650232 180106 None 0 Human Functional pIC50 = 7.4 7.4 1288 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 387 6 3 6 2.7 CCCCC1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
CHEMBL4747035 180106 None 0 Human Functional pIC50 = 7.4 7.4 1288 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 387 6 3 6 2.7 CCCCC1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
135907792 113015 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 293 3 1 5 2.9 Cc1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
CHEMBL3310779 113015 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 293 3 1 5 2.9 Cc1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
122187269 123085 None 0 Human Functional pIC50 = 5.4 5.4 -2 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 458 8 3 8 1.5 O=C(Nc1ccc(F)cc1)c1cnc(N(Cc2ccccn2)Cc2ccc(B(O)O)cn2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3609019 123085 None 0 Human Functional pIC50 = 5.4 5.4 -2 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 458 8 3 8 1.5 O=C(Nc1ccc(F)cc1)c1cnc(N(Cc2ccccn2)Cc2ccc(B(O)O)cn2)nc1 10.1016/j.bmcl.2015.07.090
172449533 195622 None 0 Human Functional pIC50 = 6.4 6.4 5 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 366 6 3 7 2.5 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5407300 195622 None 0 Human Functional pIC50 = 6.4 6.4 5 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 366 6 3 7 2.5 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
172443106 194986 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 336 5 2 6 3.1 CC(C)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5394443 194986 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 336 5 2 6 3.1 CC(C)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5094410 217981 None 0 Human Functional pIC50 = 5.4 5.4 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccccc1C(F)(F)F)Nc1ccc2c(c1O)S(=O)(=O)CCC2 10.1021/acs.jmedchem.1c01219
44626319 200877 None 0 Human Functional pIC50 = 7.3 7.3 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 346 7 3 7 1.1 CCN(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2009.08.014
CHEMBL577075 200877 None 0 Human Functional pIC50 = 7.3 7.3 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 346 7 3 7 1.1 CCN(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2009.08.014
44432391 147854 None 0 Human Functional pIC50 = 6.3 6.3 75 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 375 1 3 5 3.4 O=S1(=O)N=C(Nc2cccc(F)c2Cl)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL393253 147854 None 0 Human Functional pIC50 = 6.3 6.3 75 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 375 1 3 5 3.4 O=S1(=O)N=C(Nc2cccc(F)c2Cl)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
135907780 113012 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 399 5 1 6 4.6 COc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1C 10.1016/j.bmcl.2014.06.011
CHEMBL3310776 113012 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 399 5 1 6 4.6 COc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1C 10.1016/j.bmcl.2014.06.011
24958934 104708 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 398 6 1 6 4.2 Oc1cc(CSc2cccc(F)c2F)nc2nc(CCc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3105079 104708 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 398 6 1 6 4.2 Oc1cc(CSc2cccc(F)c2F)nc2nc(CCc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
162667020 182564 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 345 3 3 6 1.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@@H](C)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4786309 182564 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 345 3 3 6 1.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@@H](C)N2)c1O 10.1021/acsmedchemlett.1c00113
135907772 113014 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 369 4 1 5 4.6 Cc1cccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)c1 10.1016/j.bmcl.2014.06.011
CHEMBL3310778 113014 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 369 4 1 5 4.6 Cc1cccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)c1 10.1016/j.bmcl.2014.06.011
155531736 171777 None 0 Human Functional pIC50 = 7.3 7.3 60 2
Antagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 395 5 3 6 2.6 O=C(c1cccc(Nc2c(NC3C[C@@H]4CC[C@H]3C4)c(=O)c2=O)c1O)N1CCCC1 10.1016/j.ejmech.2019.111853
CHEMBL4466314 171777 None 0 Human Functional pIC50 = 7.3 7.3 60 2
Antagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 395 5 3 6 2.6 O=C(c1cccc(Nc2c(NC3C[C@@H]4CC[C@H]3C4)c(=O)c2=O)c1O)N1CCCC1 10.1016/j.ejmech.2019.111853
9927727 103979 None 0 Human Functional pIC50 = 7.3 7.3 - 1
Antagonist activity at CXCR2 in human neutrophils assessed as reduction in GROalpha stimulated intracellular calcium mobilisation by FLIPR assayAntagonist activity at CXCR2 in human neutrophils assessed as reduction in GROalpha stimulated intracellular calcium mobilisation by FLIPR assay
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2ccccc2Cl)nn1Cc1cccc(Cl)c1 10.1016/j.ejmech.2019.111853
CHEMBL309253 103979 None 0 Human Functional pIC50 = 7.3 7.3 - 1
Antagonist activity at CXCR2 in human neutrophils assessed as reduction in GROalpha stimulated intracellular calcium mobilisation by FLIPR assayAntagonist activity at CXCR2 in human neutrophils assessed as reduction in GROalpha stimulated intracellular calcium mobilisation by FLIPR assay
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2ccccc2Cl)nn1Cc1cccc(Cl)c1 10.1016/j.ejmech.2019.111853
10200589 94993 None 0 Human Functional pIC50 = 7.3 7.3 2 2
Inhibition of CXCL1-induced human neutrophil chemotaxisInhibition of CXCL1-induced human neutrophil chemotaxis
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
CHEMBL254370 94993 None 0 Human Functional pIC50 = 7.3 7.3 2 2
Inhibition of CXCL1-induced human neutrophil chemotaxisInhibition of CXCL1-induced human neutrophil chemotaxis
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
136074342 113027 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 297 4 1 5 3.8 CC(Sc1nc(O)c(C#N)c(C2CC2)n1)c1ccccc1 10.1016/j.bmcl.2014.06.011
CHEMBL3310790 113027 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 297 4 1 5 3.8 CC(Sc1nc(O)c(C#N)c(C2CC2)n1)c1ccccc1 10.1016/j.bmcl.2014.06.011
24959664 104698 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 416 5 1 6 5.0 Oc1cc(CSc2ccc(Cl)cc2Cl)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104910 104698 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 416 5 1 6 5.0 Oc1cc(CSc2ccc(Cl)cc2Cl)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
172463086 196614 None 0 Human Functional pIC50 = 5.3 5.3 -4 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 330 7 3 7 1.9 C[C@H](CO)Nc1nc(SCCc2ccccc2)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5427907 196614 None 0 Human Functional pIC50 = 5.3 5.3 -4 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 330 7 3 7 1.9 C[C@H](CO)Nc1nc(SCCc2ccccc2)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
122187264 123081 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 457 8 3 7 2.2 O=C(Nc1ccc(F)cc1)c1ccc(N(Cc2ccccn2)Cc2ccc(B(O)O)cn2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3609014 123081 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 457 8 3 7 2.2 O=C(Nc1ccc(F)cc1)c1ccc(N(Cc2ccccn2)Cc2ccc(B(O)O)cn2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL5076154 216904 None 0 Human Functional pIC50 = 7.3 7.3 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccccc1Br)Nc1ccc2c(c1O)S(=O)(=O)CC=C2 10.1021/acs.jmedchem.1c01219
11304851 154695 None 0 Human Functional pIC50 = 6.3 6.3 46 4
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 426 4 3 8 3.7 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Oc1ccccc1)N2 10.1016/j.bmcl.2007.05.011
CHEMBL399203 154695 None 0 Human Functional pIC50 = 6.3 6.3 46 4
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 426 4 3 8 3.7 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Oc1ccccc1)N2 10.1016/j.bmcl.2007.05.011
135907779 113018 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 347 4 1 5 4.3 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CCCC1 10.1016/j.bmcl.2014.06.011
CHEMBL3310781 113018 None 0 Human Functional pIC50 = 5.3 5.3 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 347 4 1 5 4.3 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CCCC1 10.1016/j.bmcl.2014.06.011
24780598 1316 None 38 Human Functional pIC50 = 8.3 8.3 85 2
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl nan
8500 1316 None 38 Human Functional pIC50 = 8.3 8.3 85 2
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl nan
CHEMBL3039531 1316 None 38 Human Functional pIC50 = 8.3 8.3 85 2
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl nan
DB11922 1316 None 38 Human Functional pIC50 = 8.3 8.3 85 2
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl nan
57649039 142629 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 423 5 4 5 3.4 CCc1ccccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CCNC2)c1O nan
CHEMBL3890888 142629 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 423 5 4 5 3.4 CCc1ccccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CCNC2)c1O nan
57649037 142793 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 444 4 4 6 3.3 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O nan
CHEMBL3892206 142793 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 444 4 4 6 3.3 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O nan
50996598 142858 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 489 4 4 7 3.5 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O)Nc1cccc2c1OC(F)(F)O2 nan
CHEMBL3892666 142858 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 489 4 4 7 3.5 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O)Nc1cccc2c1OC(F)(F)O2 nan
50996778 143227 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 533 5 3 6 4.9 CCOC(=O)N1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 nan
CHEMBL3895808 143227 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 533 5 3 6 4.9 CCOC(=O)N1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 nan
50996594 143871 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 413 4 4 5 2.9 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CNC2)c1O nan
CHEMBL3901031 143871 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 413 4 4 5 2.9 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CNC2)c1O nan
50995535 144536 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 461 4 4 5 4.0 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O)Nc1cccc(F)c1Cl nan
CHEMBL3906495 144536 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 461 4 4 5 4.0 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O)Nc1cccc(F)c1Cl nan
57649033 145024 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 487 6 4 6 4.6 O=C(Nc1ccccc1Oc1ccccc1)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCNC2)c1O nan
CHEMBL3910320 145024 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 487 6 4 6 4.6 O=C(Nc1ccccc1Oc1ccccc1)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCNC2)c1O nan
50996421 145078 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 461 5 4 5 3.9 O=C(Nc1ccc(Cl)c(S(=O)(=O)CC2CCNC2)c1O)Nc1cccc(F)c1Cl nan
CHEMBL3910854 145078 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 461 5 4 5 3.9 O=C(Nc1ccc(Cl)c(S(=O)(=O)CC2CCNC2)c1O)Nc1cccc(F)c1Cl nan
57649040 145283 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 527 6 4 6 5.5 O=C(Nc1ccccc1Oc1ccccc1)Nc1ccc(Cl)c(S(=O)(=O)C2C[C@@H]3CC[C@H](C2)N3)c1O nan
CHEMBL3912422 145283 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 527 6 4 6 5.5 O=C(Nc1ccccc1Oc1ccccc1)Nc1ccc(Cl)c(S(=O)(=O)C2C[C@@H]3CC[C@H](C2)N3)c1O nan
57649042 145365 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 447 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCNC2)c1O)Nc1cccc(F)c1Cl nan
CHEMBL3912983 145365 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 447 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCNC2)c1O)Nc1cccc(F)c1Cl nan
57649022 145635 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 479 5 4 6 3.7 O=C(Nc1ccccc1OC(F)(F)F)Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CCNC2)c1O nan
CHEMBL3915083 145635 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 479 5 4 6 3.7 O=C(Nc1ccccc1OC(F)(F)F)Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CCNC2)c1O nan
50996424 145797 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 477 4 4 5 4.5 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O)Nc1cccc(Cl)c1Cl nan
CHEMBL3916281 145797 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 477 4 4 5 4.5 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O)Nc1cccc(Cl)c1Cl nan
50996422 147144 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 437 5 4 5 3.8 CCc1ccccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O nan
CHEMBL3926993 147144 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 437 5 4 5 3.8 CCc1ccccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O nan
50996595 147269 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 493 5 4 6 4.1 O=C(Nc1ccccc1OC(F)(F)F)Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O nan
CHEMBL3927944 147269 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 493 5 4 6 4.1 O=C(Nc1ccccc1OC(F)(F)F)Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O nan
16755746 147477 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 444 4 4 6 3.3 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O nan
CHEMBL3929680 147477 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 444 4 4 6 3.3 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O nan
50996596 147619 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 437 5 4 5 3.8 CCc1ccccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O nan
CHEMBL3930695 147619 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 437 5 4 5 3.8 CCc1ccccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O nan
50997127 148033 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 513 5 3 6 4.5 CCOC(=O)N1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3C)c2O)CC1 nan
CHEMBL3933806 148033 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 513 5 3 6 4.5 CCOC(=O)N1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3C)c2O)CC1 nan
57649024 148358 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 487 4 4 5 4.5 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2C[C@@H]3CC[C@H](C2)N3)c1O)Nc1cccc(F)c1Cl nan
CHEMBL3936567 148358 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 487 4 4 5 4.5 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2C[C@@H]3CC[C@H](C2)N3)c1O)Nc1cccc(F)c1Cl nan
58994916 149034 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 481 4 3 5 4.5 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@@H]3CC[C@H](C2)N3C)c1O nan
CHEMBL3941989 149034 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 481 4 3 5 4.5 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@@H]3CC[C@H](C2)N3C)c1O nan
50996245 149542 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 441 5 4 5 3.5 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)CC2CCNC2)c1O nan
CHEMBL3946021 149542 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 441 5 4 5 3.5 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)CC2CCNC2)c1O nan
50996777 149834 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 501 6 4 6 5.0 O=C(Nc1ccccc1Oc1ccccc1)Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O nan
CHEMBL3948111 149834 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 501 6 4 6 5.0 O=C(Nc1ccccc1Oc1ccccc1)Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O nan
57649029 149928 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 470 4 4 6 3.8 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)C2C[C@@H]3CC[C@H](C2)N3)c1O nan
CHEMBL3948929 149928 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 470 4 4 6 3.8 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)C2C[C@@H]3CC[C@H](C2)N3)c1O nan
24780599 150050 None 1 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 444 4 4 6 3.3 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCCNC2)c1O nan
CHEMBL3949893 150050 None 1 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 444 4 4 6 3.3 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCCNC2)c1O nan
57649043 150087 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 475 4 4 7 3.1 O=C(Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CCNC2)c1O)Nc1cccc2c1OC(F)(F)O2 nan
CHEMBL3950195 150087 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 475 4 4 7 3.1 O=C(Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CCNC2)c1O)Nc1cccc2c1OC(F)(F)O2 nan
50996243 150103 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 493 6 4 6 4.0 O=C(Nc1ccccc1OC(F)(F)F)Nc1ccc(Cl)c(S(=O)(=O)CC2CCNC2)c1O nan
CHEMBL3950351 150103 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 493 6 4 6 4.0 O=C(Nc1ccccc1OC(F)(F)F)Nc1ccc(Cl)c(S(=O)(=O)CC2CCNC2)c1O nan
50996423 150221 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 493 5 4 6 4.1 O=C(Nc1ccccc1OC(F)(F)F)Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O nan
CHEMBL3951311 150221 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 493 5 4 6 4.1 O=C(Nc1ccccc1OC(F)(F)F)Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O nan
50996246 150375 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 433 4 4 5 3.2 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CNC2)c1O)Nc1cccc(F)c1Cl nan
CHEMBL3952713 150375 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 433 4 4 5 3.2 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CNC2)c1O)Nc1cccc(F)c1Cl nan
57649026 150402 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 467 4 4 5 4.2 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2C[C@@H]3CC[C@H](C2)N3)c1O nan
CHEMBL3952903 150402 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 467 4 4 5 4.2 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2C[C@@H]3CC[C@H](C2)N3)c1O nan
50996244 150424 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 416 4 4 6 2.5 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)C2CNC2)c1O nan
CHEMBL3953055 150424 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 416 4 4 6 2.5 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)C2CNC2)c1O nan
50995536 150522 None 5 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 441 4 4 5 3.7 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O nan
CHEMBL3953988 150522 None 5 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 441 4 4 5 3.7 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O nan
50996776 150987 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 573 7 3 7 5.9 CCOC(=O)N1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3ccccc3Oc3ccccc3)c2O)CC1 nan
CHEMBL3957549 150987 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 573 7 3 7 5.9 CCOC(=O)N1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3ccccc3Oc3ccccc3)c2O)CC1 nan
24780600 151311 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 461 4 4 5 4.0 O=C(Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCCNC2)c1O)Nc1cccc(F)c1Cl nan
CHEMBL3960024 151311 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 461 4 4 5 4.0 O=C(Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCCNC2)c1O)Nc1cccc(F)c1Cl nan
57649038 152045 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 447 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CCNC2)c1O)Nc1cccc(F)c1Cl nan
CHEMBL3966527 152045 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 447 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CCNC2)c1O)Nc1cccc(F)c1Cl nan
50996425 152182 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 461 4 4 5 4.0 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O)Nc1cccc(F)c1Cl nan
CHEMBL3967642 152182 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 461 4 4 5 4.0 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O)Nc1cccc(F)c1Cl nan
50996426 152472 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 441 4 4 5 3.7 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O nan
CHEMBL3970321 152472 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 441 4 4 5 3.7 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O nan
57649032 152596 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 427 4 4 5 3.3 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCNC2)c1O nan
CHEMBL3971309 152596 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 427 4 4 5 3.3 Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCNC2)c1O nan
57649036 152907 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 430 4 4 6 2.9 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCNC2)c1O nan
CHEMBL3973880 152907 None 0 Human Functional pIC50 = 8.3 8.3 - 1
Antagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assayAntagonist activity at CXCR2 (unknown origin) expressed in CHO-K1 cells co-expressing Galpha-16 assessed as inhibition of IL8-induced calcium mobilization measured after 10 mins by Fluo-4AM dye based FLIPR assay
ChEMBL 430 4 4 6 2.9 O=C(Nc1cccnc1Cl)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCNC2)c1O nan
8497 2737 None 41 Human Functional pIC50 = 8.3 8.3 1 4
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.ejmech.2023.115240
9865554 2737 None 41 Human Functional pIC50 = 8.3 8.3 1 4
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.ejmech.2023.115240
CHEMBL216981 2737 None 41 Human Functional pIC50 = 8.3 8.3 1 4
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.ejmech.2023.115240
24879232 155445 None 1 Human Functional pIC50 = 8.3 8.3 43 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 428 7 2 4 3.1 CN(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL403313 155445 None 1 Human Functional pIC50 = 8.3 8.3 43 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 428 7 2 4 3.1 CN(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
135964204 113026 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 283 4 1 5 3.2 N#Cc1c(O)nc(SCc2ccccc2)nc1C1CC1 10.1016/j.bmcl.2014.06.011
CHEMBL3310789 113026 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 283 4 1 5 3.2 N#Cc1c(O)nc(SCc2ccccc2)nc1C1CC1 10.1016/j.bmcl.2014.06.011
24958936 104706 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 376 4 1 6 4.4 Oc1cc(CSc2cccc(F)c2F)nc2nc(C3CCCCC3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3105077 104706 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 376 4 1 6 4.4 Oc1cc(CSc2cccc(F)c2F)nc2nc(C3CCCCC3)nn12 10.1016/j.bmcl.2013.11.074
91937330 114992 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 365 6 3 6 1.7 O=C(Nc1ccncc1)c1ccc(SCc2ccccc2B(O)O)nc1 10.1021/jm500827t
CHEMBL3342317 114992 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 365 6 3 6 1.7 O=C(Nc1ccncc1)c1ccc(SCc2ccccc2B(O)O)nc1 10.1021/jm500827t
11371755 88005 None 0 Human Functional pIC50 = 6.3 6.3 109 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 357 1 3 5 3.3 O=S1(=O)N=C(Nc2ccccc2Cl)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL234186 88005 None 0 Human Functional pIC50 = 6.3 6.3 109 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 357 1 3 5 3.3 O=S1(=O)N=C(Nc2ccccc2Cl)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
172441907 194981 None 0 Human Functional pIC50 = 5.3 5.3 -3 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 336 7 3 7 2.6 C[C@H](CO)Nc1nc(SCCC2CCCCC2)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5394402 194981 None 0 Human Functional pIC50 = 5.3 5.3 -3 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 336 7 3 7 2.6 C[C@H](CO)Nc1nc(SCCC2CCCCC2)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
45485757 199966 None 0 Human Functional pIC50 = 7.3 7.3 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 394 7 3 7 2.3 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.08.014
CHEMBL570042 199966 None 0 Human Functional pIC50 = 7.3 7.3 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 394 7 3 7 2.3 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.08.014
162652658 180545 None 0 Human Functional pIC50 = 7.3 7.3 407 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 441 4 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccccc3Cl)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4752486 180545 None 0 Human Functional pIC50 = 7.3 7.3 407 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 441 4 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccccc3Cl)N2)c1O 10.1021/acsmedchemlett.1c00113
46896680 114981 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 332 5 1 4 3.7 O=C(Nc1ccc(F)cc1)c1ccc(SCC2CCCO2)nc1 10.1021/jm500827t
CHEMBL3342282 114981 None 0 Human Functional pIC50 = 6.3 6.3 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 332 5 1 4 3.7 O=C(Nc1ccc(F)cc1)c1ccc(SCC2CCCO2)nc1 10.1021/jm500827t
44447944 155718 None 0 Rabbit Functional pIC50 = 5.2 5.2 -38 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 453 5 3 3 3.5 CS(=O)(=O)NC(=O)NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL404661 155718 None 0 Rabbit Functional pIC50 = 5.2 5.2 -38 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 453 5 3 3 3.5 CS(=O)(=O)NC(=O)NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL5075579 216872 None 0 Human Functional pIC50 = 5.2 5.2 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccc(Cl)cc1Cl)Nc1ccc2c(c1O)S(=O)(=O)CC=C2 10.1021/acs.jmedchem.1c01219
135949064 113024 None 1 Human Functional pIC50 = 8.2 8.2 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 349 5 2 6 2.7 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1[C@H]1C[C@@H]1CO 10.1016/j.bmcl.2014.06.011
CHEMBL3310787 113024 None 1 Human Functional pIC50 = 8.2 8.2 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 349 5 2 6 2.7 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1[C@H]1C[C@@H]1CO 10.1016/j.bmcl.2014.06.011
162667668 182540 None 1 Human Functional pIC50 = 8.2 8.2 776 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 407 4 3 6 2.9 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccccc3)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4786074 182540 None 1 Human Functional pIC50 = 8.2 8.2 776 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 407 4 3 6 2.9 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccccc3)N2)c1O 10.1021/acsmedchemlett.1c00113
46897162 3716 None 15 Human Functional pIC50 = 7.2 7.2 6 2
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CVCL8-induced [35S]GTPgammaS binding after 60 minsAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CVCL8-induced [35S]GTPgammaS binding after 60 mins
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1021/jm500827t
8501 3716 None 15 Human Functional pIC50 = 7.2 7.2 6 2
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CVCL8-induced [35S]GTPgammaS binding after 60 minsAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CVCL8-induced [35S]GTPgammaS binding after 60 mins
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1021/jm500827t
CHEMBL3342269 3716 None 15 Human Functional pIC50 = 7.2 7.2 6 2
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CVCL8-induced [35S]GTPgammaS binding after 60 minsAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CVCL8-induced [35S]GTPgammaS binding after 60 mins
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1021/jm500827t
11750288 169676 None 0 Human Functional pIC50 = 6.2 6.2 25 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 412 2 3 7 2.6 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Br)N2 10.1016/j.bmcl.2007.05.011
CHEMBL443583 169676 None 0 Human Functional pIC50 = 6.2 6.2 25 2
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 412 2 3 7 2.6 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Br)N2 10.1016/j.bmcl.2007.05.011
23642171 126882 None 0 Human Functional pIC50 = 6.2 6.2 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 397 8 2 4 4.5 CC(C)(NC(=O)c1ccc2ccsc2c1OCCCc1ccccc1)C(=O)O nan
CHEMBL3654437 126882 None 0 Human Functional pIC50 = 6.2 6.2 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 397 8 2 4 4.5 CC(C)(NC(=O)c1ccc2ccsc2c1OCCCc1ccccc1)C(=O)O nan
57831224 125909 None 0 Human Functional pIC50 = 5.2 5.2 - 1
Calicum Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes).Calicum Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes).
ChEMBL 523 7 2 5 5.5 O=C(NC1(C(=O)O)CCOCC1)c1cc(F)c2ccccc2c1OCc1ccc(SC(F)(F)F)cc1 nan
CHEMBL3648348 125909 None 0 Human Functional pIC50 = 5.2 5.2 - 1
Calicum Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes).Calicum Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes).
ChEMBL 523 7 2 5 5.5 O=C(NC1(C(=O)O)CCOCC1)c1cc(F)c2ccccc2c1OCc1ccc(SC(F)(F)F)cc1 nan
45485788 199826 None 0 Human Functional pIC50 = 5.2 5.2 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 426 8 3 7 2.4 CCN(Cc1ccc(F)cc1)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2009.08.014
CHEMBL569210 199826 None 0 Human Functional pIC50 = 5.2 5.2 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 426 8 3 7 2.4 CCN(Cc1ccc(F)cc1)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2009.08.014
136074343 113028 None 0 Human Functional pIC50 = 5.2 5.2 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 311 4 1 5 4.0 CC(C)(Sc1nc(O)c(C#N)c(C2CC2)n1)c1ccccc1 10.1016/j.bmcl.2014.06.011
CHEMBL3310791 113028 None 0 Human Functional pIC50 = 5.2 5.2 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 311 4 1 5 4.0 CC(C)(Sc1nc(O)c(C#N)c(C2CC2)n1)c1ccccc1 10.1016/j.bmcl.2014.06.011
136165388 196848 None 17 Human Functional pIC50 = 5.2 5.2 1 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 475 4 3 7 3.1 Cc1ccc([C@H](NC2=NS(=O)(=O)N=C2Nc2ccc(C)c(C(=O)N(C)C)c2O)C(C)(C)C)o1 10.1016/j.ejmech.2023.115240
CHEMBL5433301 196848 None 17 Human Functional pIC50 = 5.2 5.2 1 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 475 4 3 7 3.1 Cc1ccc([C@H](NC2=NS(=O)(=O)N=C2Nc2ccc(C)c(C(=O)N(C)C)c2O)C(C)(C)C)o1 10.1016/j.ejmech.2023.115240
24959665 104696 None 0 Human Functional pIC50 = 5.2 5.2 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 432 6 1 7 4.6 Oc1cc(CSc2cccc(OC(F)(F)F)c2)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104908 104696 None 0 Human Functional pIC50 = 5.2 5.2 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 432 6 1 7 4.6 Oc1cc(CSc2cccc(OC(F)(F)F)c2)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
122187271 123086 None 0 Human Functional pIC50 = 6.2 6.2 -1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 447 8 3 8 1.7 O=C(Nc1ccc(F)cc1)c1cnc(N(Cc2ccc(B(O)O)cn2)Cc2ccco2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3609021 123086 None 0 Human Functional pIC50 = 6.2 6.2 -1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 447 8 3 8 1.7 O=C(Nc1ccc(F)cc1)c1cnc(N(Cc2ccc(B(O)O)cn2)Cc2ccco2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL5078788 217074 None 0 Human Functional pIC50 = 7.2 7.2 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=C(Nc1ccccc1Cl)Nc1ccc2c(c1O)S(=O)(=O)CC=C2 10.1021/acs.jmedchem.1c01219
163322284 190266 None 3 Human Functional pIC50 = 6.2 6.2 14 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 352 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5173775 190266 None 3 Human Functional pIC50 = 6.2 6.2 14 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 352 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
162673727 183089 None 0 Human Functional pIC50 = 7.2 7.2 218 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 373 5 3 6 2.3 CCCC1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
CHEMBL4793352 183089 None 0 Human Functional pIC50 = 7.2 7.2 218 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 373 5 3 6 2.3 CCCC1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
136074341 113025 None 0 Human Functional pIC50 = 8.2 8.2 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 362 5 2 6 2.2 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1[C@H]1C[C@@H]1C(N)=O 10.1016/j.bmcl.2014.06.011
CHEMBL3310788 113025 None 0 Human Functional pIC50 = 8.2 8.2 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 362 5 2 6 2.2 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1[C@H]1C[C@@H]1C(N)=O 10.1016/j.bmcl.2014.06.011
44447923 95520 None 0 Human Functional pIC50 = 7.2 7.2 38 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 453 6 2 4 4.1 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)C(F)(F)F)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL257178 95520 None 0 Human Functional pIC50 = 7.2 7.2 38 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 453 6 2 4 4.1 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)C(F)(F)F)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL5081756 217252 None 0 Human Functional pIC50 = 6.2 6.2 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=c1c(Nc2ccc3c(c2O)S(=O)(=O)CC=C3)c(Nc2cccc(F)c2Cl)c1=O 10.1021/acs.jmedchem.1c01219
24879232 155445 None 1 Rabbit Functional pIC50 = 6.2 6.2 -43 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 428 7 2 4 3.1 CN(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL403313 155445 None 1 Rabbit Functional pIC50 = 6.2 6.2 -43 2
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 428 7 2 4 3.1 CN(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
135907759 113010 None 1 Human Functional pIC50 = 6.2 6.2 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 385 5 1 6 4.3 COc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1 10.1016/j.bmcl.2014.06.011
CHEMBL3310774 113010 None 1 Human Functional pIC50 = 6.2 6.2 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 385 5 1 6 4.3 COc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1 10.1016/j.bmcl.2014.06.011
122187254 123070 None 0 Human Functional pIC50 = 6.1 6.1 -1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 365 6 4 5 1.8 O=C(Nc1ccc(F)cc1)c1ccc(NCc2cccc(B(O)O)c2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3609002 123070 None 0 Human Functional pIC50 = 6.1 6.1 -1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 365 6 4 5 1.8 O=C(Nc1ccc(F)cc1)c1ccc(NCc2cccc(B(O)O)c2)nc1 10.1016/j.bmcl.2015.07.090
135907766 113008 None 0 Human Functional pIC50 = 5.1 5.1 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 389 4 1 5 4.9 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1-c1ccc(Cl)cc1 10.1016/j.bmcl.2014.06.011
CHEMBL3310772 113008 None 0 Human Functional pIC50 = 5.1 5.1 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 389 4 1 5 4.9 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1-c1ccc(Cl)cc1 10.1016/j.bmcl.2014.06.011
45485784 201494 None 0 Human Functional pIC50 = 7.1 7.1 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 395 7 3 8 1.7 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccn1 10.1016/j.bmcl.2009.08.014
CHEMBL585928 201494 None 0 Human Functional pIC50 = 7.1 7.1 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 395 7 3 8 1.7 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccn1 10.1016/j.bmcl.2009.08.014
46897356 114987 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 396 6 1 5 4.6 COC(=O)c1ccccc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1021/jm500827t
CHEMBL3342310 114987 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 396 6 1 5 4.6 COC(=O)c1ccccc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1021/jm500827t
1105988 33212 None 12 Human Functional pIC50 = 5.1 5.1 - 1
Antagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assayAntagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assay
ChEMBL 435 4 1 4 6.2 CC(=O)c1c(C)oc2c1cc(NS(=O)(=O)c1ccc(C(C)(C)C)cc1)c1ccccc12 10.1016/j.ejmech.2023.115175
CHEMBL1417864 33212 None 12 Human Functional pIC50 = 5.1 5.1 - 1
Antagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assayAntagonist activity at CXCL8-activated CXCR2 (unknown origin) overexpressed in human U2OS cells preincubated for 30 mins followed by CXCL8 addition measured after 5 hrs by beta-lactamase reporter gene assay
ChEMBL 435 4 1 4 6.2 CC(=O)c1c(C)oc2c1cc(NS(=O)(=O)c1ccc(C(C)(C)C)cc1)c1ccccc12 10.1016/j.ejmech.2023.115175
168272758 190639 None 0 Human Functional pIC50 = 5.1 5.1 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]ccc12 10.1016/j.ejmech.2023.115240
CHEMBL5179622 190639 None 0 Human Functional pIC50 = 5.1 5.1 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]ccc12 10.1016/j.ejmech.2023.115240
1163244 181802 None 2 Human Functional pIC50 = 5.1 5.1 - 1
Inhibition of CXCR2 (unknown origin) expressed in HEK293T cells cotransfected with GFP-p22F assessed as reduction in IL-8-induced cAMP incubated for 10 mins followed by IL-8 stimulation and measured after 10 mins by luminescence based assayInhibition of CXCR2 (unknown origin) expressed in HEK293T cells cotransfected with GFP-p22F assessed as reduction in IL-8-induced cAMP incubated for 10 mins followed by IL-8 stimulation and measured after 10 mins by luminescence based assay
ChEMBL 382 2 0 7 4.3 CSc1nnc2n(-c3ccccc3)c(=O)c3c4c(sc3n12)CCC[C@H]4C 10.1016/j.ejmech.2020.112387
CHEMBL4776704 181802 None 2 Human Functional pIC50 = 5.1 5.1 - 1
Inhibition of CXCR2 (unknown origin) expressed in HEK293T cells cotransfected with GFP-p22F assessed as reduction in IL-8-induced cAMP incubated for 10 mins followed by IL-8 stimulation and measured after 10 mins by luminescence based assayInhibition of CXCR2 (unknown origin) expressed in HEK293T cells cotransfected with GFP-p22F assessed as reduction in IL-8-induced cAMP incubated for 10 mins followed by IL-8 stimulation and measured after 10 mins by luminescence based assay
ChEMBL 382 2 0 7 4.3 CSc1nnc2n(-c3ccccc3)c(=O)c3c4c(sc3n12)CCC[C@H]4C 10.1016/j.ejmech.2020.112387
59446384 114995 None 0 Human Functional pIC50 = 7.1 7.1 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 473 8 2 6 3.4 O=C(c1ccc(SCc2ccccc2B(O)O)nc1)N(Cc1ccccn1)c1ccc(F)cc1 10.1021/jm500827t
CHEMBL3342320 114995 None 0 Human Functional pIC50 = 7.1 7.1 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 473 8 2 6 3.4 O=C(c1ccc(SCc2ccccc2B(O)O)nc1)N(Cc1ccccn1)c1ccc(F)cc1 10.1021/jm500827t
CHEMBL5070965 216738 None 0 Human Functional pIC50 = 7.1 7.1 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=c1c(Nc2ccccc2Br)c(Nc2ccc3c(c2O)S(=O)(=O)CC=C3)c1=O 10.1021/acs.jmedchem.1c01219
135907763 113013 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 371 4 2 6 4.0 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1-c1ccc(O)cc1 10.1016/j.bmcl.2014.06.011
CHEMBL3310777 113013 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 371 4 2 6 4.0 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1-c1ccc(O)cc1 10.1016/j.bmcl.2014.06.011
990571 172580 None 0 Human Functional pIC50 = 5.1 5.1 - 1
Antagonist activity at GFP-tagged CXCR2 (unknown origin) expressed in 293T cells assessed as suppression of IL-8-induced inhibition of forskolin-stimulated cAMP accumulation preincubated for 10 mins followed by IL-8 addition and measured after 10 mins by cAMP assayAntagonist activity at GFP-tagged CXCR2 (unknown origin) expressed in 293T cells assessed as suppression of IL-8-induced inhibition of forskolin-stimulated cAMP accumulation preincubated for 10 mins followed by IL-8 addition and measured after 10 mins by cAMP assay
ChEMBL 396 3 0 7 4.6 CCSc1nnc2n(-c3ccccc3)c(=O)c3c4c(sc3n12)CCC[C@H]4C 10.1016/j.ejmech.2019.111853
CHEMBL4482876 172580 None 0 Human Functional pIC50 = 5.1 5.1 - 1
Antagonist activity at GFP-tagged CXCR2 (unknown origin) expressed in 293T cells assessed as suppression of IL-8-induced inhibition of forskolin-stimulated cAMP accumulation preincubated for 10 mins followed by IL-8 addition and measured after 10 mins by cAMP assayAntagonist activity at GFP-tagged CXCR2 (unknown origin) expressed in 293T cells assessed as suppression of IL-8-induced inhibition of forskolin-stimulated cAMP accumulation preincubated for 10 mins followed by IL-8 addition and measured after 10 mins by cAMP assay
ChEMBL 396 3 0 7 4.6 CCSc1nnc2n(-c3ccccc3)c(=O)c3c4c(sc3n12)CCC[C@H]4C 10.1016/j.ejmech.2019.111853
24959666 104695 None 0 Human Functional pIC50 = 5.1 5.1 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 410 5 1 6 5.0 Cc1cc(SCc2cc(O)n3nc(Cc4ccccc4)nc3n2)c(C)cc1Cl 10.1016/j.bmcl.2013.11.074
CHEMBL3104907 104695 None 0 Human Functional pIC50 = 5.1 5.1 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 410 5 1 6 5.0 Cc1cc(SCc2cc(O)n3nc(Cc4ccccc4)nc3n2)c(C)cc1Cl 10.1016/j.bmcl.2013.11.074
11440492 152731 None 0 Human Functional pIC50 = 7.1 7.1 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.ejmech.2023.115240
CHEMBL397237 152731 None 0 Human Functional pIC50 = 7.1 7.1 - 1
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.ejmech.2023.115240
24970254 126883 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 417 8 2 5 4.1 CC(C)(NC(=O)c1ccc2ccsc2c1OCCOc1ccc(F)cc1)C(=O)O nan
CHEMBL3654438 126883 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 417 8 2 5 4.1 CC(C)(NC(=O)c1ccc2ccsc2c1OCCOc1ccc(F)cc1)C(=O)O nan
122187257 123074 None 0 Human Functional pIC50 = 7.1 7.1 20 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 380 6 3 6 1.2 CN(Cc1ccc(B(O)O)cn1)c1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
CHEMBL3609006 123074 None 0 Human Functional pIC50 = 7.1 7.1 20 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 380 6 3 6 1.2 CN(Cc1ccc(B(O)O)cn1)c1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
24952757 104714 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 293 3 1 5 3.0 Oc1cc(CSc2cccc(F)c2F)nc2ccnn12 10.1016/j.bmcl.2013.11.074
CHEMBL3105085 104714 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 293 3 1 5 3.0 Oc1cc(CSc2cccc(F)c2F)nc2ccnn12 10.1016/j.bmcl.2013.11.074
24958937 104690 None 2 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 348 5 1 6 3.7 Oc1cc(CSc2ccccc2)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104900 104690 None 2 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 348 5 1 6 3.7 Oc1cc(CSc2ccccc2)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
45485758 199967 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 412 7 3 7 2.4 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(F)cc1 10.1016/j.bmcl.2009.08.014
CHEMBL570043 199967 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 412 7 3 7 2.4 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(F)cc1 10.1016/j.bmcl.2009.08.014
45485798 201070 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 440 7 3 7 2.1 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(=O)c1ccc(F)cc1 10.1016/j.bmcl.2009.08.014
CHEMBL578807 201070 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 440 7 3 7 2.1 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(=O)c1ccc(F)cc1 10.1016/j.bmcl.2009.08.014
24958935 104707 None 2 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 370 4 1 6 4.1 Oc1cc(CSc2cccc(F)c2F)nc2nc(-c3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3105078 104707 None 2 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 370 4 1 6 4.1 Oc1cc(CSc2cccc(F)c2F)nc2nc(-c3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
24953816 104711 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 373 4 1 6 4.6 Cc1ccoc1-c1cc2nc(CSc3cccc(F)c3F)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
CHEMBL3105082 104711 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 373 4 1 6 4.6 Cc1ccoc1-c1cc2nc(CSc3cccc(F)c3F)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
172454542 195701 None 0 Human Functional pIC50 = 5.1 5.1 1 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 352 7 2 7 2.4 COCCNc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
CHEMBL5409317 195701 None 0 Human Functional pIC50 = 5.1 5.1 1 2
Antagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assayAntagonist activity at CXCR2 in human CD4 cells by fluorescence based calcium mobilization assay
ChEMBL 352 7 2 7 2.4 COCCNc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2023.115240
91937333 114996 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 473 8 2 6 3.4 O=C(c1ccc(SCc2ccccc2B(O)O)nc1)N(Cc1ccncc1)c1ccc(F)cc1 10.1021/jm500827t
CHEMBL3342321 114996 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 473 8 2 6 3.4 O=C(c1ccc(SCc2ccccc2B(O)O)nc1)N(Cc1ccncc1)c1ccc(F)cc1 10.1021/jm500827t
162659583 181483 None 0 Human Functional pIC50 = 8.1 8.1 602 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 423 6 3 7 2.1 COCCS(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccccc3)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4763312 181483 None 0 Human Functional pIC50 = 8.1 8.1 602 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 423 6 3 7 2.1 COCCS(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccccc3)N2)c1O 10.1021/acsmedchemlett.1c00113
44447944 155718 None 0 Human Functional pIC50 = 7.1 7.1 38 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 453 5 3 3 3.5 CS(=O)(=O)NC(=O)NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL404661 155718 None 0 Human Functional pIC50 = 7.1 7.1 38 2
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 453 5 3 3 3.5 CS(=O)(=O)NC(=O)NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2008.01.127
135907782 113017 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 321 4 1 5 3.7 CC(C)c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
CHEMBL3310780 113017 None 0 Human Functional pIC50 = 6.1 6.1 - 1
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 321 4 1 5 3.7 CC(C)c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
24958574 104702 None 2 Human Functional pIC50 = 6.0 6.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 336 4 1 6 3.5 CC(C)c1nc2nc(CSc3cccc(F)c3F)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
CHEMBL3104914 104702 None 2 Human Functional pIC50 = 6.0 6.0 - 1
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 336 4 1 6 3.5 CC(C)c1nc2nc(CSc3cccc(F)c3F)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
162656425 180985 None 0 Human Functional pIC50 = 6.0 6.0 41 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 441 4 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccc(Cl)cc3)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4757462 180985 None 0 Human Functional pIC50 = 6.0 6.0 41 2
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 441 4 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccc(Cl)cc3)N2)c1O 10.1021/acsmedchemlett.1c00113
122187259 123075 None 0 Human Functional pIC50 = 6.0 6.0 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 366 6 4 6 1.2 O=C(Nc1ccc(F)cc1)c1cnc(NCc2cccc(B(O)O)c2)nc1 10.1016/j.bmcl.2015.07.090
CHEMBL3609008 123075 None 0 Human Functional pIC50 = 6.0 6.0 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 366 6 4 6 1.2 O=C(Nc1ccc(F)cc1)c1cnc(NCc2cccc(B(O)O)c2)nc1 10.1016/j.bmcl.2015.07.090
24768854 125241 None 0 Human Functional pIC50 = 6.0 6.0 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 431 8 2 3 5.4 CC(CCc1ccccc1)Oc1c(C(=O)NC2(C(=O)O)CCCC2)ccc2ccccc12 nan
CHEMBL3645131 125241 None 0 Human Functional pIC50 = 6.0 6.0 - 1
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 431 8 2 3 5.4 CC(CCc1ccccc1)Oc1c(C(=O)NC2(C(=O)O)CCCC2)ccc2ccccc12 nan
122187262 123079 None 0 Human Functional pIC50 = 6.0 6.0 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 381 6 3 7 0.6 CN(Cc1ccc(B(O)O)cn1)c1ncc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
CHEMBL3609012 123079 None 0 Human Functional pIC50 = 6.0 6.0 1 2
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 381 6 3 7 0.6 CN(Cc1ccc(B(O)O)cn1)c1ncc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
CHEMBL5093947 217949 None 11 Human Functional pIC50 = 7.0 7.0 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None Cc1c(F)cccc1NC(=O)Nc1ccc2c(c1O)S(=O)(=O)CCC2 10.1021/acs.jmedchem.1c01219
162646248 179674 None 0 Human Functional pIC50 = 7.0 7.0 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 421 5 3 6 2.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@@H](Cc3ccccc3)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4741864 179674 None 0 Human Functional pIC50 = 7.0 7.0 - 1
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 421 5 3 6 2.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@@H](Cc3ccccc3)N2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL5084752 217422 None 0 Human Functional pIC50 = 5 5.0 - 1
Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assayAntagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced beta-arrestin recruitment preincubated for 30 mins followed by addition of agonist incubated for 90 mins by beta arrestin assay
ChEMBL None None None O=c1c(Nc2ccc3c(c2O)S(=O)(=O)CCC3)c(Nc2cccc(Cl)c2Cl)c1=O 10.1021/acs.jmedchem.1c01219
11440492 152731 None 0 Human Functional pKd = 9 9.0 - 1
Antagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPRAntagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPR
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL397237 152731 None 0 Human Functional pKd = 9 9.0 - 1
Antagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPRAntagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPR
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
12073810 171655 None 18 Human Functional pKd = 8.9 8.9 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2015.01.067
CHEMBL446458 171655 None 18 Human Functional pKd = 8.9 8.9 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2015.01.067
10003645 118103 None 1 Human Functional pKd = 8.7 8.7 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 445 9 3 7 2.2 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403850 118103 None 1 Human Functional pKd = 8.7 8.7 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 445 9 3 7 2.2 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
10479451 118104 None 0 Human Functional pKd = 8 8.0 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 461 9 3 7 2.7 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403851 118104 None 0 Human Functional pKd = 8 8.0 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 461 9 3 7 2.7 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
11754699 118107 None 1 Human Functional pKd = 8 8.0 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 475 9 3 8 1.8 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCOCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403854 118107 None 1 Human Functional pKd = 8 8.0 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 475 9 3 8 1.8 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCOCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
10072910 118105 None 0 Human Functional pKd = 7.9 7.9 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 459 9 3 7 2.6 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403852 118105 None 0 Human Functional pKd = 7.9 7.9 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 459 9 3 7 2.6 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
11440492 152731 None 0 Human Functional pKd = 7.9 7.9 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2015.01.067
CHEMBL397237 152731 None 0 Human Functional pKd = 7.9 7.9 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2015.01.067
10050534 118106 None 0 Human Functional pKd = 7.8 7.8 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 473 9 3 7 3.0 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCCCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403853 118106 None 0 Human Functional pKd = 7.8 7.8 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 473 9 3 7 3.0 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCCCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
57833185 118108 None 0 Human Functional pKd = 7.8 7.8 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 491 9 3 8 2.3 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCOCC2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403855 118108 None 0 Human Functional pKd = 7.8 7.8 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 491 9 3 8 2.3 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCOCC2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
10345330 118100 None 0 Human Functional pKd = 6.7 6.7 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 486 9 3 9 2.9 C[C@H](CO)Nc1cc(NS(=O)(=O)c2cn(C)cn2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403847 118100 None 0 Human Functional pKd = 6.7 6.7 - 1
Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysisAntagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis
ChEMBL 486 9 3 9 2.9 C[C@H](CO)Nc1cc(NS(=O)(=O)c2cn(C)cn2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
8497 2737 None 41 Human Functional pIC50 = 10.3 10.3 1 4
UnclassifiedUnclassified
Guide to Pharmacology 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 17181143
8497 2737 None 41 Human Functional pIC50 = 10.3 10.3 1 4
UnclassifiedUnclassified
Guide to Pharmacology 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 24218476
9865554 2737 None 41 Human Functional pIC50 = 10.3 10.3 1 4
UnclassifiedUnclassified
Guide to Pharmacology 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 17181143
9865554 2737 None 41 Human Functional pIC50 = 10.3 10.3 1 4
UnclassifiedUnclassified
Guide to Pharmacology 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 24218476
CHEMBL216981 2737 None 41 Human Functional pIC50 = 10.3 10.3 1 4
UnclassifiedUnclassified
Guide to Pharmacology 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 17181143
CHEMBL216981 2737 None 41 Human Functional pIC50 = 10.3 10.3 1 4
UnclassifiedUnclassified
Guide to Pharmacology 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 24218476
8498 3315 None 44 Human Functional pIC50 = 6.4 6.4 -33 2
UnclassifiedUnclassified
Guide to Pharmacology 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 15282370
9838712 3315 None 44 Human Functional pIC50 = 6.4 6.4 -33 2
UnclassifiedUnclassified
Guide to Pharmacology 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 15282370
9838712.0 3315 None 44 Human Functional pIC50 = 6.4 6.4 -33 2
UnclassifiedUnclassified
Guide to Pharmacology 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 15282370
CHEMBL191413 3315 None 44 Human Functional pIC50 = 6.4 6.4 -33 2
UnclassifiedUnclassified
Guide to Pharmacology 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 15282370
DB12614 3315 None 44 Human Functional pIC50 = 6.4 6.4 -33 2
UnclassifiedUnclassified
Guide to Pharmacology 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 15282370
46897162 3716 None 15 Human Functional pIC50 = 7.2 7.2 6 2
UnclassifiedUnclassified
Guide to Pharmacology 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 25254640
8501 3716 None 15 Human Functional pIC50 = 7.2 7.2 6 2
UnclassifiedUnclassified
Guide to Pharmacology 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 25254640
CHEMBL3342269 3716 None 15 Human Functional pIC50 = 7.2 7.2 6 2
UnclassifiedUnclassified
Guide to Pharmacology 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 25254640
10479502 1548 None 26 Human Functional pIC50 = 7.7 7.7 - 1
UnclassifiedUnclassified
Guide to Pharmacology 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 24218476
8499 1548 None 26 Human Functional pIC50 = 7.7 7.7 - 1
UnclassifiedUnclassified
Guide to Pharmacology 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 24218476
CHEMBL2178579 1548 None 26 Human Functional pIC50 = 7.7 7.7 - 1
UnclassifiedUnclassified
Guide to Pharmacology 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 24218476
DB12135 1548 None 26 Human Functional pIC50 = 7.7 7.7 - 1
UnclassifiedUnclassified
Guide to Pharmacology 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 24218476
3854666 3501 None 58 Human Functional pIC50 = 7.7 7.7 -1 2
UnclassifiedUnclassified
Guide to Pharmacology 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 9553055
833 3501 None 58 Human Functional pIC50 = 7.7 7.7 -1 2
UnclassifiedUnclassified
Guide to Pharmacology 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 9553055
CHEMBL239767 3501 None 58 Human Functional pIC50 = 7.7 7.7 -1 2
UnclassifiedUnclassified
Guide to Pharmacology 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 9553055
830 1264 None 0 Human Functional pIC50 = 7.8 7.8 - 1
UnclassifiedUnclassified
Guide to Pharmacology None None None None 8702798
24780598 1316 None 38 Human Functional pIC50 = 7.9 7.9 85 2
UnclassifiedUnclassified
Guide to Pharmacology 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 26092545
8500 1316 None 38 Human Functional pIC50 = 7.9 7.9 85 2
UnclassifiedUnclassified
Guide to Pharmacology 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 26092545
CHEMBL3039531 1316 None 38 Human Functional pIC50 = 7.9 7.9 85 2
UnclassifiedUnclassified
Guide to Pharmacology 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 26092545
DB11922 1316 None 38 Human Functional pIC50 = 7.9 7.9 85 2
UnclassifiedUnclassified
Guide to Pharmacology 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 26092545
829 1262 None 0 Human Functional pIC50 = 8.0 8.0 - 1
UnclassifiedUnclassified
Guide to Pharmacology None None None None 8702798
827 1255 None 0 Human Functional pIC50 = 8.1 8.1 - 1
UnclassifiedUnclassified
Guide to Pharmacology None None None None 8702798
8496 3979 None 0 Human Functional pIC50 = 8.3 8.3 7 2
UnclassifiedUnclassified
Guide to Pharmacology None None None None 20044480
828 1258 None 0 Human Functional pIC50 = 8.5 8.5 - 1
UnclassifiedUnclassified
Guide to Pharmacology None None None None 8702798
3618472 2893 None 12 Human Functional pIC50 None 6.3 6.3 45 2
UnclassifiedUnclassified
Guide to Pharmacology 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 9553055
834 2893 None 12 Human Functional pIC50 None 6.3 6.3 45 2
UnclassifiedUnclassified
Guide to Pharmacology 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 9553055
CHEMBL280711 2893 None 12 Human Functional pIC50 None 6.3 6.3 45 2
UnclassifiedUnclassified
Guide to Pharmacology 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 9553055




Ligands (move mouse cursor over ligand name to see structure) Receptor Activity Chemical information
Sel. page Common
name
GPCRdb
ID
Reference
ligand
Vendors

Species

Assay
Type
Activity
Type
Activity
Relation
Activity
Value
p-value
(-log)
Fold
selectivity
Tested
GPCRs
Assay
Description
Source

Mol
weight
Rot
Bonds
H don

H acc

LogP

Smiles

DOI

8497 2737 None 41 Human Binding pIC50 = 10.3 10.3 39 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/jm300682j
9865554 2737 None 41 Human Binding pIC50 = 10.3 10.3 39 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/jm300682j
CHEMBL216981 2737 None 41 Human Binding pIC50 = 10.3 10.3 39 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/jm300682j
11372270 67525 None 26 Human Binding pIC50 = 10 10.0 - 0
Inhibition of CXCR2 (unknown origin)Inhibition of CXCR2 (unknown origin)
ChEMBL 375 5 1 6 1.1 C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1 10.1021/acs.jmedchem.8b00875
11372270.0 67525 None 26 Human Binding pIC50 = 10 10.0 - 0
Inhibition of CXCR2 (unknown origin)Inhibition of CXCR2 (unknown origin)
ChEMBL 375 5 1 6 1.1 C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1 10.1021/acs.jmedchem.8b00875
CHEMBL189475 67525 None 26 Human Binding pIC50 = 10 10.0 - 0
Inhibition of CXCR2 (unknown origin)Inhibition of CXCR2 (unknown origin)
ChEMBL 375 5 1 6 1.1 C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1 10.1021/acs.jmedchem.8b00875
CHEMBL4442431 67525 None 26 Human Binding pIC50 = 10 10.0 - 0
Inhibition of CXCR2 (unknown origin)Inhibition of CXCR2 (unknown origin)
ChEMBL 375 5 1 6 1.1 C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1 10.1021/acs.jmedchem.8b00875
88545431 171496 None 0 Mouse Binding pIC50 = 10 10.0 - 0
Inhibition of CXCR2-mediated chemotaxis in mouse BAF3 cellsInhibition of CXCR2-mediated chemotaxis in mouse BAF3 cells
ChEMBL 478 7 3 8 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCN4CCC[C@H]4C3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.ejmech.2019.111853
CHEMBL4462143 171496 None 0 Mouse Binding pIC50 = 10 10.0 - 0
Inhibition of CXCR2-mediated chemotaxis in mouse BAF3 cellsInhibition of CXCR2-mediated chemotaxis in mouse BAF3 cells
ChEMBL 478 7 3 8 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCN4CCC[C@H]4C3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.ejmech.2019.111853
44626319 200877 None 0 Human Binding pIC50 = 9.9 9.9 81 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 346 7 3 7 1.1 CCN(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.ejmech.2019.111853
CHEMBL577075 200877 None 0 Human Binding pIC50 = 9.9 9.9 81 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 346 7 3 7 1.1 CCN(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.ejmech.2019.111853
137633598 156522 None 0 Human Binding pIC50 = 9.8 9.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 445 5 3 5 4.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)CC(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4066904 156522 None 0 Human Binding pIC50 = 9.8 9.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 445 5 3 5 4.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)CC(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
118540892 157820 None 0 Human Binding pIC50 = 9.7 9.7 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 377 3 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4082136 157820 None 0 Human Binding pIC50 = 9.7 9.7 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 377 3 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
118554832 159325 None 0 Human Binding pIC50 = 9.7 9.7 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 432 4 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4098864 159325 None 0 Human Binding pIC50 = 9.7 9.7 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 432 4 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
72548703 161661 None 0 Human Binding pIC50 = 9.6 9.6 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor after 60 mins by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor after 60 mins by scintillation counting analysis
ChEMBL 583 8 3 6 5.8 CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12 10.1016/j.bmcl.2018.03.093
CHEMBL4128926 161661 None 0 Human Binding pIC50 = 9.6 9.6 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor after 60 mins by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor after 60 mins by scintillation counting analysis
ChEMBL 583 8 3 6 5.8 CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12 10.1016/j.bmcl.2018.03.093
129316069 155944 None 0 Human Binding pIC50 = 9.6 9.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 436 6 4 5 3.4 CC(C)(CCO)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4060139 155944 None 0 Human Binding pIC50 = 9.6 9.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 436 6 4 5 3.4 CC(C)(CCO)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
118554743 156125 None 0 Human Binding pIC50 = 9.6 9.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 5 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C2COC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4062361 156125 None 0 Human Binding pIC50 = 9.6 9.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 5 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C2COC2)c1O 10.1021/acs.jmedchem.7b01854
118540867 157001 None 0 Human Binding pIC50 = 9.6 9.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 4 5 3.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CC[C@@H](O)C2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4072270 157001 None 0 Human Binding pIC50 = 9.6 9.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 4 5 3.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CC[C@@H](O)C2)c1O 10.1021/acs.jmedchem.7b01854
129316028 157406 None 0 Human Binding pIC50 = 9.5 9.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 4.0 CCC1(S(=O)(=O)c2c(Cl)ccc(NC(=O)N[C@@H]3CCC=C3C)c2O)CCOCC1 10.1021/acs.jmedchem.7b01854
CHEMBL4077201 157406 None 0 Human Binding pIC50 = 9.5 9.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 4.0 CCC1(S(=O)(=O)c2c(Cl)ccc(NC(=O)N[C@@H]3CCC=C3C)c2O)CCOCC1 10.1021/acs.jmedchem.7b01854
58180205 140891 None 0 Human Binding pIC50 = 9.5 9.5 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 446 4 3 4 5.2 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818853 140891 None 0 Human Binding pIC50 = 9.5 9.5 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 446 4 3 4 5.2 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
58180198 140903 None 0 Human Binding pIC50 = 9.5 9.5 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 432 4 3 4 4.8 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818984 140903 None 0 Human Binding pIC50 = 9.5 9.5 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 432 4 3 4 4.8 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
58180199 140937 None 0 Human Binding pIC50 = 9.5 9.5 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 460 4 3 4 5.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3819480 140937 None 0 Human Binding pIC50 = 9.5 9.5 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 460 4 3 4 5.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
127049431 140817 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL3817901 140817 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acs.jmedchem.7b01854
123190913 156516 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 372 4 3 4 3.5 CC1=CCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4066818 156516 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 372 4 3 4 3.5 CC1=CCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
129316018 156832 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 467 5 3 5 4.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(C3CCC3)CC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4070506 156832 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 467 5 3 5 4.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(C3CCC3)CC2)c1O 10.1021/acs.jmedchem.7b01854
118540730 158215 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 394 4 3 4 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(F)F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4086957 158215 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 394 4 3 4 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(F)F)c1O 10.1021/acs.jmedchem.7b01854
127052173 140870 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 543 4 3 5 5.9 CN1CCC2(CCC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)CC2)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818581 140870 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 543 4 3 5 5.9 CN1CCC2(CCC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)CC2)CC1 10.1021/acsmedchemlett.5b00489
127051854 140911 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 487 4 3 5 4.4 CN1CC2(CC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)C2)C1 10.1021/acsmedchemlett.5b00489
CHEMBL3819163 140911 None 0 Human Binding pIC50 = 9.4 9.4 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 487 4 3 5 4.4 CN1CC2(CC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)C2)C1 10.1021/acsmedchemlett.5b00489
118554794 156493 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4066510 156493 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
118554809 157808 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 452 4 3 5 3.7 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O)N[C@@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
CHEMBL4082031 157808 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 452 4 3 5 3.7 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O)N[C@@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
118554742 158343 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 456 5 3 5 4.3 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C2CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4088551 158343 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 456 5 3 5 4.3 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C2CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
118554882 159712 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 440 4 3 4 4.4 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4103349 159712 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 440 4 3 4 4.4 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
127049431 140817 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3817901 140817 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
127049370 140845 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 461 4 3 5 4.0 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
CHEMBL3818277 140845 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 461 4 3 5 4.0 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
127048710 140885 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 464 4 3 5 4.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818793 140885 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 464 4 3 5 4.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
127049371 140890 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 489 4 3 5 4.7 CN1CCC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818827 140890 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 489 4 3 5 4.7 CN1CCC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
127050964 140918 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 425 3 3 3 5.1 O=C(Nc1ccc(Cl)c(C(=O)N2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3819221 140918 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 425 3 3 3 5.1 O=C(Nc1ccc(Cl)c(C(=O)N2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
127049430 140925 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 422 4 3 4 4.8 CCS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3819295 140925 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 422 4 3 4 4.8 CCS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
127020968 140939 None 31 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 475 4 3 5 4.4 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819512 140939 None 31 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 475 4 3 5 4.4 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
127051212 140945 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 434 3 3 4 5.1 CC(C)(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3819569 140945 None 0 Human Binding pIC50 = 9.3 9.3 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 434 3 3 4 5.1 CC(C)(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
129315964 157544 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 404 5 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CF)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4079102 157544 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 404 5 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CF)c1O 10.1021/acs.jmedchem.7b01854
118554787 159334 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 459 6 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(CCF)CC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4098979 159334 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 459 6 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(CCF)CC2)c1O 10.1021/acs.jmedchem.7b01854
127049432 140840 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 436 4 3 4 5.2 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3818216 140840 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 436 4 3 4 5.2 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
11599650 140861 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 478 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818458 140861 None 0 Human Binding pIC50 = 9.2 9.2 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 478 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
118554754 158432 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 418 4 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4089421 158432 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 418 4 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
127050016 140888 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 478 4 3 5 4.9 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818820 140888 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 478 4 3 5 4.9 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
9956678 140896 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 476 4 3 5 3.4 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818917 140896 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 476 4 3 5 3.4 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
127049422 140942 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 492 4 3 5 3.9 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819542 140942 None 0 Human Binding pIC50 = 9.1 9.1 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 492 4 3 5 3.9 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
100951623 156564 None 16 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4067429 156564 None 16 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
118554834 157304 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 426 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CC3(COC3)C2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4076053 157304 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 426 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CC3(COC3)C2)c1O 10.1021/acs.jmedchem.7b01854
118540482 157330 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 453 5 3 5 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N3CCCC3)C2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4076428 157330 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 453 5 3 5 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N3CCCC3)C2)c1O 10.1021/acs.jmedchem.7b01854
118554836 158889 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 392 4 3 4 3.6 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4094324 158889 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 392 4 3 4 3.6 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
130191301 159015 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 386 3 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4095602 159015 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 386 3 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
118540567 159203 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 427 5 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N(C)C)C2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4097602 159203 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 427 5 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N(C)C)C2)c1O 10.1021/acs.jmedchem.7b01854
118540525 159484 None 15 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4100674 159484 None 15 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
127052174 140850 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 411 3 3 3 4.7 O=C(Nc1ccc(Cl)c(C(=O)N2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818323 140850 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 411 3 3 3 4.7 O=C(Nc1ccc(Cl)c(C(=O)N2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
127049108 140931 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 490 5 3 5 3.8 CCN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819382 140931 None 0 Human Binding pIC50 = 9 9.0 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 490 5 3 5 3.8 CCN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
12073810 171655 None 18 Human Binding pIC50 = 9 9.0 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2015.01.067
CHEMBL446458 171655 None 18 Human Binding pIC50 = 9 9.0 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2015.01.067
44455014 95404 None 0 Human Binding pIC50 = 9 9.0 - 1
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 379 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)cnc12 10.1016/j.bmcl.2007.11.039
CHEMBL256668 95404 None 0 Human Binding pIC50 = 9 9.0 - 1
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 379 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)cnc12 10.1016/j.bmcl.2007.11.039
11858154 155430 None 19 Human Binding pIC50 = 9 9.0 2691 2
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 400 6 3 7 3.3 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL403225 155430 None 19 Human Binding pIC50 = 9 9.0 2691 2
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 400 6 3 7 3.3 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
12073810 171655 None 18 Human Binding pIC50 = 9 9.0 - 1
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL446458 171655 None 18 Human Binding pIC50 = 9 9.0 - 1
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
118540528 156142 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4062546 156142 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
129316053 157335 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 3.9 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)[C@@H]2CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4076478 157335 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 3.9 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)[C@@H]2CCOC2)c1O 10.1021/acs.jmedchem.7b01854
118554755 157599 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 446 5 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(CF)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4079718 157599 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 446 5 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(CF)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
129315983 157981 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 402 6 3 5 3.1 COCC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4084077 157981 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 402 6 3 5 3.1 COCC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2C)c1O 10.1021/acs.jmedchem.7b01854
127049049 140835 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 477 4 3 5 4.5 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
CHEMBL3818179 140835 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 477 4 3 5 4.5 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
127049048 140851 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 489 5 3 5 4.7 CCN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818331 140851 None 0 Human Binding pIC50 = 8.9 8.9 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 489 5 3 5 4.7 CCN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
10310100 93529 None 29 Human Binding pIC50 = 8.9 8.9 3 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 425 8 3 7 3.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C(C)C)co1 10.1016/j.bmcl.2007.04.016
CHEMBL246108 93529 None 29 Human Binding pIC50 = 8.9 8.9 3 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 425 8 3 7 3.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C(C)C)co1 10.1016/j.bmcl.2007.04.016
129316073 157804 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4081963 157804 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
129315999 157985 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 3.9 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)[C@H]2CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4084135 157985 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 3.9 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)[C@H]2CCOC2)c1O 10.1021/acs.jmedchem.7b01854
118540796 159286 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 390 4 3 4 3.8 CC1=C(F)CCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4098536 159286 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 390 4 3 4 3.8 CC1=C(F)CCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
127049047 140941 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 491 4 3 5 4.9 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819521 140941 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 491 4 3 5 4.9 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
127049427 140948 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 504 5 3 5 4.2 CC(C)N1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819603 140948 None 0 Human Binding pIC50 = 8.8 8.8 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 504 5 3 5 4.2 CC(C)N1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
129316076 155932 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4060060 155932 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
129316027 156977 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 437 6 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(F)(F)CN(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4072010 156977 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 437 6 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(F)(F)CN(C)C)c1O 10.1021/acs.jmedchem.7b01854
127052172 140909 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 515 4 3 5 5.1 CN1CCC2(CC1)CC(S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c1O)C2 10.1021/acsmedchemlett.5b00489
CHEMBL3819070 140909 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 515 4 3 5 5.1 CN1CCC2(CC1)CC(S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c1O)C2 10.1021/acsmedchemlett.5b00489
127050017 140844 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 477 4 4 5 4.5 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818269 140844 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 477 4 4 5 4.5 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
127052172 140909 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 515 4 3 5 5.1 CN1CCC2(CC1)CC(S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c1O)C2 10.1021/acsmedchemlett.5b00489
CHEMBL3819070 140909 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 515 4 3 5 5.1 CN1CCC2(CC1)CC(S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c1O)C2 10.1021/acsmedchemlett.5b00489
9887803 140924 None 26 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 409 3 4 4 3.6 NS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3819292 140924 None 26 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 409 3 4 4 3.6 NS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
123227682 156299 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 376 4 3 4 3.4 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC=C2F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4064349 156299 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 376 4 3 4 3.4 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC=C2F)c1O 10.1021/acs.jmedchem.7b01854
137633482 156690 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 406 4 3 4 4.0 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4068799 156690 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 406 4 3 4 4.0 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
137638965 156958 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 374 4 3 4 3.5 CC1CCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4071768 156958 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 374 4 3 4 3.5 CC1CCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
137644508 158566 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 372 4 3 4 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2C=CCCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4090813 158566 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 372 4 3 4 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2C=CCCC2)c1O 10.1021/acs.jmedchem.7b01854
137654230 158802 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 360 4 3 4 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4093313 158802 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 360 4 3 4 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC2)c1O 10.1021/acs.jmedchem.7b01854
127049431 140817 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3817901 140817 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
127049429 140813 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 507 4 3 5 4.8 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
CHEMBL3817880 140813 None 0 Human Binding pIC50 = 8 8.0 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 507 4 3 5 4.8 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
44393541 66171 None 1 Human Binding pIC50 = 8 8.0 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 383 3 4 3 3.6 NC(=O)c1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
CHEMBL184185 66171 None 1 Human Binding pIC50 = 8 8.0 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 383 3 4 3 3.6 NC(=O)c1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
9841667 140836 None 41 Human Binding pIC50 = 8 8.0 1000 2
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1016/s0960-894x(02)00188-9
CHEMBL38182 140836 None 41 Human Binding pIC50 = 8 8.0 1000 2
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1016/s0960-894x(02)00188-9
57833135 118094 None 0 Human Binding pIC50 = 8 8.0 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 422 8 3 7 2.8 C[C@H](CO)Nc1cc(NS(=O)(=O)C(F)(F)F)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403840 118094 None 0 Human Binding pIC50 = 8 8.0 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 422 8 3 7 2.8 C[C@H](CO)Nc1cc(NS(=O)(=O)C(F)(F)F)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
10269706 80122 None 0 Human Binding pIC50 = 8 8.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 357 3 3 6 1.8 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C2CCCCC2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL213130 80122 None 0 Human Binding pIC50 = 8 8.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 357 3 3 6 1.8 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C2CCCCC2)c1O 10.1016/j.bmcl.2006.04.082
9966717 137328 None 0 Human Binding pIC50 = 8 8.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 317 3 3 6 0.9 CC(C)/N=c1\c(O)c(O)\c1=N/c1cccc(C(=O)N(C)C)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL375175 137328 None 0 Human Binding pIC50 = 8 8.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 317 3 3 6 0.9 CC(C)/N=c1\c(O)c(O)\c1=N/c1cccc(C(=O)N(C)C)c1O 10.1016/j.bmcl.2006.04.082
44439708 13908 None 0 Human Binding pIC50 = 8 8.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 568 6 3 8 3.2 CN1CCCN(S(=O)(=O)c2c(Cl)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL1196279 13908 None 0 Human Binding pIC50 = 8 8.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 568 6 3 8 3.2 CN1CCCN(S(=O)(=O)c2c(Cl)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL556367 13908 None 0 Human Binding pIC50 = 8 8.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 568 6 3 8 3.2 CN1CCCN(S(=O)(=O)c2c(Cl)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
44446608 94733 None 0 Human Binding pIC50 = 8.0 8.0 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 384 7 3 8 2.0 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cocn1 10.1016/j.bmcl.2008.01.024
CHEMBL252697 94733 None 0 Human Binding pIC50 = 8.0 8.0 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 384 7 3 8 2.0 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cocn1 10.1016/j.bmcl.2008.01.024
136087088 116052 None 0 Human Binding pIC50 = 7 7.0 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 453 5 3 6 3.9 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)C(F)(F)F)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355242 116052 None 0 Human Binding pIC50 = 7 7.0 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 453 5 3 6 3.9 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)C(F)(F)F)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
118540482 157330 None 0 Human Binding pIC50 = 7 7.0 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 453 5 3 5 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N3CCCC3)C2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4076428 157330 None 0 Human Binding pIC50 = 7 7.0 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 453 5 3 5 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N3CCCC3)C2)c1O 10.1021/acs.jmedchem.7b01854
129315964 157544 None 0 Human Binding pIC50 = 7 7.0 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 404 5 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CF)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4079102 157544 None 0 Human Binding pIC50 = 7 7.0 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 404 5 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CF)c1O 10.1021/acs.jmedchem.7b01854
129316030 158292 None 0 Human Binding pIC50 = 7 7.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 452 4 3 5 3.7 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O)N[C@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
CHEMBL4087900 158292 None 0 Human Binding pIC50 = 7 7.0 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 452 4 3 5 3.7 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O)N[C@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
127049371 140890 None 0 Human Binding pIC50 = 7 7.0 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 489 4 3 5 4.7 CN1CCC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818827 140890 None 0 Human Binding pIC50 = 7 7.0 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 489 4 3 5 4.7 CN1CCC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
8498 3315 None 44 Human Binding pIC50 = 7 7.0 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
9838712 3315 None 44 Human Binding pIC50 = 7 7.0 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
9838712.0 3315 None 44 Human Binding pIC50 = 7 7.0 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
CHEMBL191413 3315 None 44 Human Binding pIC50 = 7 7.0 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
DB12614 3315 None 44 Human Binding pIC50 = 7 7.0 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
163322282 191744 None 3 Human Binding pIC50 = 7 7.0 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 352 6 2 7 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2oncc12 10.1016/j.ejmech.2022.114268
CHEMBL5195797 191744 None 3 Human Binding pIC50 = 7 7.0 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 352 6 2 7 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2oncc12 10.1016/j.ejmech.2022.114268
8498 3315 None 44 Human Binding pIC50 = 7 7.0 - 0
Displacement of 125I-IL-8 from CXCR2 (unknown origin)Displacement of 125I-IL-8 from CXCR2 (unknown origin)
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1016/j.ejmech.2023.115175
9838712 3315 None 44 Human Binding pIC50 = 7 7.0 - 0
Displacement of 125I-IL-8 from CXCR2 (unknown origin)Displacement of 125I-IL-8 from CXCR2 (unknown origin)
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1016/j.ejmech.2023.115175
9838712.0 3315 None 44 Human Binding pIC50 = 7 7.0 - 0
Displacement of 125I-IL-8 from CXCR2 (unknown origin)Displacement of 125I-IL-8 from CXCR2 (unknown origin)
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1016/j.ejmech.2023.115175
CHEMBL191413 3315 None 44 Human Binding pIC50 = 7 7.0 - 0
Displacement of 125I-IL-8 from CXCR2 (unknown origin)Displacement of 125I-IL-8 from CXCR2 (unknown origin)
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1016/j.ejmech.2023.115175
DB12614 3315 None 44 Human Binding pIC50 = 7 7.0 - 0
Displacement of 125I-IL-8 from CXCR2 (unknown origin)Displacement of 125I-IL-8 from CXCR2 (unknown origin)
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1016/j.ejmech.2023.115175
9946476 87377 None 0 Human Binding pIC50 = 7 7.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 351 6 3 9 2.7 CC(C)(CO)Nc1nc(SCc2ccco2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL233262 87377 None 0 Human Binding pIC50 = 7 7.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 351 6 3 9 2.7 CC(C)(CO)Nc1nc(SCc2ccco2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
44431193 150471 None 0 Human Binding pIC50 = 7 7.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 439 9 3 8 4.7 CC[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NC(C)C)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL395340 150471 None 0 Human Binding pIC50 = 7 7.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 439 9 3 8 4.7 CC[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NC(C)C)sc12 10.1016/j.bmcl.2007.02.080
44431186 167873 None 0 Human Binding pIC50 = 7 7.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 439 9 4 9 3.0 OCC(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NC3CC3)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL430381 167873 None 0 Human Binding pIC50 = 7 7.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 439 9 4 9 3.0 OCC(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NC3CC3)sc12 10.1016/j.bmcl.2007.02.080
71555295 132871 None 0 Human Binding pIC50 = 7 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 565 8 3 10 3.8 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCC[C@@H]4C(=O)OC(C)(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701187 132871 None 0 Human Binding pIC50 = 7 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 565 8 3 10 3.8 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCC[C@@H]4C(=O)OC(C)(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
71555297 132874 None 0 Human Binding pIC50 = 7 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 438 8 3 8 3.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)C(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701190 132874 None 0 Human Binding pIC50 = 7 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 438 8 3 8 3.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)C(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
9841667 140836 None 41 Human Binding pIC50 = 7 7.0 1000 2
Inhibition of wild type CXCR2 (unknown origin)Inhibition of wild type CXCR2 (unknown origin)
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1021/acs.jmedchem.6b01309
CHEMBL38182 140836 None 41 Human Binding pIC50 = 7 7.0 1000 2
Inhibition of wild type CXCR2 (unknown origin)Inhibition of wild type CXCR2 (unknown origin)
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1021/acs.jmedchem.6b01309
137633598 156522 None 0 Human Binding pIC50 = 6 6.0 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 445 5 3 5 4.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)CC(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4066904 156522 None 0 Human Binding pIC50 = 6 6.0 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 445 5 3 5 4.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)CC(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
127049422 140942 None 0 Human Binding pIC50 = 6 6.0 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 492 4 3 5 3.9 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819542 140942 None 0 Human Binding pIC50 = 6 6.0 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 492 4 3 5 3.9 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
44414038 78200 None 0 Human Binding pIC50 = 6 6.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 324 3 4 6 1.8 O=C(O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL210448 78200 None 0 Human Binding pIC50 = 6 6.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 324 3 4 6 1.8 O=C(O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
22288470 87379 None 0 Human Binding pIC50 = 6 6.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 382 6 3 10 2.9 Cc1nc(CSc2nc(NC(C)(C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.02.080
CHEMBL233264 87379 None 0 Human Binding pIC50 = 6 6.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 382 6 3 10 2.9 Cc1nc(CSc2nc(NC(C)(C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.02.080
9795327 203253 None 0 Human Binding pIC50 = 6 6.0 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 266 2 1 2 2.4 O=C(Nc1ccc(F)cc1)c1ccc(Cl)[n+]([O-])c1 10.1016/s0960-894x(01)00326-2
CHEMBL60066 203253 None 0 Human Binding pIC50 = 6 6.0 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 266 2 1 2 2.4 O=C(Nc1ccc(F)cc1)c1ccc(Cl)[n+]([O-])c1 10.1016/s0960-894x(01)00326-2
9817855 208446 None 0 Human Binding pIC50 = 6 6.0 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 301 3 1 4 3.9 Sc1nc(-c2cccc(Cl)c2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL84755 208446 None 0 Human Binding pIC50 = 6 6.0 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 301 3 1 4 3.9 Sc1nc(-c2cccc(Cl)c2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
11599650 140861 None 0 Human Binding pIC50 = 5 5.0 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 478 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818458 140861 None 0 Human Binding pIC50 = 5 5.0 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 478 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
135546485 73496 None 0 Human Binding pIC50 = 5 5.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 255 5 1 6 3.1 CCCCCSc1nc(O)c2scnc2n1 10.1016/j.bmcl.2005.10.091
CHEMBL201672 73496 None 0 Human Binding pIC50 = 5 5.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 255 5 1 6 3.1 CCCCCSc1nc(O)c2scnc2n1 10.1016/j.bmcl.2005.10.091
135673987 73685 None 0 Human Binding pIC50 = 5 5.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 270 5 2 7 2.7 CCCCCSc1nc(O)c2sc(N)nc2n1 10.1016/j.bmcl.2005.10.091
CHEMBL201799 73685 None 0 Human Binding pIC50 = 5 5.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 270 5 2 7 2.7 CCCCCSc1nc(O)c2sc(N)nc2n1 10.1016/j.bmcl.2005.10.091
44407558 73686 None 0 Human Binding pIC50 = 5 5.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 289 3 2 7 2.5 Nc1nc2nc(SCc3ccccc3)nc(N)c2s1 10.1016/j.bmcl.2005.10.091
CHEMBL201800 73686 None 0 Human Binding pIC50 = 5 5.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 289 3 2 7 2.5 Nc1nc2nc(SCc3ccccc3)nc(N)c2s1 10.1016/j.bmcl.2005.10.091
11329244 71140 None 6 Human Binding pIC50 = 5 5.0 - 0
Inhibition of C-X-C chemokine receptor type 2Inhibition of C-X-C chemokine receptor type 2
ChEMBL 486 7 2 5 5.4 CC(=O)c1sc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)nc1C 10.1021/jm049530m
CHEMBL195433 71140 None 6 Human Binding pIC50 = 5 5.0 - 0
Inhibition of C-X-C chemokine receptor type 2Inhibition of C-X-C chemokine receptor type 2
ChEMBL 486 7 2 5 5.4 CC(=O)c1sc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)nc1C 10.1021/jm049530m
11272103 124442 None 0 Human Binding pIC50 = 5 5.0 - 0
Inhibition of C-X-C chemokine receptor type 2Inhibition of C-X-C chemokine receptor type 2
ChEMBL 505 7 2 6 4.7 Cn1nnnc1-c1cccc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)c1 10.1021/jm049530m
CHEMBL363840 124442 None 0 Human Binding pIC50 = 5 5.0 - 0
Inhibition of C-X-C chemokine receptor type 2Inhibition of C-X-C chemokine receptor type 2
ChEMBL 505 7 2 6 4.7 Cn1nnnc1-c1cccc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)c1 10.1021/jm049530m
44318749 208444 None 0 Human Binding pIC50 = 5 5.0 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 365 4 1 5 4.6 COc1ccc(Cn2nc(-c3ccc(Cl)cc3Cl)nc2S)cc1 10.1016/s0960-894x(03)00561-4
CHEMBL84752 208444 None 0 Human Binding pIC50 = 5 5.0 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 365 4 1 5 4.6 COc1ccc(Cn2nc(-c3ccc(Cl)cc3Cl)nc2S)cc1 10.1016/s0960-894x(03)00561-4
91937340 127334 None 0 Human Binding pIC50 = 5.0 5.0 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 387 5 2 6 2.5 O=C(Nc1ccc(F)cn1)c1ccc(S(=O)(=O)Cc2ccccc2O)nc1 nan
CHEMBL3658347 127334 None 0 Human Binding pIC50 = 5.0 5.0 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 387 5 2 6 2.5 O=C(Nc1ccc(F)cn1)c1ccc(S(=O)(=O)Cc2ccccc2O)nc1 nan
71525700 133384 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 399 7 3 9 2.2 COc1ccc(Nc2c(NC(c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c(O)n1 nan
CHEMBL3704566 133384 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 399 7 3 9 2.2 COc1ccc(Nc2c(NC(c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c(O)n1 nan
91937331 114993 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 380 6 4 6 2.0 O=C(Nc1ccc(O)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 nan
CHEMBL3342318 114993 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 380 6 4 6 2.0 O=C(Nc1ccc(O)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 nan
71526066 144502 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 555 9 2 9 4.3 CCOC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1F nan
CHEMBL3906175 144502 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 555 9 2 9 4.3 CCOC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1F nan
71526603 132868 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 453 8 3 8 2.9 CCC1(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c2ccc(C)o2)COC1 nan
CHEMBL3701184 132868 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 453 8 3 8 2.9 CCC1(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c2ccc(C)o2)COC1 nan
71525793 133379 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 441 7 3 8 2.7 CN(C)C(=O)c1cccc(Nc2c(NC(c3cccs3)C3(C)COC3)c(=O)c2=O)c1O nan
CHEMBL3704561 133379 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 441 7 3 8 2.7 CN(C)C(=O)c1cccc(Nc2c(NC(c3cccs3)C3(C)COC3)c(=O)c2=O)c1O nan
168279497 190860 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cc[nH]c12 10.1016/j.ejmech.2022.114268
CHEMBL5182926 190860 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cc[nH]c12 10.1016/j.ejmech.2022.114268
46897259 126886 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 480 7 1 6 5.6 CC(=O)Oc1ccc(OC(F)(F)F)cc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 nan
CHEMBL3654442 126886 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 480 7 1 6 5.6 CC(=O)Oc1ccc(OC(F)(F)F)cc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 nan
162676579 183655 None 0 Human Binding pIC50 = 5.0 5.0 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 486 4 2 5 6.9 CC1CCCc2sc(NC(=S)Nc3ccc(OC(F)(F)F)cc3)c(C(=O)OC(C)(C)C)c21 10.1016/j.ejmech.2020.112387
CHEMBL4800160 183655 None 0 Human Binding pIC50 = 5.0 5.0 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 486 4 2 5 6.9 CC1CCCc2sc(NC(=S)Nc3ccc(OC(F)(F)F)cc3)c(C(=O)OC(C)(C)C)c21 10.1016/j.ejmech.2020.112387
71526607 132870 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 481 7 4 9 2.0 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CC[C@H](O)C4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701186 132870 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 481 7 4 9 2.0 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CC[C@H](O)C4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
71526065 153258 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 569 9 2 9 4.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCC[C@H]4C(=O)OC(C)C)c3F)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3976863 153258 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 569 9 2 9 4.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCC[C@H]4C(=O)OC(C)C)c3F)c(=O)c2=O)C2CCCS2)o1 nan
11818139 94148 None 0 Human Binding pIC50 = 5.0 5.0 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccccc1)Nc1cc([N+](=O)[O-])ccc1O 10.1021/jm034248l
CHEMBL24912 94148 None 0 Human Binding pIC50 = 5.0 5.0 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccccc1)Nc1cc([N+](=O)[O-])ccc1O 10.1021/jm034248l
163322283 190918 None 3 Human Binding pIC50 = 7.0 7.0 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 362 6 2 6 3.4 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cnccc12 10.1016/j.ejmech.2022.114268
CHEMBL5183834 190918 None 3 Human Binding pIC50 = 7.0 7.0 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 362 6 2 6 3.4 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cnccc12 10.1016/j.ejmech.2022.114268
9849040 152921 None 1 Human Binding pIC50 = 7.0 7.0 - 0
Compound binding was evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human C-X-C chemokine receptor type 2Compound binding was evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human C-X-C chemokine receptor type 2
ChEMBL 504 10 1 6 7.9 CCN(CC)CCCCNc1nc2cc(Cl)c(Cl)cc2nc1-c1ccc(-c2cccs2)s1 10.1016/s0960-894x(01)00326-2
CHEMBL39740 152921 None 1 Human Binding pIC50 = 7.0 7.0 - 0
Compound binding was evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human C-X-C chemokine receptor type 2Compound binding was evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human C-X-C chemokine receptor type 2
ChEMBL 504 10 1 6 7.9 CCN(CC)CCCCNc1nc2cc(Cl)c(Cl)cc2nc1-c1ccc(-c2cccs2)s1 10.1016/s0960-894x(01)00326-2
9849040 152921 None 1 Human Binding pIC50 = 7.0 7.0 - 0
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2
ChEMBL 504 10 1 6 7.9 CCN(CC)CCCCNc1nc2cc(Cl)c(Cl)cc2nc1-c1ccc(-c2cccs2)s1 10.1016/s0960-894x(02)00188-9
CHEMBL39740 152921 None 1 Human Binding pIC50 = 7.0 7.0 - 0
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2
ChEMBL 504 10 1 6 7.9 CCN(CC)CCCCNc1nc2cc(Cl)c(Cl)cc2nc1-c1ccc(-c2cccs2)s1 10.1016/s0960-894x(02)00188-9
162643191 181785 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 408 3 2 5 4.7 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccc(F)cc2)sc2c1CCOC2 10.1016/j.ejmech.2020.112387
CHEMBL4776480 181785 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 408 3 2 5 4.7 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccc(F)cc2)sc2c1CCOC2 10.1016/j.ejmech.2020.112387
44447932 95717 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 456 10 3 4 3.9 CCCCNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL258038 95717 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 456 10 3 4 3.9 CCCCNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
44447931 155475 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 456 9 2 4 3.9 CCN(CC)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL403497 155475 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 456 9 2 4 3.9 CCN(CC)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
71550940 145740 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 469 7 3 8 3.6 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCSCC2)o1 nan
CHEMBL3915853 145740 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 469 7 3 8 3.6 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCSCC2)o1 nan
44419412 83202 None 0 Human Binding pIC50 = 7.0 7.0 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 435 5 3 5 3.8 CC(C)c1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL218334 83202 None 0 Human Binding pIC50 = 7.0 7.0 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 435 5 3 5 3.8 CC(C)c1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
46897355 127302 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 464 6 1 5 5.1 CC1(C)OB(c2ccc(CSc3ccc(C(=O)Nc4ccc(F)cc4)cn3)cc2)OC1(C)C nan
CHEMBL3658241 127302 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 464 6 1 5 5.1 CC1(C)OB(c2ccc(CSc3ccc(C(=O)Nc4ccc(F)cc4)cn3)cc2)OC1(C)C nan
44393543 12814 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 369 3 4 3 3.9 NCc1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
CHEMBL1188250 12814 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 369 3 4 3 3.9 NCc1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
CHEMBL535818 12814 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 369 3 4 3 3.9 NCc1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
134135498 144100 None 0 Human Binding pIC50 = 6.9 6.9 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 523 8 3 8 4.3 Cc1ccc([C@@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3902863 144100 None 0 Human Binding pIC50 = 6.9 6.9 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 523 8 3 8 4.3 Cc1ccc([C@@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2CCCS2)o1 nan
59446418 127313 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 434 7 2 7 3.6 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc(-c2nn[nH]n2)cc1 nan
CHEMBL3658288 127313 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 434 7 2 7 3.6 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc(-c2nn[nH]n2)cc1 nan
91937334 127329 None 0 Human Binding pIC50 = 6.9 6.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 384 6 3 7 1.2 O=C(Nc1ccc(F)cn1)c1cnc(SCc2ccccc2B(O)O)nc1 nan
CHEMBL3658340 127329 None 0 Human Binding pIC50 = 6.9 6.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 384 6 3 7 1.2 O=C(Nc1ccc(F)cn1)c1cnc(SCc2ccccc2B(O)O)nc1 nan
91937342 127336 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 471 6 2 7 3.4 O=C(Nc1ccc(F)cn1)c1ccc(S(=O)(=O)Cc2cc(OC(F)(F)F)ccc2O)nc1 nan
CHEMBL3658349 127336 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 471 6 2 7 3.4 O=C(Nc1ccc(F)cn1)c1ccc(S(=O)(=O)Cc2cc(OC(F)(F)F)ccc2O)nc1 nan
9868309 65607 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 447 4 3 4 3.7 CN(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
CHEMBL183222 65607 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 447 4 3 4 3.7 CN(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
44419483 83286 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 564 8 4 7 3.6 CCC(CC)(NS(=O)(=O)c1cccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCOCC1 10.1016/j.bmcl.2006.08.042
CHEMBL218744 83286 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 564 8 4 7 3.6 CCC(CC)(NS(=O)(=O)c1cccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCOCC1 10.1016/j.bmcl.2006.08.042
44419546 84595 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 461 4 3 5 3.7 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2C(F)(F)F)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL222075 84595 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 461 4 3 5 3.7 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2C(F)(F)F)c1O 10.1016/j.bmcl.2006.08.042
44446645 94925 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2
ChEMBL 398 7 3 8 2.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)on1 10.1016/j.bmcl.2008.01.024
CHEMBL253927 94925 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2
ChEMBL 398 7 3 8 2.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)on1 10.1016/j.bmcl.2008.01.024
24780598 1316 None 38 Human Binding pIC50 = 7.9 7.9 - 1
Displacement of [125I]-CXCL8 from human CXCR2 transfected in CHO-K1 cell membrane incubated for 45 mins by scintillation proximity binding assayDisplacement of [125I]-CXCL8 from human CXCR2 transfected in CHO-K1 cell membrane incubated for 45 mins by scintillation proximity binding assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1016/j.ejmech.2023.115175
8500 1316 None 38 Human Binding pIC50 = 7.9 7.9 - 1
Displacement of [125I]-CXCL8 from human CXCR2 transfected in CHO-K1 cell membrane incubated for 45 mins by scintillation proximity binding assayDisplacement of [125I]-CXCL8 from human CXCR2 transfected in CHO-K1 cell membrane incubated for 45 mins by scintillation proximity binding assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1016/j.ejmech.2023.115175
CHEMBL3039531 1316 None 38 Human Binding pIC50 = 7.9 7.9 - 1
Displacement of [125I]-CXCL8 from human CXCR2 transfected in CHO-K1 cell membrane incubated for 45 mins by scintillation proximity binding assayDisplacement of [125I]-CXCL8 from human CXCR2 transfected in CHO-K1 cell membrane incubated for 45 mins by scintillation proximity binding assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1016/j.ejmech.2023.115175
DB11922 1316 None 38 Human Binding pIC50 = 7.9 7.9 - 1
Displacement of [125I]-CXCL8 from human CXCR2 transfected in CHO-K1 cell membrane incubated for 45 mins by scintillation proximity binding assayDisplacement of [125I]-CXCL8 from human CXCR2 transfected in CHO-K1 cell membrane incubated for 45 mins by scintillation proximity binding assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1016/j.ejmech.2023.115175
137637097 156170 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 386 4 3 4 3.8 CC1=CCCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4062881 156170 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 386 4 3 4 3.8 CC1=CCCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
58180198 140903 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 432 4 3 4 4.8 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818984 140903 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 432 4 3 4 4.8 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
9910064 118089 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 420 8 3 7 2.7 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403835 118089 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 420 8 3 7 2.7 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
10345330 118100 None 0 Human Binding pIC50 = 7.9 7.9 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 486 9 3 9 2.9 C[C@H](CO)Nc1cc(NS(=O)(=O)c2cn(C)cn2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403847 118100 None 0 Human Binding pIC50 = 7.9 7.9 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 486 9 3 9 2.9 C[C@H](CO)Nc1cc(NS(=O)(=O)c2cn(C)cn2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
23519822 87259 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL232846 87259 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
23519825 149816 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 381 6 3 8 3.4 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL394799 149816 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 381 6 3 8 3.4 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
9969306 143986 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 368 6 3 10 2.5 Cc1nc(CSc2nc(N[C@H](C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.11.039
CHEMBL390191 143986 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 368 6 3 10 2.5 Cc1nc(CSc2nc(N[C@H](C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.11.039
9885291 98340 None 0 Human Binding pIC50 = 6.9 6.9 4 2
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 361 7 3 8 3.1 CC[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
CHEMBL274737 98340 None 0 Human Binding pIC50 = 6.9 6.9 4 2
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 361 7 3 8 3.1 CC[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
44447946 95047 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 515 6 3 3 5.0 O=C(NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12)NS(=O)(=O)c1ccccc1 10.1016/j.bmcl.2008.01.127
CHEMBL254773 95047 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 515 6 3 3 5.0 O=C(NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12)NS(=O)(=O)c1ccccc1 10.1016/j.bmcl.2008.01.127
44447928 95666 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL257829 95666 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
44432392 88049 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 419 1 3 5 3.5 O=S1(=O)N=C(Nc2ccc(F)cc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL234396 88049 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 419 1 3 5 3.5 O=S1(=O)N=C(Nc2ccc(F)cc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
10018018 154028 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2 (CXCR2 filter mat binding assay)Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2 (CXCR2 filter mat binding assay)
ChEMBL 306 5 2 4 2.7 O=C(O)CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/s0960-894x(02)00188-9
CHEMBL39835 154028 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2 (CXCR2 filter mat binding assay)Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2 (CXCR2 filter mat binding assay)
ChEMBL 306 5 2 4 2.7 O=C(O)CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/s0960-894x(02)00188-9
46896583 114982 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 435 6 1 5 6.2 Cc1nc(-c2ccccc2)sc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 nan
CHEMBL3342290 114982 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 435 6 1 5 6.2 Cc1nc(-c2ccccc2)sc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 nan
46897354 126889 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 482 6 1 5 5.2 CC1(C)OB(c2ccc(F)cc2CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C nan
CHEMBL3654445 126889 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 482 6 1 5 5.2 CC1(C)OB(c2ccc(F)cc2CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C nan
91937329 127327 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 456 8 1 4 6.0 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)C(c2ccccc2)c2ccccc2)nc1 nan
CHEMBL3658336 127327 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 456 8 1 4 6.0 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)C(c2ccccc2)c2ccccc2)nc1 nan
91937341 127335 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 455 6 2 6 3.8 O=C(Nc1ccc(F)cn1)c1ccc([S+]([O-])Cc2cc(OC(F)(F)F)ccc2O)nc1 nan
CHEMBL3658348 127335 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 455 6 2 6 3.8 O=C(Nc1ccc(F)cn1)c1ccc([S+]([O-])Cc2cc(OC(F)(F)F)ccc2O)nc1 nan
136087080 116044 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 399 6 3 6 3.3 CC(C)Cc1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
CHEMBL3355234 116044 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 399 6 3 6 3.3 CC(C)Cc1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
136087087 116051 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 417 6 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)CF)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355241 116051 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 417 6 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)CF)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
136087089 116053 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 403 5 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)F)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355243 116053 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 403 5 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)F)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
118540528 156142 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4062546 156142 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
118540567 159203 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 427 5 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N(C)C)C2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4097602 159203 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 427 5 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N(C)C)C2)c1O 10.1021/acs.jmedchem.7b01854
129316051 156405 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 429 6 3 5 3.4 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CN(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4065522 156405 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 429 6 3 5 3.4 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CN(C)C)c1O 10.1021/acs.jmedchem.7b01854
9969306 143986 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 368 6 3 10 2.5 Cc1nc(CSc2nc(N[C@H](C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.02.080
CHEMBL390191 143986 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 368 6 3 10 2.5 Cc1nc(CSc2nc(N[C@H](C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.02.080
91937303 127318 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 500 6 1 5 6.4 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2csc3ccc(Br)cc23)nc1 nan
CHEMBL3658311 127318 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 500 6 1 5 6.4 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2csc3ccc(Br)cc23)nc1 nan
71526251 150874 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 469 7 3 9 2.6 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@@H]2COC(C)(C)O2)o1 nan
CHEMBL3956663 150874 None 0 Human Binding pIC50 = 5.9 5.9 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 469 7 3 9 2.6 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@@H]2COC(C)(C)O2)o1 nan
137644193 158383 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 376 4 3 5 2.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4088965 158383 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 376 4 3 5 2.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
11440492 152731 None 0 Human Binding pIC50 = 7.9 7.9 - 1
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.ejmech.2022.114268
CHEMBL397237 152731 None 0 Human Binding pIC50 = 7.9 7.9 - 1
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.ejmech.2022.114268
163322282 191744 None 3 Human Binding pIC50 = 7.9 7.9 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 352 6 2 7 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2oncc12 10.1016/j.ejmech.2022.114268
CHEMBL5195797 191744 None 3 Human Binding pIC50 = 7.9 7.9 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 352 6 2 7 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2oncc12 10.1016/j.ejmech.2022.114268
11857680 97683 None 0 Human Binding pIC50 = 7.9 7.9 - 1
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 347 6 3 8 2.8 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL271013 97683 None 0 Human Binding pIC50 = 7.9 7.9 - 1
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 347 6 3 8 2.8 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
44419449 166201 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 469 5 3 5 4.3 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2-c2ccccc2)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL425985 166201 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 469 5 3 5 4.3 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2-c2ccccc2)c1O 10.1016/j.bmcl.2006.08.042
44439704 11900 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 538 6 3 8 2.3 CN1CCN(S(=O)(=O)c2c(F)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL1182475 11900 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 538 6 3 8 2.3 CN1CCN(S(=O)(=O)c2c(F)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL239982 11900 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 538 6 3 8 2.3 CN1CCN(S(=O)(=O)c2c(F)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
23519822 87259 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL232846 87259 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
44455234 95474 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 366 6 4 7 2.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(N)nc12 10.1016/j.bmcl.2007.11.039
CHEMBL257006 95474 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 366 6 4 7 2.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(N)nc12 10.1016/j.bmcl.2007.11.039
11857680 97683 None 0 Human Binding pIC50 = 7.9 7.9 - 1
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 347 6 3 8 2.8 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL271013 97683 None 0 Human Binding pIC50 = 7.9 7.9 - 1
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 347 6 3 8 2.8 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
153842018 191136 None 3 Human Binding pIC50 = 6.9 6.9 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 368 6 2 7 3.5 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ncsc12 10.1016/j.ejmech.2022.114268
CHEMBL5186932 191136 None 3 Human Binding pIC50 = 6.9 6.9 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 368 6 2 7 3.5 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ncsc12 10.1016/j.ejmech.2022.114268
9967031 101002 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 324 4 1 4 1.5 CCS(=O)(=O)c1ccc(C(=O)Nc2ccc(F)cc2)c[n+]1[O-] 10.1016/s0960-894x(01)00326-2
CHEMBL294095 101002 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 324 4 1 4 1.5 CCS(=O)(=O)c1ccc(C(=O)Nc2ccc(F)cc2)c[n+]1[O-] 10.1016/s0960-894x(01)00326-2
9883149 205187 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 310 3 1 4 1.1 CS(=O)(=O)c1ccc(C(=O)Nc2ccc(F)cc2)c[n+]1[O-] 10.1016/s0960-894x(01)00326-2
CHEMBL61835 205187 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 310 3 1 4 1.1 CS(=O)(=O)c1ccc(C(=O)Nc2ccc(F)cc2)c[n+]1[O-] 10.1016/s0960-894x(01)00326-2
46897163 119147 None 5 Human Binding pIC50 = 6.9 6.9 - 0
Inhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assayInhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assay
ChEMBL 466 7 3 6 3.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 10.1016/j.bmcl.2015.04.041
CHEMBL3426944 119147 None 5 Human Binding pIC50 = 6.9 6.9 - 0
Inhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assayInhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assay
ChEMBL 466 7 3 6 3.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 10.1016/j.bmcl.2015.04.041
135555955 135909 None 3 Human Binding pIC50 = 5.9 5.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 290 3 2 7 2.7 Nc1nc2nc(SCc3ccccc3)nc(O)c2s1 10.1016/j.bmcl.2005.10.091
CHEMBL373067 135909 None 3 Human Binding pIC50 = 5.9 5.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 290 3 2 7 2.7 Nc1nc2nc(SCc3ccccc3)nc(O)c2s1 10.1016/j.bmcl.2005.10.091
44447919 95804 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 427 8 2 4 4.0 CCCS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL258438 95804 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 427 8 2 4 4.0 CCCS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
71525977 150292 None 0 Human Binding pIC50 = 6.9 6.9 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3951994 150292 None 0 Human Binding pIC50 = 6.9 6.9 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
71525977 150292 None 0 Human Binding pIC50 = 6.9 6.9 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3951994 150292 None 0 Human Binding pIC50 = 6.9 6.9 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL11359 9782 None 0 Human Binding pIC50 = 4.9 4.9 -3 4
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)
ChEMBL None None None None nan
44414247 168824 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 413 6 4 6 3.2 O=C(NCc1ccccc1)c1cccc(Nc2c(O)c(=O)/c2=N\c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL436940 168824 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 413 6 4 6 3.2 O=C(NCc1ccccc1)c1cccc(Nc2c(O)c(=O)/c2=N\c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
44414232 78718 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 331 2 3 6 1.3 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C(C)(C)C)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL211247 78718 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 331 2 3 6 1.3 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C(C)(C)C)c1O 10.1016/j.bmcl.2006.04.082
9841701 90600 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 357 5 4 6 2.2 NC(=O)c1c(Cl)ccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c1O 10.1016/j.bmcl.2006.12.067
CHEMBL238743 90600 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 357 5 4 6 2.2 NC(=O)c1c(Cl)ccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c1O 10.1016/j.bmcl.2006.12.067
11625425 140551 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 397 6 3 8 3.4 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
CHEMBL380947 140551 None 0 Human Binding pIC50 = 7.9 7.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 397 6 3 8 3.4 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
91937313 127321 None 0 Human Binding pIC50 = 7.9 7.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 415 7 1 8 3.2 COC(=O)c1cc(C(=O)CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)on1 nan
CHEMBL3658321 127321 None 0 Human Binding pIC50 = 7.9 7.9 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 415 7 1 8 3.2 COC(=O)c1cc(C(=O)CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)on1 nan
44455117 155511 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 377 6 2 7 3.1 Cc1cnc2nc(SCc3cccc(F)c3F)nc(N[C@H](C)CO)c2n1 10.1016/j.bmcl.2007.11.039
CHEMBL403702 155511 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 377 6 2 7 3.1 Cc1cnc2nc(SCc3cccc(F)c3F)nc(N[C@H](C)CO)c2n1 10.1016/j.bmcl.2007.11.039
44447949 95074 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 462 6 3 4 4.1 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCNC(=O)NS(=O)(=O)c3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL254978 95074 None 0 Human Binding pIC50 = 6.9 6.9 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 462 6 3 4 4.1 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCNC(=O)NS(=O)(=O)c3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
44407698 73255 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 453 9 3 9 4.9 CC[C@@H](CO)Nc1nc(SCc2cccc(Oc3ccccc3)c2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
CHEMBL201204 73255 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 453 9 3 9 4.9 CC[C@@H](CO)Nc1nc(SCc2cccc(Oc3ccccc3)c2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
44447920 155576 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 475 8 2 4 4.8 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)Cc3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL404062 155576 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 475 8 2 4 4.8 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)Cc3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
9904302 208471 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 297 4 1 5 3.3 COc1ccccc1-c1nc(S)n(Cc2ccccc2)n1 10.1016/s0960-894x(03)00561-4
CHEMBL84957 208471 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 297 4 1 5 3.3 COc1ccccc1-c1nc(S)n(Cc2ccccc2)n1 10.1016/s0960-894x(03)00561-4
9903859 208788 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 281 3 1 4 3.6 Cc1ccccc1-c1nc(S)n(Cc2ccccc2)n1 10.1016/s0960-894x(03)00561-4
CHEMBL87282 208788 None 0 Human Binding pIC50 = 5.9 5.9 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 281 3 1 4 3.6 Cc1ccccc1-c1nc(S)n(Cc2ccccc2)n1 10.1016/s0960-894x(03)00561-4
71525696 133380 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 455 7 3 8 3.0 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)s1 nan
CHEMBL3704562 133380 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 455 7 3 8 3.0 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)s1 nan
46897449 114988 None 0 Human Binding pIC50 = 5.8 5.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2C(=O)O)nc1 nan
CHEMBL3342311 114988 None 0 Human Binding pIC50 = 5.8 5.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2C(=O)O)nc1 nan
44419411 141936 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 421 5 3 5 3.2 CCc1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL386505 141936 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 421 5 3 5 3.2 CCc1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
9879541 78057 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 305 3 3 6 2.2 N#Cc1ccc(Nc2c(O)c(=O)/c2=N\c2ccccc2)c(O)c1 10.1016/j.bmcl.2006.12.067
CHEMBL209859 78057 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 305 3 3 6 2.2 N#Cc1ccc(Nc2c(O)c(=O)/c2=N\c2ccccc2)c(O)c1 10.1016/j.bmcl.2006.12.067
9821417 90719 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 383 4 3 6 3.1 N#Cc1ccc(Nc2c(Nc3ccccc3Br)c(=O)c2=O)c(O)c1 10.1016/j.bmcl.2006.12.067
CHEMBL239136 90719 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 383 4 3 6 3.1 N#Cc1ccc(Nc2c(Nc3ccccc3Br)c(=O)c2=O)c(O)c1 10.1016/j.bmcl.2006.12.067
44439701 91109 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 415 6 3 7 2.3 Cc1ccccc1Nc1c(Nc2ccc(C)c(S(=O)(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL239768 91109 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 415 6 3 7 2.3 Cc1ccccc1Nc1c(Nc2ccc(C)c(S(=O)(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2006.12.067
9968028 83324 None 0 Human Binding pIC50 = 7.8 7.8 - 1
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 345 7 3 6 2.0 CCC(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1021/jm0609622
CHEMBL218964 83324 None 0 Human Binding pIC50 = 7.8 7.8 - 1
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 345 7 3 6 2.0 CCC(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1021/jm0609622
71526254 144905 None 0 Human Binding pIC50 = 7.8 7.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 523 8 3 8 4.3 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3909470 144905 None 0 Human Binding pIC50 = 7.8 7.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 523 8 3 8 4.3 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2CCCS2)o1 nan
71525977 150292 None 0 Human Binding pIC50 = 7.8 7.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3951994 150292 None 0 Human Binding pIC50 = 7.8 7.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
136087083 116047 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 397 5 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3CCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355237 116047 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 397 5 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3CCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
136087086 116050 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 411 5 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3(C)CCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355240 116050 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 411 5 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3(C)CCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
44431207 87297 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2cccc(F)c2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL233059 87297 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2cccc(F)c2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
44431210 87375 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 415 6 3 8 4.1 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2Cl)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL233260 87375 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 415 6 3 8 4.1 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2Cl)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
44431171 143481 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 413 7 4 9 2.4 C[C@@H](O)[C@@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL389791 143481 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 413 7 4 9 2.4 C[C@@H](O)[C@@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
9841667 140836 None 41 Human Binding pIC50 = 6.8 6.8 1000 2
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1016/j.ejmech.2020.112387
CHEMBL38182 140836 None 41 Human Binding pIC50 = 6.8 6.8 1000 2
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1016/j.ejmech.2020.112387
44447939 94990 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 470 7 2 5 2.9 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)N3CCOCC3)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL254366 94990 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 470 7 2 5 2.9 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)N3CCOCC3)c2c1 10.1016/j.bmcl.2008.01.127
44446578 94978 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 527 8 3 7 5.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(-c2ccccc2C(F)(F)F)o1 10.1016/j.bmcl.2008.01.024
CHEMBL254308 94978 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 527 8 3 7 5.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(-c2ccccc2C(F)(F)F)o1 10.1016/j.bmcl.2008.01.024
136060643 87595 None 0 Human Binding pIC50 = 4.8 4.8 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 303 2 3 5 1.9 CC[C@@H](C)NC1=NS(=O)(=O)c2cc(Cl)cc(O)c2N1 10.1016/j.bmcl.2007.05.011
CHEMBL233551 87595 None 0 Human Binding pIC50 = 4.8 4.8 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 303 2 3 5 1.9 CC[C@@H](C)NC1=NS(=O)(=O)c2cc(Cl)cc(O)c2N1 10.1016/j.bmcl.2007.05.011
134149652 148290 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 513 11 4 11 2.6 COC(=O)CNCC(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
CHEMBL3935902 148290 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 513 11 4 11 2.6 COC(=O)CNCC(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
71555288 148603 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 467 7 3 8 3.3 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCOCC2)o1 nan
CHEMBL3938406 148603 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 467 7 3 8 3.3 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCOCC2)o1 nan
168279497 190860 None 0 Human Binding pIC50 = 4.8 4.8 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cc[nH]c12 10.1016/j.ejmech.2022.114268
CHEMBL5182926 190860 None 0 Human Binding pIC50 = 4.8 4.8 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cc[nH]c12 10.1016/j.ejmech.2022.114268
118540892 157820 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 377 3 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4082136 157820 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 377 3 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
118540525 159484 None 15 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4100674 159484 None 15 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
137639152 157038 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 388 4 3 4 3.9 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC2(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4072677 157038 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 388 4 3 4 3.9 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC2(C)C)c1O 10.1021/acs.jmedchem.7b01854
127049432 140840 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 436 4 3 4 5.2 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3818216 140840 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 436 4 3 4 5.2 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
127049048 140851 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 489 5 3 5 4.7 CCN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818331 140851 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 489 5 3 5 4.7 CCN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
127049047 140941 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 491 4 3 5 4.9 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819521 140941 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 491 4 3 5 4.9 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
57833203 118090 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 436 8 3 7 3.2 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2cccc(Cl)c2Cl)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403836 118090 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 436 8 3 7 3.2 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2cccc(Cl)c2Cl)n1 10.1016/j.bmcl.2015.01.067
57833215 118092 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 396 10 3 7 2.7 CCCS(=O)(=O)Nc1cc(N[C@H](C)CO)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403838 118092 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 396 10 3 7 2.7 CCCS(=O)(=O)Nc1cc(N[C@H](C)CO)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
137645186 158030 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 404 5 3 5 3.3 COC1CCCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4084545 158030 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 404 5 3 5 3.3 COC1CCCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
44431198 93359 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 455 10 3 9 3.3 CCN(CC)c1nc2nc(SCc3cccc(F)c3F)nc(NC(CO)CO)c2s1 10.1016/j.bmcl.2007.02.080
CHEMBL245182 93359 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 455 10 3 9 3.3 CCN(CC)c1nc2nc(SCc3cccc(F)c3F)nc(NC(CO)CO)c2s1 10.1016/j.bmcl.2007.02.080
127049429 140813 None 0 Human Binding pIC50 = 4.8 4.8 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 507 4 3 5 4.8 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
CHEMBL3817880 140813 None 0 Human Binding pIC50 = 4.8 4.8 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 507 4 3 5 4.8 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
46896265 127305 None 0 Human Binding pIC50 = 5.8 5.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 426 7 1 6 4.4 O=C(Nc1ccc(F)cc1)c1ccc(SCCOc2cccc3c2OCCO3)nc1 nan
CHEMBL3658247 127305 None 0 Human Binding pIC50 = 5.8 5.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 426 7 1 6 4.4 O=C(Nc1ccc(F)cc1)c1ccc(SCCOc2cccc3c2OCCO3)nc1 nan
44419555 142029 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 626 9 5 7 4.5 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCC[C@@H]1C(=O)O 10.1016/j.bmcl.2006.08.042
CHEMBL387136 142029 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 626 9 5 7 4.5 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCC[C@@H]1C(=O)O 10.1016/j.bmcl.2006.08.042
44455010 155499 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 403 6 3 7 2.6 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)c(C#N)cc12 10.1016/j.bmcl.2007.11.039
CHEMBL403656 155499 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 403 6 3 7 2.6 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)c(C#N)cc12 10.1016/j.bmcl.2007.11.039
71526159 145487 None 0 Human Binding pIC50 = 7.8 7.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 525 8 3 9 3.6 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3913959 145487 None 0 Human Binding pIC50 = 7.8 7.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 525 8 3 9 3.6 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
91937271 127311 None 0 Human Binding pIC50 = 7.8 7.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 445 7 1 6 5.0 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc(Cl)c([N+](=O)[O-])c1 nan
CHEMBL3658278 127311 None 0 Human Binding pIC50 = 7.8 7.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 445 7 1 6 5.0 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc(Cl)c([N+](=O)[O-])c1 nan
44446605 94893 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 461 7 3 7 3.4 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1occc1Br 10.1016/j.bmcl.2008.01.024
CHEMBL253707 94893 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 461 7 3 7 3.4 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1occc1Br 10.1016/j.bmcl.2008.01.024
44447924 155583 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 429 7 2 5 3.3 COc1cc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(C)(=O)=O)c2cc1C#N 10.1016/j.bmcl.2008.01.127
CHEMBL404088 155583 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 429 7 2 5 3.3 COc1cc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(C)(=O)=O)c2cc1C#N 10.1016/j.bmcl.2008.01.127
162668484 182679 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 418 4 2 5 4.8 C[C@@H](NC(=S)Nc1sc2c(c1C(=O)OC(C)(C)C)CCOC2)c1ccccc1 10.1016/j.ejmech.2020.112387
CHEMBL4787874 182679 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 418 4 2 5 4.8 C[C@@H](NC(=S)Nc1sc2c(c1C(=O)OC(C)(C)C)CCOC2)c1ccccc1 10.1016/j.ejmech.2020.112387
162674635 183527 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 474 4 2 6 5.5 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccc(OC(F)(F)F)cc2)sc2c1CCOC2 10.1016/j.ejmech.2020.112387
CHEMBL4798569 183527 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 474 4 2 6 5.5 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccc(OC(F)(F)F)cc2)sc2c1CCOC2 10.1016/j.ejmech.2020.112387
44432394 153472 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 419 1 3 5 3.5 O=S1(=O)N=C(Nc2c(F)cccc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL397869 153472 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 419 1 3 5 3.5 O=S1(=O)N=C(Nc2c(F)cccc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
46897452 114984 None 0 Human Binding pIC50 = 5.8 5.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 406 5 1 3 6.1 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc(Cl)c(Cl)c2)nc1 nan
CHEMBL3342303 114984 None 0 Human Binding pIC50 = 5.8 5.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 406 5 1 3 6.1 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc(Cl)c(Cl)c2)nc1 nan
91937336 127332 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 417 6 3 6 2.5 O=C(Nc1ccc(F)cn1)c1cnc(SCc2ccccc2B(O)O)c(Cl)c1 nan
CHEMBL3658343 127332 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 417 6 3 6 2.5 O=C(Nc1ccc(F)cn1)c1cnc(SCc2ccccc2B(O)O)c(Cl)c1 nan
135286501 172219 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 546 8 3 10 2.6 Cc1ccc([C@H](Nc2c(Nc3cccc(S(=O)(=O)N4CCN(C)CC4)c3O)c(=O)c2=O)[C@H]2CCCS2)o1 10.1016/j.ejmech.2019.111853
CHEMBL4472754 172219 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 546 8 3 10 2.6 Cc1ccc([C@H](Nc2c(Nc3cccc(S(=O)(=O)N4CCN(C)CC4)c3O)c(=O)c2=O)[C@H]2CCCS2)o1 10.1016/j.ejmech.2019.111853
44419439 84257 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 407 4 3 5 3.0 Cc1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL220860 84257 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 407 4 3 5 3.0 Cc1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
44419476 136476 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 562 8 4 7 4.6 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2C)c1O)N1C[C@H](C)O[C@H](C)C1 10.1016/j.bmcl.2006.08.042
CHEMBL373522 136476 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 562 8 4 7 4.6 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2C)c1O)N1C[C@H](C)O[C@H](C)C1 10.1016/j.bmcl.2006.08.042
16098485 10414 None 0 Human Binding pIC50 = 7.8 7.8 - 1
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 379 6 3 6 2.6 C[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
CHEMBL1162935 10414 None 0 Human Binding pIC50 = 7.8 7.8 - 1
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 379 6 3 6 2.6 C[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
71526345 150414 None 0 Human Binding pIC50 = 7.8 7.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 580 8 3 10 3.3 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N4CCN(C)CC4)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3952996 150414 None 0 Human Binding pIC50 = 7.8 7.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 580 8 3 10 3.3 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N4CCN(C)CC4)c3O)c(=O)c2=O)C2CCCS2)o1 nan
44446568 155626 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 451 7 3 7 3.6 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(F)(F)F)o1 10.1016/j.bmcl.2008.01.024
CHEMBL404250 155626 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 451 7 3 7 3.6 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(F)(F)F)o1 10.1016/j.bmcl.2008.01.024
44447917 95160 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 452 6 2 3 4.1 CS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL255481 95160 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 452 6 2 3 4.1 CS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2008.01.127
71526341 153656 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 435 7 3 7 2.8 CN(C)C(=O)c1cccc(Nc2c(NC(c3ccccc3)C3CCCO3)c(=O)c2=O)c1O nan
CHEMBL3980279 153656 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 435 7 3 7 2.8 CN(C)C(=O)c1cccc(Nc2c(NC(c3ccccc3)C3CCCO3)c(=O)c2=O)c1O nan
44318556 107106 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 427 5 1 5 6.4 Sc1nc(-c2ccc(Cl)cc2Cl)nn1Cc1cccc(Oc2ccccc2)c1 10.1016/s0960-894x(03)00561-4
CHEMBL315588 107106 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 427 5 1 5 6.4 Sc1nc(-c2ccc(Cl)cc2Cl)nn1Cc1cccc(Oc2ccccc2)c1 10.1016/s0960-894x(03)00561-4
162673706 183316 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 404 3 2 5 5.1 CC1COCc2sc(NC(=S)Nc3ccccc3)c(C(=O)OC(C)(C)C)c21 10.1016/j.ejmech.2020.112387
CHEMBL4795943 183316 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 404 3 2 5 5.1 CC1COCc2sc(NC(=S)Nc3ccccc3)c(C(=O)OC(C)(C)C)c21 10.1016/j.ejmech.2020.112387
10309077 165943 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 359 3 3 7 0.7 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C2CCOCC2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL424887 165943 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 359 3 3 7 0.7 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C2CCOCC2)c1O 10.1016/j.bmcl.2006.04.082
44446572 94827 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 454 8 3 8 2.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(=O)N(C)C)o1 10.1016/j.bmcl.2008.01.024
CHEMBL253255 94827 None 0 Human Binding pIC50 = 6.8 6.8 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 454 8 3 8 2.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(=O)N(C)C)o1 10.1016/j.bmcl.2008.01.024
168275518 190615 None 0 Human Binding pIC50 = 4.8 4.8 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 367 6 2 6 4.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ccsc12 10.1016/j.ejmech.2022.114268
CHEMBL5179345 190615 None 0 Human Binding pIC50 = 4.8 4.8 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 367 6 2 6 4.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ccsc12 10.1016/j.ejmech.2022.114268
44439682 148113 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 294 4 3 5 2.8 Cc1cccc(O)c1Nc1c(Nc2ccccc2)c(=O)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL393452 148113 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 294 4 3 5 2.8 Cc1cccc(O)c1Nc1c(Nc2ccccc2)c(=O)c1=O 10.1016/j.bmcl.2006.12.067
46897451 114989 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 406 6 2 6 3.9 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2-c2nn[nH]n2)nc1 nan
CHEMBL3342312 114989 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 406 6 2 6 3.9 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2-c2nn[nH]n2)nc1 nan
71526160 159951 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 439 7 3 8 2.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@H]2CCCO2)o1 nan
CHEMBL4106677 159951 None 0 Human Binding pIC50 = 6.8 6.8 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 439 7 3 8 2.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@H]2CCCO2)o1 nan
10143778 12909 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 544 7 3 8 3.8 O=c1c(Nc2ccccc2)c(Nc2ccc(Cl)c(S(=O)(=O)N3CCC(N4CCCCC4)CC3)c2O)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL1188997 12909 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 544 7 3 8 3.8 O=c1c(Nc2ccccc2)c(Nc2ccc(Cl)c(S(=O)(=O)N3CCC(N4CCCCC4)CC3)c2O)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL537883 12909 None 0 Human Binding pIC50 = 7.8 7.8 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 544 7 3 8 3.8 O=c1c(Nc2ccccc2)c(Nc2ccc(Cl)c(S(=O)(=O)N3CCC(N4CCCCC4)CC3)c2O)c1=O 10.1016/j.bmcl.2006.12.067
162644160 181893 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 388 3 2 4 5.4 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1CCCC2 10.1016/j.ejmech.2020.112387
CHEMBL4777868 181893 None 0 Human Binding pIC50 = 5.8 5.8 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 388 3 2 4 5.4 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1CCCC2 10.1016/j.ejmech.2020.112387
91937304 127319 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 422 6 1 5 5.7 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2cc3ccccc3s2)nc1 nan
CHEMBL3658312 127319 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 422 6 1 5 5.7 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2cc3ccccc3s2)nc1 nan
91937270 127310 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 434 6 1 4 5.8 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc(Cl)c(Cl)c1 nan
CHEMBL3658277 127310 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 434 6 1 4 5.8 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc(Cl)c(Cl)c1 nan
44626319 200877 None 0 Human Binding pIC50 = 5.7 5.7 81 2
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 346 7 3 7 1.1 CCN(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2009.08.014
CHEMBL577075 200877 None 0 Human Binding pIC50 = 5.7 5.7 81 2
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 346 7 3 7 1.1 CCN(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2009.08.014
44447925 155411 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 413 6 2 4 3.6 Cc1cc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(C)(=O)=O)c2cc1C#N 10.1016/j.bmcl.2008.01.127
CHEMBL403084 155411 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 413 6 2 4 3.6 Cc1cc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(C)(=O)=O)c2cc1C#N 10.1016/j.bmcl.2008.01.127
9968028 83324 None 0 Human Binding pIC50 = 7.7 7.7 - 1
Inhibition of human CXCR2-mediated chemotaxis expressed in mouse BaF3 cellsInhibition of human CXCR2-mediated chemotaxis expressed in mouse BaF3 cells
ChEMBL 345 7 3 6 2.0 CCC(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.ejmech.2020.112872
CHEMBL218964 83324 None 0 Human Binding pIC50 = 7.7 7.7 - 1
Inhibition of human CXCR2-mediated chemotaxis expressed in mouse BaF3 cellsInhibition of human CXCR2-mediated chemotaxis expressed in mouse BaF3 cells
ChEMBL 345 7 3 6 2.0 CCC(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.ejmech.2020.112872
136087084 116048 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 411 5 3 6 3.7 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3CCCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355238 116048 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 411 5 3 6 3.7 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3CCCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
44431182 151371 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 423 8 3 8 4.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NC3CC3)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL396043 151371 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 423 8 3 8 4.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NC3CC3)sc12 10.1016/j.bmcl.2007.02.080
162669638 182684 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 454 4 2 6 5.5 CCOC(=O)c1c(NC(=S)Nc2ccc3c(c2)OC(F)(F)O3)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4787966 182684 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 454 4 2 6 5.5 CCOC(=O)c1c(NC(=S)Nc2ccc3c(c2)OC(F)(F)O3)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
91937316 127322 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 424 6 1 6 4.2 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc2c(c1)OCCO2 nan
CHEMBL3658323 127322 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 424 6 1 6 4.2 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc2c(c1)OCCO2 nan
71526250 142738 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 541 8 2 9 3.9 COC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)[C@H]3CCCS3)c(=O)c2=O)c1F nan
CHEMBL3891755 142738 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 541 8 2 9 3.9 COC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)[C@H]3CCCS3)c(=O)c2=O)c1F nan
46897164 119150 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 3 5 2.4 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cccc(B(O)O)c2)nc1 nan
CHEMBL3426948 119150 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 3 5 2.4 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cccc(B(O)O)c2)nc1 nan
71525697 133381 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 425 7 3 8 2.2 CN(C)C(=O)c1cccc(Nc2c(NC(c3ccco3)C3(C)COC3)c(=O)c2=O)c1O nan
CHEMBL3704563 133381 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 425 7 3 8 2.2 CN(C)C(=O)c1cccc(Nc2c(NC(c3ccco3)C3(C)COC3)c(=O)c2=O)c1O nan
136087079 115996 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 385 6 3 6 3.0 CCCc1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
CHEMBL3354834 115996 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 385 6 3 6 3.0 CCCc1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
129316076 155932 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4060060 155932 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
118554794 156493 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4066510 156493 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
118554787 159334 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 459 6 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(CCF)CC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4098979 159334 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 459 6 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(CCF)CC2)c1O 10.1021/acs.jmedchem.7b01854
137645182 158023 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 374 4 3 4 3.5 CC1CCC(NC(=O)Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)C1 10.1021/acs.jmedchem.7b01854
CHEMBL4084474 158023 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 374 4 3 4 3.5 CC1CCC(NC(=O)Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)C1 10.1021/acs.jmedchem.7b01854
59446380 114997 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 440 8 3 6 1.9 O=C(O)CN(C(=O)c1ccc(SCc2ccccc2B(O)O)nc1)c1ccc(F)cc1 nan
CHEMBL3342323 114997 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 440 8 3 6 1.9 O=C(O)CN(C(=O)c1ccc(SCc2ccccc2B(O)O)nc1)c1ccc(F)cc1 nan
127049108 140931 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 490 5 3 5 3.8 CCN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819382 140931 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 490 5 3 5 3.8 CCN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
127049427 140948 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 504 5 3 5 4.2 CC(C)N1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819603 140948 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 504 5 3 5 4.2 CC(C)N1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
9928389 194001 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 351 5 3 6 2.2 CN(C)C(=O)c1cccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c1O 10.1039/D1MD00058F
CHEMBL5276296 194001 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 351 5 3 6 2.2 CN(C)C(=O)c1cccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c1O 10.1039/D1MD00058F
49763036 175446 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Displacement of [125I]IL-8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL-8 from human CXCR2 expressed in CHO cells
ChEMBL 398 7 3 8 2.3 CC[C@@H](Nc1c(Nc2ccnc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.ejmech.2019.111853
CHEMBL4574181 175446 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Displacement of [125I]IL-8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL-8 from human CXCR2 expressed in CHO cells
ChEMBL 398 7 3 8 2.3 CC[C@@H](Nc1c(Nc2ccnc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.ejmech.2019.111853
9928389 79640 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 351 3 3 6 1.8 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL211468 79640 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 351 3 3 6 1.8 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
10134701 142078 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 385 3 3 6 2.5 CN(C)C(=O)c1cc(Cl)cc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL387431 142078 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 385 3 3 6 2.5 CN(C)C(=O)c1cc(Cl)cc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
23519852 97682 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 366 6 3 7 2.6 C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL271012 97682 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 366 6 3 7 2.6 C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
44454985 97895 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 437 7 3 9 1.9 COC(=O)c1nc2c(N[C@H](C)CO)nc(SCc3cccc(F)c3F)nc2[nH]c1=O 10.1016/j.bmcl.2007.11.039
CHEMBL272105 97895 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 437 7 3 9 1.9 COC(=O)c1nc2c(N[C@H](C)CO)nc(SCc3cccc(F)c3F)nc2[nH]c1=O 10.1016/j.bmcl.2007.11.039
25110787 155193 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2
ChEMBL 461 7 3 7 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(Br)co1 10.1016/j.bmcl.2008.01.024
CHEMBL401939 155193 None 0 Human Binding pIC50 = 8.7 8.7 - 0
Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2
ChEMBL 461 7 3 7 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(Br)co1 10.1016/j.bmcl.2008.01.024
118554789 157356 None 0 Human Binding pIC50 = 8.6 8.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 477 6 3 5 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(CC(F)F)CC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4076676 157356 None 0 Human Binding pIC50 = 8.6 8.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 477 6 3 5 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(CC(F)F)CC2)c1O 10.1021/acs.jmedchem.7b01854
10479451 118104 None 0 Human Binding pIC50 = 8.6 8.6 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 461 9 3 7 2.7 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403851 118104 None 0 Human Binding pIC50 = 8.6 8.6 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 461 9 3 7 2.7 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
8497 2737 None 41 Human Binding pIC50 = 8.6 8.6 39 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1039/D1MD00058F
9865554 2737 None 41 Human Binding pIC50 = 8.6 8.6 39 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1039/D1MD00058F
CHEMBL216981 2737 None 41 Human Binding pIC50 = 8.6 8.6 39 2
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1039/D1MD00058F
8497 2737 None 41 Human Binding pIC50 = 8.6 8.6 39 2
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/jm0609622
9865554 2737 None 41 Human Binding pIC50 = 8.6 8.6 39 2
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/jm0609622
CHEMBL216981 2737 None 41 Human Binding pIC50 = 8.6 8.6 39 2
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/jm0609622
44446570 166611 None 0 Human Binding pIC50 = 8.6 8.6 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 413 8 4 8 2.1 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(CO)o1 10.1016/j.bmcl.2008.01.024
CHEMBL427888 166611 None 0 Human Binding pIC50 = 8.6 8.6 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 413 8 4 8 2.1 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(CO)o1 10.1016/j.bmcl.2008.01.024
10186524 12887 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 524 6 3 8 3.1 CN1CCCN(S(=O)(=O)c2c(Cl)ccc(Nc3c(Nc4ccccc4Cl)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL1188821 12887 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 524 6 3 8 3.1 CN1CCCN(S(=O)(=O)c2c(Cl)ccc(Nc3c(Nc4ccccc4Cl)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL537441 12887 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 524 6 3 8 3.1 CN1CCCN(S(=O)(=O)c2c(Cl)ccc(Nc3c(Nc4ccccc4Cl)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
71526342 144275 None 0 Human Binding pIC50 = 7.7 7.7 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 513 9 3 10 2.9 COC(=O)CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
CHEMBL3904195 144275 None 0 Human Binding pIC50 = 7.7 7.7 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 513 9 3 10 2.9 COC(=O)CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
11184341 95207 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 253 2 3 3 2.9 N#Cc1ccc(NC(=O)Nc2ccccc2)c(O)c1 10.1016/j.bmcl.2006.12.067
CHEMBL25573 95207 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 253 2 3 3 2.9 N#Cc1ccc(NC(=O)Nc2ccccc2)c(O)c1 10.1016/j.bmcl.2006.12.067
11184341 95207 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 253 2 3 3 2.9 N#Cc1ccc(NC(=O)Nc2ccccc2)c(O)c1 10.1021/jm034248l
CHEMBL25573 95207 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 253 2 3 3 2.9 N#Cc1ccc(NC(=O)Nc2ccccc2)c(O)c1 10.1021/jm034248l
162671201 182985 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 442 4 2 4 6.2 CCOC(=O)c1c(NC(=S)Nc2ccc(C(F)(F)F)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4791845 182985 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 442 4 2 4 6.2 CCOC(=O)c1c(NC(=S)Nc2ccc(C(F)(F)F)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
1485055 35431 None 19 Human Binding pIC50 = 5.7 5.7 - 0
Displacement of [125I]GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cellsDisplacement of [125I]GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cells
ChEMBL 271 3 1 5 3.0 Cc1cc2nc(CSc3ccccc3)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
CHEMBL1437942 35431 None 19 Human Binding pIC50 = 5.7 5.7 - 0
Displacement of [125I]GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cellsDisplacement of [125I]GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cells
ChEMBL 271 3 1 5 3.0 Cc1cc2nc(CSc3ccccc3)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
17903305 208593 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 273 3 1 5 3.3 Sc1nc(-c2cccs2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL86001 208593 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 273 3 1 5 3.3 Sc1nc(-c2cccs2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
17903294 208594 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2cc(Cl)cc(Cl)c2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL86002 208594 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2cc(Cl)cc(Cl)c2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
135508400 87596 None 0 Human Binding pIC50 = 4.7 4.7 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 315 1 3 5 2.0 O=S1(=O)N=C(NC2CCCC2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL233552 87596 None 0 Human Binding pIC50 = 4.7 4.7 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 315 1 3 5 2.0 O=S1(=O)N=C(NC2CCCC2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
44439676 146499 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 294 4 3 5 2.8 Cc1ccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c(O)c1 10.1016/j.bmcl.2006.12.067
CHEMBL392181 146499 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 294 4 3 5 2.8 Cc1ccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c(O)c1 10.1016/j.bmcl.2006.12.067
71525698 133382 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 439 7 3 8 2.5 Cc1coc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)c1 nan
CHEMBL3704564 133382 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 439 7 3 8 2.5 Cc1coc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)c1 nan
135497124 174583 None 0 Human Binding pIC50 = 7.7 7.7 -6 2
Displacement of [125I]CXCL1 from CXCR2 receptor in human PMN assessed as myeloperoxidase releaseDisplacement of [125I]CXCL1 from CXCR2 receptor in human PMN assessed as myeloperoxidase release
ChEMBL 429 6 3 8 4.8 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)C)c2O)C(C)(C)C)o1 10.1016/j.bmcl.2009.01.027
CHEMBL455431 174583 None 0 Human Binding pIC50 = 7.7 7.7 -6 2
Displacement of [125I]CXCL1 from CXCR2 receptor in human PMN assessed as myeloperoxidase releaseDisplacement of [125I]CXCL1 from CXCR2 receptor in human PMN assessed as myeloperoxidase release
ChEMBL 429 6 3 8 4.8 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)C)c2O)C(C)(C)C)o1 10.1016/j.bmcl.2009.01.027
71526067 143987 None 0 Human Binding pIC50 = 7.7 7.7 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 539 8 3 10 3.5 COC(=O)[C@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
CHEMBL3901913 143987 None 0 Human Binding pIC50 = 7.7 7.7 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 539 8 3 10 3.5 COC(=O)[C@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
44446631 94867 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 433 7 3 7 3.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1sccc1Cl 10.1016/j.bmcl.2008.01.024
CHEMBL253504 94867 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 433 7 3 7 3.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1sccc1Cl 10.1016/j.bmcl.2008.01.024
46897163 119147 None 5 Human Binding pIC50 = 7.7 7.7 - 0
Inhibition of CXCR2 (unknown origin) transfected with RBL cellsInhibition of CXCR2 (unknown origin) transfected with RBL cells
ChEMBL 466 7 3 6 3.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 10.1016/j.bmcl.2015.04.041
CHEMBL3426944 119147 None 5 Human Binding pIC50 = 7.7 7.7 - 0
Inhibition of CXCR2 (unknown origin) transfected with RBL cellsInhibition of CXCR2 (unknown origin) transfected with RBL cells
ChEMBL 466 7 3 6 3.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 10.1016/j.bmcl.2015.04.041
91937267 127309 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 400 6 1 4 5.1 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1cccc(Cl)c1 nan
CHEMBL3658274 127309 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 400 6 1 4 5.1 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1cccc(Cl)c1 nan
162672731 183124 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 392 4 2 4 5.3 CCOC(=O)c1c(NC(=S)Nc2ccc(F)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4793810 183124 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 392 4 2 4 5.3 CCOC(=O)c1c(NC(=S)Nc2ccc(F)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
71555444 149281 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 453 7 3 8 2.9 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCOCC2)o1 nan
CHEMBL3943808 149281 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 453 7 3 8 2.9 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCOCC2)o1 nan
46897450 114986 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 2 4 4.5 O=C(O)c1cccc(CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)c1 nan
CHEMBL3342309 114986 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 2 4 4.5 O=C(O)c1cccc(CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)c1 nan
46896482 127307 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 380 5 1 6 4.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc3nonc3c2)nc1 nan
CHEMBL3658260 127307 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 380 5 1 6 4.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc3nonc3c2)nc1 nan
3854666 3501 None 58 Human Binding pIC50 = 7.7 7.7 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1021/jm300682j
833 3501 None 58 Human Binding pIC50 = 7.7 7.7 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1021/jm300682j
CHEMBL239767 3501 None 58 Human Binding pIC50 = 7.7 7.7 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1021/jm300682j
3854666 3501 None 58 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of 125I-IL-8 from CXCR2 (unknown origin) expressed in CHO cell membrane incubated for 1 hr by liquid scintillation counter analysisDisplacement of 125I-IL-8 from CXCR2 (unknown origin) expressed in CHO cell membrane incubated for 1 hr by liquid scintillation counter analysis
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1016/j.ejmech.2023.115175
833 3501 None 58 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of 125I-IL-8 from CXCR2 (unknown origin) expressed in CHO cell membrane incubated for 1 hr by liquid scintillation counter analysisDisplacement of 125I-IL-8 from CXCR2 (unknown origin) expressed in CHO cell membrane incubated for 1 hr by liquid scintillation counter analysis
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1016/j.ejmech.2023.115175
CHEMBL239767 3501 None 58 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of 125I-IL-8 from CXCR2 (unknown origin) expressed in CHO cell membrane incubated for 1 hr by liquid scintillation counter analysisDisplacement of 125I-IL-8 from CXCR2 (unknown origin) expressed in CHO cell membrane incubated for 1 hr by liquid scintillation counter analysis
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1016/j.ejmech.2023.115175
44419558 141859 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 611 8 5 7 4.4 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCC(N)CC1 10.1016/j.bmcl.2006.08.042
CHEMBL386072 141859 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 611 8 5 7 4.4 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCC(N)CC1 10.1016/j.bmcl.2006.08.042
44414071 138506 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 337 3 4 6 1.5 CNC(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL377397 138506 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 337 3 4 6 1.5 CNC(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
3854666 3501 None 58 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1016/j.bmcl.2006.12.067
833 3501 None 58 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1016/j.bmcl.2006.12.067
CHEMBL239767 3501 None 58 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 351 3 3 4 3.7 O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-] 10.1016/j.bmcl.2006.12.067
9880342 139569 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 325 4 3 7 2.2 O=c1c(O)c(Nc2ccc([N+](=O)[O-])cc2O)/c1=N/c1ccccc1 10.1016/j.bmcl.2006.12.067
CHEMBL379438 139569 None 0 Human Binding pIC50 = 7.7 7.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 325 4 3 7 2.2 O=c1c(O)c(Nc2ccc([N+](=O)[O-])cc2O)/c1=N/c1ccccc1 10.1016/j.bmcl.2006.12.067
46897163 119147 None 5 Human Binding pIC50 = 7.7 7.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 466 7 3 6 3.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 nan
CHEMBL3426944 119147 None 5 Human Binding pIC50 = 7.7 7.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 466 7 3 6 3.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 nan
11245544 98301 None 2 Human Binding pIC50 = 7.7 7.7 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 365 2 3 3 4.3 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c(O)c1Cl 10.1021/jm034248l
CHEMBL27446 98301 None 2 Human Binding pIC50 = 7.7 7.7 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 365 2 3 3 4.3 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c(O)c1Cl 10.1021/jm034248l
9903068 95482 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 351 6 3 6 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]ncc12 10.1016/j.bmcl.2007.11.039
CHEMBL257025 95482 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 351 6 3 6 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]ncc12 10.1016/j.bmcl.2007.11.039
44447921 95124 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 427 7 2 4 4.0 CC(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL255289 95124 None 0 Human Binding pIC50 = 6.7 6.7 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 427 7 2 4 4.0 CC(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
162669363 182871 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 458 5 2 5 6.1 CCOC(=O)c1c(NC(=S)Nc2ccc(OC(F)(F)F)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4790233 182871 None 0 Human Binding pIC50 = 5.7 5.7 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 458 5 2 5 6.1 CCOC(=O)c1c(NC(=S)Nc2ccc(OC(F)(F)F)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
78098584 143829 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 541 8 2 9 3.9 COC(=O)C1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1F nan
CHEMBL3900726 143829 None 0 Human Binding pIC50 = 6.7 6.7 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 541 8 2 9 3.9 COC(=O)C1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1F nan
91937320 127323 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 373 6 1 6 3.9 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2ccsn2)nc1 nan
CHEMBL3658327 127323 None 0 Human Binding pIC50 = 5.7 5.7 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 373 6 1 6 3.9 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2ccsn2)nc1 nan
71526252 149807 None 0 Human Binding pIC50 = 7.6 7.6 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 385 6 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccnc3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3947915 149807 None 0 Human Binding pIC50 = 7.6 7.6 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 385 6 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccnc3O)c(=O)c2=O)C2CCCS2)o1 nan
44432397 87968 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 399 2 3 5 4.3 O=S1(=O)N=C(Nc2ccccc2-c2ccccc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL233961 87968 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 399 2 3 5 4.3 O=S1(=O)N=C(Nc2ccccc2-c2ccccc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
162670127 182722 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 390 3 2 5 4.6 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1CCOC2 10.1016/j.ejmech.2020.112387
CHEMBL4788391 182722 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 390 3 2 5 4.6 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1CCOC2 10.1016/j.ejmech.2020.112387
17903316 105511 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 297 4 1 5 3.3 COc1ccc(-c2nc(S)n(Cc3ccccc3)n2)cc1 10.1016/s0960-894x(03)00561-4
CHEMBL312060 105511 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 297 4 1 5 3.3 COc1ccc(-c2nc(S)n(Cc3ccccc3)n2)cc1 10.1016/s0960-894x(03)00561-4
16098479 83397 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 393 7 3 6 3.0 CC[C@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
CHEMBL219347 83397 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 393 7 3 6 3.0 CC[C@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
21015140 165859 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 280 3 3 5 2.3 O=c1c(O)c(Nc2ccccc2)/c1=N/c1ccccc1O 10.1016/j.bmcl.2006.12.067
CHEMBL424694 165859 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 280 3 3 5 2.3 O=c1c(O)c(Nc2ccccc2)/c1=N/c1ccccc1O 10.1016/j.bmcl.2006.12.067
16098484 141818 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 365 6 3 6 2.0 CN(C)C(=O)c1cccc(Nc2c(NCc3ccccc3)c(=O)c2=O)c1O 10.1021/jm0609622
CHEMBL385784 141818 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 365 6 3 6 2.0 CN(C)C(=O)c1cccc(Nc2c(NCc3ccccc3)c(=O)c2=O)c1O 10.1021/jm0609622
44447943 95020 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 442 7 2 4 3.4 Cc1cc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)N(C)C)c2cc1C#N 10.1016/j.bmcl.2008.01.127
CHEMBL254568 95020 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 442 7 2 4 3.4 Cc1cc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)N(C)C)c2cc1C#N 10.1016/j.bmcl.2008.01.127
162673032 183175 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 418 4 2 5 4.8 C[C@H](NC(=S)Nc1sc2c(c1C(=O)OC(C)(C)C)CCOC2)c1ccccc1 10.1016/j.ejmech.2020.112387
CHEMBL4794294 183175 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 418 4 2 5 4.8 C[C@H](NC(=S)Nc1sc2c(c1C(=O)OC(C)(C)C)CCOC2)c1ccccc1 10.1016/j.ejmech.2020.112387
44432384 88004 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 323 1 3 5 2.6 O=S1(=O)N=C(Nc2ccccc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL234184 88004 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 323 1 3 5 2.6 O=S1(=O)N=C(Nc2ccccc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
12229851 208509 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 267 3 1 4 3.3 Sc1nc(-c2ccccc2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL85267 208509 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 267 3 1 4 3.3 Sc1nc(-c2ccccc2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
16098478 83426 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 379 6 3 6 2.6 C[C@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
CHEMBL219472 83426 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 379 6 3 6 2.6 C[C@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
71525510 133373 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 453 7 3 8 2.8 Cc1cc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)oc1C nan
CHEMBL3704555 133373 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 453 7 3 8 2.8 Cc1cc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)oc1C nan
168275518 190615 None 0 Human Binding pIC50 = 4.6 4.6 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 367 6 2 6 4.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ccsc12 10.1016/j.ejmech.2022.114268
CHEMBL5179345 190615 None 0 Human Binding pIC50 = 4.6 4.6 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 367 6 2 6 4.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ccsc12 10.1016/j.ejmech.2022.114268
168293276 192252 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 351 6 3 6 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]cnc12 10.1016/j.ejmech.2022.114268
CHEMBL5203743 192252 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 351 6 3 6 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]cnc12 10.1016/j.ejmech.2022.114268
9949456 98871 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 331 2 3 3 3.7 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c(O)c1 10.1016/j.bmcl.2006.12.067
CHEMBL27863 98871 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 331 2 3 3 3.7 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c(O)c1 10.1016/j.bmcl.2006.12.067
71553689 133383 None 0 Human Binding pIC50 = 7.6 7.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 467 8 3 8 3.3 CC(C)c1coc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)c1 nan
CHEMBL3704565 133383 None 0 Human Binding pIC50 = 7.6 7.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 467 8 3 8 3.3 CC(C)c1coc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)c1 nan
9949456 98871 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 331 2 3 3 3.7 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c(O)c1 10.1021/jm034248l
CHEMBL27863 98871 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 331 2 3 3 3.7 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c(O)c1 10.1021/jm034248l
136087093 116056 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 417 4 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c(F)c(C(C)(C)C)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355247 116056 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 417 4 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c(F)c(C(C)(C)C)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
137634452 156280 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 372 4 3 4 3.1 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC3CC32)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4064083 156280 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 372 4 3 4 3.1 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC3CC32)c1O 10.1021/acs.jmedchem.7b01854
123626575 158615 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 426 4 3 4 4.0 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC=C2C(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4091344 158615 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 426 4 3 4 4.0 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC=C2C(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
127052173 140870 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 543 4 3 5 5.9 CN1CCC2(CCC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)CC2)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818581 140870 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 543 4 3 5 5.9 CN1CCC2(CCC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)CC2)CC1 10.1021/acsmedchemlett.5b00489
58180205 140891 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 446 4 3 4 5.2 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818853 140891 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 446 4 3 4 5.2 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
127020968 140939 None 31 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 475 4 3 5 4.4 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819512 140939 None 31 Human Binding pIC50 = 7.6 7.6 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 475 4 3 5 4.4 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
68084172 118097 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 455 9 3 8 3.2 C[C@H](CO)Nc1cc(NS(=O)(=O)c2ccc(C#N)cc2)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403843 118097 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 455 9 3 8 3.2 C[C@H](CO)Nc1cc(NS(=O)(=O)c2ccc(C#N)cc2)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
44407774 140432 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 397 7 3 8 3.4 CC[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL380732 140432 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 397 7 3 8 3.4 CC[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
11625425 140551 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 397 6 3 8 3.4 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL380947 140551 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 397 6 3 8 3.4 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
168293276 192252 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 351 6 3 6 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]cnc12 10.1016/j.ejmech.2022.114268
CHEMBL5203743 192252 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 351 6 3 6 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]cnc12 10.1016/j.ejmech.2022.114268
44447944 155718 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 453 5 3 3 3.5 CS(=O)(=O)NC(=O)NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL404661 155718 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 453 5 3 3 3.5 CS(=O)(=O)NC(=O)NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2008.01.127
44432415 87421 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 353 2 3 6 2.6 COc1ccccc1NC1=NS(=O)(=O)c2cc(Cl)cc(O)c2N1 10.1016/j.bmcl.2007.05.011
CHEMBL233345 87421 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 353 2 3 6 2.6 COc1ccccc1NC1=NS(=O)(=O)c2cc(Cl)cc(O)c2N1 10.1016/j.bmcl.2007.05.011
162667135 182603 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 402 3 2 4 6.0 CC1CCCc2sc(NC(=S)Nc3ccccc3)c(C(=O)OC(C)(C)C)c21 10.1016/j.ejmech.2020.112387
CHEMBL4786878 182603 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 402 3 2 4 6.0 CC1CCCc2sc(NC(=S)Nc3ccccc3)c(C(=O)OC(C)(C)C)c21 10.1016/j.ejmech.2020.112387
162673547 183158 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 435 5 3 3 5.9 CC1CCCc2sc(NC(=S)Nc3ccccc3)c(C(=O)NCc3ccccc3)c21 10.1016/j.ejmech.2020.112387
CHEMBL4794114 183158 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 435 5 3 3 5.9 CC1CCCc2sc(NC(=S)Nc3ccccc3)c(C(=O)NCc3ccccc3)c21 10.1016/j.ejmech.2020.112387
155545500 173491 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in human U2OS cells cp-expressing betaarrestin-2/TEV protease and beta lactamase assessed as effect on beta-arrestin2 recruitment preincubated for 30 mins followed by IL-8 addition and further incubated for 5 hrs subsequently adding CCF4-AM staining and measured after 2 hrs by Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in human U2OS cells cp-expressing betaarrestin-2/TEV protease and beta lactamase assessed as effect on beta-arrestin2 recruitment preincubated for 30 mins followed by IL-8 addition and further incubated for 5 hrs subsequently adding CCF4-AM staining and measured after 2 hrs by Tango assay
ChEMBL 464 5 2 3 6.3 C[C@@H](NC1=C(C(=O)Nc2ccc(Cl)c(C(F)(F)F)c2)C(=O)CC(C)(C)C1)c1ccccc1 10.1016/j.ejmech.2019.111853
CHEMBL4527955 173491 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in human U2OS cells cp-expressing betaarrestin-2/TEV protease and beta lactamase assessed as effect on beta-arrestin2 recruitment preincubated for 30 mins followed by IL-8 addition and further incubated for 5 hrs subsequently adding CCF4-AM staining and measured after 2 hrs by Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in human U2OS cells cp-expressing betaarrestin-2/TEV protease and beta lactamase assessed as effect on beta-arrestin2 recruitment preincubated for 30 mins followed by IL-8 addition and further incubated for 5 hrs subsequently adding CCF4-AM staining and measured after 2 hrs by Tango assay
ChEMBL 464 5 2 3 6.3 C[C@@H](NC1=C(C(=O)Nc2ccc(Cl)c(C(F)(F)F)c2)C(=O)CC(C)(C)C1)c1ccccc1 10.1016/j.ejmech.2019.111853
44454958 95483 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 331 6 4 6 1.7 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2[nH]c(=O)[nH]c12 10.1016/j.bmcl.2007.11.039
CHEMBL257027 95483 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 331 6 4 6 1.7 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2[nH]c(=O)[nH]c12 10.1016/j.bmcl.2007.11.039
10263767 92019 None 1 Human Binding pIC50 = 4.6 4.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 242 2 3 2 3.3 Cc1ccc(NC(=O)Nc2ccccc2)c(O)c1 10.1016/j.bmcl.2006.12.067
CHEMBL241514 92019 None 1 Human Binding pIC50 = 4.6 4.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 242 2 3 2 3.3 Cc1ccc(NC(=O)Nc2ccccc2)c(O)c1 10.1016/j.bmcl.2006.12.067
136087078 115995 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 371 5 3 6 2.6 CCc1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
CHEMBL3354833 115995 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 371 5 3 6 2.6 CCc1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
136087095 116058 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 413 4 3 6 3.7 Cc1c(C(C)(C)C)[nH]c(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)nc1=O 10.1016/j.bmcl.2014.10.003
CHEMBL3355249 116058 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 413 4 3 6 3.7 Cc1c(C(C)(C)C)[nH]c(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)nc1=O 10.1016/j.bmcl.2014.10.003
118554755 157599 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 446 5 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(CF)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4079718 157599 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 446 5 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(CF)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
129316073 157804 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4081963 157804 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
137653746 158810 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 390 5 3 5 2.9 CO[C@@H]1CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4093397 158810 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 390 5 3 5 2.9 CO[C@@H]1CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
127049049 140835 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 477 4 3 5 4.5 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
CHEMBL3818179 140835 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 477 4 3 5 4.5 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
136087071 115989 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 383 4 3 6 2.5 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c3c([nH]2)CCC3)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3354825 115989 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 383 4 3 6 2.5 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c3c([nH]2)CCC3)c1O 10.1016/j.bmcl.2014.10.003
136087074 115992 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 409 5 3 7 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(-c3ccco3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3354829 115992 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 409 5 3 7 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(-c3ccco3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
136087075 115993 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 422 5 3 7 3.1 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(-c3cccn3C)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3354830 115993 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 422 5 3 7 3.1 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(-c3cccn3C)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
136087091 116055 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 387 6 3 7 2.2 COCc1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
CHEMBL3355245 116055 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 387 6 3 7 2.2 COCc1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
129315976 156639 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 406 4 3 5 2.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2COC2)c1O)N[C@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
CHEMBL4068230 156639 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 406 4 3 5 2.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2COC2)c1O)N[C@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
71525424 132879 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 475 8 3 9 2.1 Cc1ccc(C(Nc2c(Nc3cccc(S(=O)(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701195 132879 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 475 8 3 9 2.1 Cc1ccc(C(Nc2c(Nc3cccc(S(=O)(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
11750288 169676 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 412 2 3 7 2.6 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Br)N2 10.1016/j.bmcl.2007.05.011
CHEMBL443583 169676 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 412 2 3 7 2.6 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Br)N2 10.1016/j.bmcl.2007.05.011
71525885 133387 None 0 Human Binding pIC50 = 7.6 7.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 507 8 3 8 3.5 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3704569 133387 None 0 Human Binding pIC50 = 7.6 7.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 507 8 3 8 3.5 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
44447922 95519 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 461 7 2 4 4.7 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)c3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL257177 95519 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 461 7 2 4 4.7 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)c3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
44447937 155382 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 458 10 3 5 2.8 COCCNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL402942 155382 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 458 10 3 5 2.8 COCCNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
71525344 132875 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 465 7 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCCC4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701191 132875 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 465 7 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCCC4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
44439723 12326 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 406 5 3 7 1.9 CN1CCN(C(=O)c2cccc(Nc3c(Nc4ccccc4)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL1185146 12326 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 406 5 3 7 1.9 CN1CCN(C(=O)c2cccc(Nc3c(Nc4ccccc4)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL392473 12326 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 406 5 3 7 1.9 CN1CCN(C(=O)c2cccc(Nc3c(Nc4ccccc4)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
153842018 191136 None 3 Human Binding pIC50 = 6.6 6.6 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 368 6 2 7 3.5 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ncsc12 10.1016/j.ejmech.2022.114268
CHEMBL5186932 191136 None 3 Human Binding pIC50 = 6.6 6.6 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 368 6 2 7 3.5 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2ncsc12 10.1016/j.ejmech.2022.114268
135531169 133230 None 2 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 326 3 2 7 2.9 Nc1nc2nc(SCc3cccc(F)c3F)nc(O)c2s1 10.1016/j.bmcl.2005.10.091
CHEMBL370387 133230 None 2 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 326 3 2 7 2.9 Nc1nc2nc(SCc3cccc(F)c3F)nc(O)c2s1 10.1016/j.bmcl.2005.10.091
162665011 182229 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 421 4 3 3 6.2 CC1CCCc2sc(NC(=S)Nc3ccccc3)c(C(=O)Nc3ccccc3)c21 10.1016/j.ejmech.2020.112387
CHEMBL4782078 182229 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 421 4 3 3 6.2 CC1CCCc2sc(NC(=S)Nc3ccccc3)c(C(=O)Nc3ccccc3)c21 10.1016/j.ejmech.2020.112387
162665122 182256 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 432 4 2 5 6.0 COc1cccc(NC(=S)Nc2sc3c(c2C(=O)OC(C)(C)C)C(C)CCC3)c1 10.1016/j.ejmech.2020.112387
CHEMBL4782371 182256 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 432 4 2 5 6.0 COc1cccc(NC(=S)Nc2sc3c(c2C(=O)OC(C)(C)C)C(C)CCC3)c1 10.1016/j.ejmech.2020.112387
162668274 182657 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 388 4 2 4 5.6 CC(C)OC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4787532 182657 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 388 4 2 4 5.6 CC(C)OC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
168272758 190639 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]ccc12 10.1016/j.ejmech.2022.114268
CHEMBL5179622 190639 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]ccc12 10.1016/j.ejmech.2022.114268
71526159 145487 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 525 8 3 9 3.6 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3913959 145487 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 525 8 3 9 3.6 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
71526602 132867 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 457 8 3 8 2.5 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(CF)COC2)o1 nan
CHEMBL3701183 132867 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 457 8 3 8 2.5 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(CF)COC2)o1 nan
71525977 150292 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3951994 150292 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
46897352 114990 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 464 6 1 5 5.1 CC1(C)OB(c2ccccc2CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C nan
CHEMBL3342313 114990 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 464 6 1 5 5.1 CC1(C)OB(c2ccccc2CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C nan
44439692 90999 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 253 2 3 3 2.9 N#Cc1cccc(NC(=O)Nc2ccccc2)c1O 10.1016/j.bmcl.2006.12.067
CHEMBL239558 90999 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 253 2 3 3 2.9 N#Cc1cccc(NC(=O)Nc2ccccc2)c1O 10.1016/j.bmcl.2006.12.067
46897256 114985 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 354 5 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2O)nc1 nan
CHEMBL3342304 114985 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 354 5 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2O)nc1 nan
59446381 114991 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 448 7 3 6 3.2 O=C(Nc1ccc(OC(F)(F)F)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 nan
CHEMBL3342314 114991 None 0 Human Binding pIC50 = 6.6 6.6 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 448 7 3 6 3.2 O=C(Nc1ccc(OC(F)(F)F)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 nan
44439720 154702 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 489 5 3 6 4.1 O=C(c1c(Cl)ccc(Nc2c(Nc3ccccc3Br)c(=O)c2=O)c1O)N1CCCC1 10.1016/j.bmcl.2006.12.067
CHEMBL399223 154702 None 0 Human Binding pIC50 = 7.6 7.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 489 5 3 6 4.1 O=C(c1c(Cl)ccc(Nc2c(Nc3ccccc3Br)c(=O)c2=O)c1O)N1CCCC1 10.1016/j.bmcl.2006.12.067
46897258 126885 None 0 Human Binding pIC50 = 7.6 7.6 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 438 6 2 5 5.4 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2O)nc1 nan
CHEMBL3654441 126885 None 0 Human Binding pIC50 = 7.6 7.6 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 438 6 2 5 5.4 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2O)nc1 nan
44455116 95616 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 377 6 2 7 3.1 Cc1cnc2c(N[C@H](C)CO)nc(SCc3cccc(F)c3F)nc2n1 10.1016/j.bmcl.2007.11.039
CHEMBL257659 95616 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 377 6 2 7 3.1 Cc1cnc2c(N[C@H](C)CO)nc(SCc3cccc(F)c3F)nc2n1 10.1016/j.bmcl.2007.11.039
44455083 155573 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 363 6 2 7 2.8 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nccnc12 10.1016/j.bmcl.2007.11.039
CHEMBL404057 155573 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 363 6 2 7 2.8 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nccnc12 10.1016/j.bmcl.2007.11.039
44432435 86721 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 381 1 3 5 3.0 Cc1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Br)N2 10.1016/j.bmcl.2007.05.011
CHEMBL231710 86721 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 381 1 3 5 3.0 Cc1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Br)N2 10.1016/j.bmcl.2007.05.011
10200147 201508 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 386 5 1 4 2.7 O=C(Nc1ccc(F)cc1)c1ccc(S(=O)(=O)Cc2ccccc2)[n+]([O-])c1 10.1016/s0960-894x(01)00326-2
CHEMBL58619 201508 None 0 Human Binding pIC50 = 6.6 6.6 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 386 5 1 4 2.7 O=C(Nc1ccc(F)cc1)c1ccc(S(=O)(=O)Cc2ccccc2)[n+]([O-])c1 10.1016/s0960-894x(01)00326-2
44318921 208575 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.3 FC(F)(F)c1ccc(-c2nc(S)n(Cc3ccccc3)n2)cc1 10.1016/s0960-894x(03)00561-4
CHEMBL85872 208575 None 0 Human Binding pIC50 = 5.6 5.6 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.3 FC(F)(F)c1ccc(-c2nc(S)n(Cc3ccccc3)n2)cc1 10.1016/s0960-894x(03)00561-4
22238507 77802 None 0 Human Binding pIC50 = 4.5 4.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 294 4 2 5 2.5 CN(c1ccccc1O)c1c(Nc2ccccc2)c(=O)c1=O 10.1016/j.bmcl.2006.04.082
CHEMBL209121 77802 None 0 Human Binding pIC50 = 4.5 4.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 294 4 2 5 2.5 CN(c1ccccc1O)c1c(Nc2ccccc2)c(=O)c1=O 10.1016/j.bmcl.2006.04.082
16126703 84274 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 445 4 3 5 3.4 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2cccc(Cl)c2F)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL221039 84274 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 445 4 3 5 3.4 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2cccc(Cl)c2F)c1O 10.1016/j.bmcl.2006.08.042
71526157 151668 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 541 8 2 9 3.9 COC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1F nan
CHEMBL3963336 151668 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 541 8 2 9 3.9 COC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1F nan
91937332 114994 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 383 6 3 6 1.8 O=C(Nc1ccc(F)cn1)c1ccc(SCc2ccccc2B(O)O)nc1 nan
CHEMBL3342319 114994 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 383 6 3 6 1.8 O=C(Nc1ccc(F)cn1)c1ccc(SCc2ccccc2B(O)O)nc1 nan
9879541 78057 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 305 3 3 6 2.2 N#Cc1ccc(Nc2c(O)c(=O)/c2=N\c2ccccc2)c(O)c1 10.1016/j.bmcl.2006.04.082
CHEMBL209859 78057 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 305 3 3 6 2.2 N#Cc1ccc(Nc2c(O)c(=O)/c2=N\c2ccccc2)c(O)c1 10.1016/j.bmcl.2006.04.082
44431209 167548 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 399 6 3 8 3.5 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL429791 167548 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 399 6 3 8 3.5 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
123159150 156937 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 406 4 3 4 4.0 CC1=C(Cl)CCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4071499 156937 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 406 4 3 4 4.0 CC1=C(Cl)CCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
44446650 97440 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 394 7 3 7 2.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccn1 10.1016/j.bmcl.2008.01.024
CHEMBL269707 97440 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 394 7 3 7 2.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccn1 10.1016/j.bmcl.2008.01.024
44446647 155194 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 399 7 3 7 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccsc1 10.1016/j.bmcl.2008.01.024
CHEMBL401940 155194 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 399 7 3 7 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccsc1 10.1016/j.bmcl.2008.01.024
44447608 94599 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 433 7 3 7 3.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc2ccccc2o1 10.1016/j.bmcl.2008.01.024
CHEMBL251811 94599 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 433 7 3 7 3.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc2ccccc2o1 10.1016/j.bmcl.2008.01.024
25110787 155193 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 461 7 3 7 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(Br)co1 10.1016/j.bmcl.2008.01.024
CHEMBL401939 155193 None 0 Human Binding pIC50 = 8.5 8.5 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 461 7 3 7 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(Br)co1 10.1016/j.bmcl.2008.01.024
16098487 82144 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 409 7 3 7 2.9 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CC2)o1 10.1021/jm0609622
CHEMBL216603 82144 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 409 7 3 7 2.9 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CC2)o1 10.1021/jm0609622
10150526 82975 None 0 Human Binding pIC50 = 8.4 8.4 79 2
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 383 7 3 7 2.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccco1 10.1021/jm0609622
CHEMBL218115 82975 None 0 Human Binding pIC50 = 8.4 8.4 79 2
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 383 7 3 7 2.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccco1 10.1021/jm0609622
16098488 138050 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 425 6 3 7 3.5 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)(C)C)o1 10.1021/jm0609622
CHEMBL376414 138050 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 425 6 3 7 3.5 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)(C)C)o1 10.1021/jm0609622
44446641 94896 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 417 7 3 7 3.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(Cl)co1 10.1016/j.bmcl.2008.01.024
CHEMBL253714 94896 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 417 7 3 7 3.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(Cl)co1 10.1016/j.bmcl.2008.01.024
129315994 158477 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 422 5 4 5 3.0 CC(C)(CO)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4089896 158477 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 422 5 4 5 3.0 CC(C)(CO)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
129316000 158700 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 481 5 3 5 4.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCN(C3CCC3)CC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4092148 158700 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 481 5 3 5 4.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCN(C3CCC3)CC2)c1O 10.1021/acs.jmedchem.7b01854
127049428 140906 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 491 4 3 5 4.3 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
CHEMBL3819013 140906 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 491 4 3 5 4.3 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
10003645 118103 None 1 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 445 9 3 7 2.2 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403850 118103 None 1 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 445 9 3 7 2.2 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
11754699 118107 None 1 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 475 9 3 8 1.8 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCOCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403854 118107 None 1 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 475 9 3 8 1.8 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCOCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
11440492 152731 None 0 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2015.01.067
CHEMBL397237 152731 None 0 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2015.01.067
11440492 152731 None 0 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL397237 152731 None 0 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
44431209 167548 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 399 6 3 8 3.5 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL429791 167548 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 399 6 3 8 3.5 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
10389383 172281 None 2 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL-8 from CXCR2 in human neutrophils incubated for 3 hrs by gamma counting methodDisplacement of [125I]IL-8 from CXCR2 in human neutrophils incubated for 3 hrs by gamma counting method
ChEMBL 456 9 1 5 6.9 CCN(CC)CCCCNc1nc2cc(Cl)c(Cl)cc2nc1-c1cc2ccccc2o1 10.1016/j.ejmech.2019.111853
CHEMBL4473520 172281 None 2 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL-8 from CXCR2 in human neutrophils incubated for 3 hrs by gamma counting methodDisplacement of [125I]IL-8 from CXCR2 in human neutrophils incubated for 3 hrs by gamma counting method
ChEMBL 456 9 1 5 6.9 CCN(CC)CCCCNc1nc2cc(Cl)c(Cl)cc2nc1-c1cc2ccccc2o1 10.1016/j.ejmech.2019.111853
71526067 143987 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 539 8 3 10 3.5 COC(=O)[C@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
CHEMBL3901913 143987 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 539 8 3 10 3.5 COC(=O)[C@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
71555361 133392 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 564 8 3 10 2.4 Cc1ccc([C@H](Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N4CCN(C)CC4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3704573 133392 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 564 8 3 10 2.4 Cc1ccc([C@H](Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N4CCN(C)CC4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
44318557 107131 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 369 3 1 4 5.2 Sc1nc(-c2ccc(Cl)cc2Cl)nn1Cc1ccc(Cl)cc1 10.1016/s0960-894x(03)00561-4
CHEMBL315811 107131 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 369 3 1 4 5.2 Sc1nc(-c2ccc(Cl)cc2Cl)nn1Cc1ccc(Cl)cc1 10.1016/s0960-894x(03)00561-4
162672979 183114 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 404 5 2 5 5.2 CCOC(=O)c1c(NC(=S)Nc2cccc(OC)c2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4793669 183114 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 404 5 2 5 5.2 CCOC(=O)c1c(NC(=S)Nc2cccc(OC)c2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
44432436 86722 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 385 1 3 5 2.9 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)ccc(F)c21 10.1016/j.bmcl.2007.05.011
CHEMBL231711 86722 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 385 1 3 5 2.9 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)ccc(F)c21 10.1016/j.bmcl.2007.05.011
44439678 147847 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 294 4 3 5 2.8 Cc1ccc(O)c(Nc2c(Nc3ccccc3)c(=O)c2=O)c1 10.1016/j.bmcl.2006.12.067
CHEMBL393248 147847 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 294 4 3 5 2.8 Cc1ccc(O)c(Nc2c(Nc3ccccc3)c(=O)c2=O)c1 10.1016/j.bmcl.2006.12.067
71525425 132880 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 509 8 3 9 2.7 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701196 132880 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 509 8 3 9 2.7 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
136087085 116049 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 425 5 3 6 4.0 CC1CCCC1c1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
CHEMBL3355239 116049 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 425 5 3 6 4.0 CC1CCCC1c1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
118554752 156849 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 460 6 3 5 4.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(CCF)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4070629 156849 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 460 6 3 5 4.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(CCF)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
57833198 118088 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 404 8 3 7 2.2 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403834 118088 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 404 8 3 7 2.2 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
57833157 118096 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 464 9 3 7 4.0 C[C@H](CO)Nc1cc(NS(=O)(=O)c2ccc(Cl)cc2)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403842 118096 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 464 9 3 7 4.0 C[C@H](CO)Nc1cc(NS(=O)(=O)c2ccc(Cl)cc2)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
57833212 118099 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 470 9 3 9 2.4 C[C@H](CO)Nc1cc(NS(=O)(=O)c2cn(C)cn2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403846 118099 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 470 9 3 9 2.4 C[C@H](CO)Nc1cc(NS(=O)(=O)c2cn(C)cn2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
44431208 87374 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 381 6 3 8 3.4 C[C@H](CO)Nc1nc(SCc2ccccc2Cl)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL233259 87374 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 381 6 3 8 3.4 C[C@H](CO)Nc1nc(SCc2ccccc2Cl)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
44431211 87378 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 337 6 3 9 2.3 C[C@H](CO)Nc1nc(SCc2ccco2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL233263 87378 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 337 6 3 9 2.3 C[C@H](CO)Nc1nc(SCc2ccco2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
22649099 93362 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 399 7 4 9 2.0 Nc1nc2nc(SCc3cccc(F)c3F)nc(NC(CO)CO)c2s1 10.1016/j.bmcl.2007.02.080
CHEMBL245190 93362 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 399 7 4 9 2.0 Nc1nc2nc(SCc3cccc(F)c3F)nc(NC(CO)CO)c2s1 10.1016/j.bmcl.2007.02.080
44431189 168835 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 425 8 3 8 4.3 CC(C)Nc1nc2nc(SCc3cccc(F)c3F)nc(N[C@H](C)CO)c2s1 10.1016/j.bmcl.2007.02.080
CHEMBL437013 168835 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 425 8 3 8 4.3 CC(C)Nc1nc2nc(SCc3cccc(F)c3F)nc(N[C@H](C)CO)c2s1 10.1016/j.bmcl.2007.02.080
44414037 139354 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 324 3 4 6 1.8 O=C(O)c1ccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c(O)c1 10.1016/j.bmcl.2006.04.082
CHEMBL379046 139354 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 324 3 4 6 1.8 O=C(O)c1ccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c(O)c1 10.1016/j.bmcl.2006.04.082
58368230 127331 None 0 Human Binding pIC50 = 5.5 5.5 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 323 5 1 4 3.4 O=C(Nc1ccc(F)cn1)c1ccc(OCc2ccccc2)nc1 nan
CHEMBL3658342 127331 None 0 Human Binding pIC50 = 5.5 5.5 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 323 5 1 4 3.4 O=C(Nc1ccc(F)cn1)c1ccc(OCc2ccccc2)nc1 nan
71525795 133386 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 393 6 3 8 2.7 Cc1ccc(C(Nc2c(Nc3cccc(C#N)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3704568 133386 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 393 6 3 8 2.7 Cc1ccc(C(Nc2c(Nc3cccc(C#N)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
136087070 115988 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 397 4 3 6 2.9 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c3c([nH]2)CCCC3)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3354824 115988 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 397 4 3 6 2.9 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c3c([nH]2)CCCC3)c1O 10.1016/j.bmcl.2014.10.003
129315999 157985 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 442 5 3 5 3.9 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)[C@H]2CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4084135 157985 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 442 5 3 5 3.9 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)[C@H]2CCOC2)c1O 10.1021/acs.jmedchem.7b01854
130191301 159015 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 386 3 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4095602 159015 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 386 3 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
118554833 155998 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 495 5 3 5 4.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(CC(F)(F)F)CC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4060778 155998 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 495 5 3 5 4.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(CC(F)(F)F)CC2)c1O 10.1021/acs.jmedchem.7b01854
118554808 156266 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 406 4 3 5 2.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2COC2)c1O)N[C@@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
CHEMBL4063949 156266 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 406 4 3 5 2.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2COC2)c1O)N[C@@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
137657195 159736 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 388 4 3 4 3.9 CC1CCCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4103634 159736 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 388 4 3 4 3.9 CC1CCCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
9956678 140896 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 476 4 3 5 3.4 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818917 140896 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 476 4 3 5 3.4 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
9887803 140924 None 26 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 409 3 4 4 3.6 NS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3819292 140924 None 26 Human Binding pIC50 = 6.5 6.5 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 409 3 4 4 3.6 NS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
127049428 140906 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 491 4 3 5 4.3 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
CHEMBL3819013 140906 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 491 4 3 5 4.3 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
57833129 118086 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 354 8 3 7 1.5 CS(=O)(=O)Nc1cc(NCCO)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403832 118086 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 354 8 3 7 1.5 CS(=O)(=O)Nc1cc(NCCO)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
10267982 168040 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2
ChEMBL 320 5 1 5 2.7 COC(=O)CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/s0960-894x(02)00188-9
CHEMBL431511 168040 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2
ChEMBL 320 5 1 5 2.7 COC(=O)CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/s0960-894x(02)00188-9
9966255 91682 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 305 4 3 6 2.3 N#Cc1cccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c1O 10.1016/j.bmcl.2006.12.067
CHEMBL240817 91682 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 305 4 3 6 2.3 N#Cc1cccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c1O 10.1016/j.bmcl.2006.12.067
10222206 169356 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 392 4 3 5 3.9 O=c1c(Nc2ccc(Cl)cc2O)c(Nc2ccccc2Br)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL441144 169356 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 392 4 3 5 3.9 O=c1c(Nc2ccc(Cl)cc2O)c(Nc2ccccc2Br)c1=O 10.1016/j.bmcl.2006.12.067
21878232 200845 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 416 5 2 5 2.2 O=C(O)c1cccc(S(=O)(=O)c2ccc(C(=O)Nc3ccc(F)cc3)c[n+]2[O-])c1 10.1016/s0960-894x(01)00326-2
CHEMBL57680 200845 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 416 5 2 5 2.2 O=C(O)c1cccc(S(=O)(=O)c2ccc(C(=O)Nc3ccc(F)cc3)c[n+]2[O-])c1 10.1016/s0960-894x(01)00326-2
71525698 133382 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 439 7 3 8 2.5 Cc1coc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)c1 nan
CHEMBL3704564 133382 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 439 7 3 8 2.5 Cc1coc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)c1 nan
91937335 127330 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 367 6 3 6 1.1 O=C(Nc1ccc(F)cn1)c1ccc(OCc2ccccc2B(O)O)nc1 nan
CHEMBL3658341 127330 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 367 6 3 6 1.1 O=C(Nc1ccc(F)cn1)c1ccc(OCc2ccccc2B(O)O)nc1 nan
3618472 2893 None 12 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL-8 from CXCR2 (unknown origin) stably expressed in CHO cellsDisplacement of [125I]IL-8 from CXCR2 (unknown origin) stably expressed in CHO cells
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 10.1016/j.ejmech.2019.111853
834 2893 None 12 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL-8 from CXCR2 (unknown origin) stably expressed in CHO cellsDisplacement of [125I]IL-8 from CXCR2 (unknown origin) stably expressed in CHO cells
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 10.1016/j.ejmech.2019.111853
CHEMBL280711 2893 None 12 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL-8 from CXCR2 (unknown origin) stably expressed in CHO cellsDisplacement of [125I]IL-8 from CXCR2 (unknown origin) stably expressed in CHO cells
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 10.1016/j.ejmech.2019.111853
3618472 2893 None 12 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 10.1016/j.bmcl.2006.12.067
834 2893 None 12 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 10.1016/j.bmcl.2006.12.067
CHEMBL280711 2893 None 12 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 10.1016/j.bmcl.2006.12.067
3618472 2893 None 12 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 10.1021/jm034248l
834 2893 None 12 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 10.1021/jm034248l
CHEMBL280711 2893 None 12 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccc(cc1O)[N+](=O)[O-])Nc1ccccc1 10.1021/jm034248l
45485756 200857 None 0 Human Binding pIC50 = 5.5 5.5 - 1
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 360 6 3 7 0.6 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(C)=O 10.1016/j.bmcl.2009.08.014
CHEMBL576886 200857 None 0 Human Binding pIC50 = 5.5 5.5 - 1
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 360 6 3 7 0.6 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(C)=O 10.1016/j.bmcl.2009.08.014
24804051 104700 None 2 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cellsDisplacement of [125I]GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cells
ChEMBL 384 5 1 6 4.0 Oc1cc(CSc2cccc(F)c2F)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104912 104700 None 2 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cellsDisplacement of [125I]GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cells
ChEMBL 384 5 1 6 4.0 Oc1cc(CSc2cccc(F)c2F)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
71525423 132878 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 369 6 3 8 2.2 Cc1ccc(C(Nc2c(Nc3cccnc3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701194 132878 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 369 6 3 8 2.2 Cc1ccc(C(Nc2c(Nc3cccnc3O)c(=O)c2=O)C2(C)COC2)o1 nan
44414053 80375 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 323 3 4 6 1.2 NC(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL214286 80375 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 323 3 4 6 1.2 NC(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
162665571 182456 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 450 5 2 7 4.6 COc1ccc(NC(=S)Nc2sc3c(c2C(=O)OC(C)(C)C)CCOC3)cc1OC 10.1016/j.ejmech.2020.112387
CHEMBL4784641 182456 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 450 5 2 7 4.6 COc1ccc(NC(=S)Nc2sc3c(c2C(=O)OC(C)(C)C)CCOC3)cc1OC 10.1016/j.ejmech.2020.112387
71526605 132869 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 481 7 4 9 2.0 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CC[C@@H](O)C4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701185 132869 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 481 7 4 9 2.0 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CC[C@@H](O)C4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
71525605 133376 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 479 7 3 9 2.4 CN(C)C(=O)c1cccc(Nc2c(NC(c3ccc4c(c3)OCO4)C3(C)COC3)c(=O)c2=O)c1O nan
CHEMBL3704558 133376 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 479 7 3 9 2.4 CN(C)C(=O)c1cccc(Nc2c(NC(c3ccc4c(c3)OCO4)C3(C)COC3)c(=O)c2=O)c1O nan
44431211 87378 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 337 6 3 9 2.3 C[C@H](CO)Nc1nc(SCc2ccco2)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL233263 87378 None 0 Human Binding pIC50 = 7.5 7.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 337 6 3 9 2.3 C[C@H](CO)Nc1nc(SCc2ccco2)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
71525977 150292 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3951994 150292 None 0 Human Binding pIC50 = 7.5 7.5 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
44455012 95542 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 378 6 3 6 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)ccc12 10.1016/j.bmcl.2007.11.039
CHEMBL257269 95542 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 378 6 3 6 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)ccc12 10.1016/j.bmcl.2007.11.039
44407789 75309 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 453 9 3 9 4.9 CC[C@H](CO)Nc1nc(SCc2cccc(Oc3ccccc3)c2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
CHEMBL203715 75309 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 453 9 3 9 4.9 CC[C@H](CO)Nc1nc(SCc2cccc(Oc3ccccc3)c2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
46896263 127303 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 410 5 1 5 4.9 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cccc3c2OCCCO3)nc1 nan
CHEMBL3658245 127303 None 0 Human Binding pIC50 = 6.5 6.5 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 410 5 1 5 4.9 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cccc3c2OCCCO3)nc1 nan
9950107 106201 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 345 3 1 4 4.0 Sc1nc(-c2ccccc2Br)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL313556 106201 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 345 3 1 4 4.0 Sc1nc(-c2ccccc2Br)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
9949617 208445 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2cccc(Cl)c2Cl)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL84753 208445 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2cccc(Cl)c2Cl)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
9796076 106000 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 292 3 1 5 3.2 N#Cc1ccc(-c2nc(S)n(Cc3ccccc3)n2)cc1 10.1016/s0960-894x(03)00561-4
CHEMBL312883 106000 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 292 3 1 5 3.2 N#Cc1ccc(-c2nc(S)n(Cc3ccccc3)n2)cc1 10.1016/s0960-894x(03)00561-4
9862533 208441 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.3 FC(F)(F)c1cccc(-c2nc(S)n(Cc3ccccc3)n2)c1 10.1016/s0960-894x(03)00561-4
CHEMBL84719 208441 None 0 Human Binding pIC50 = 5.5 5.5 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.3 FC(F)(F)c1cccc(-c2nc(S)n(Cc3ccccc3)n2)c1 10.1016/s0960-894x(03)00561-4
46897162 3716 None 15 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of CXCR2 (unknown origin) transfected with RBL cellsInhibition of CXCR2 (unknown origin) transfected with RBL cells
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1016/j.bmcl.2015.04.041
8501 3716 None 15 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of CXCR2 (unknown origin) transfected with RBL cellsInhibition of CXCR2 (unknown origin) transfected with RBL cells
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1016/j.bmcl.2015.04.041
CHEMBL3342269 3716 None 15 Human Binding pIC50 = 6.5 6.5 - 0
Inhibition of CXCR2 (unknown origin) transfected with RBL cellsInhibition of CXCR2 (unknown origin) transfected with RBL cells
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1016/j.bmcl.2015.04.041
44439685 90715 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 325 5 3 7 2.4 O=c1c(Nc2ccccc2)c(Nc2c(O)cccc2[N+](=O)[O-])c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL239135 90715 None 0 Human Binding pIC50 = 6.5 6.5 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 325 5 3 7 2.4 O=c1c(Nc2ccccc2)c(Nc2c(O)cccc2[N+](=O)[O-])c1=O 10.1016/j.bmcl.2006.12.067
136036241 189232 None 0 Human Binding pIC50 = 7.4 7.4 -158 2
Displacement of [125I]CXCL1 from CXCR2 receptor in human PMN assessed as myeloperoxidase releaseDisplacement of [125I]CXCL1 from CXCR2 receptor in human PMN assessed as myeloperoxidase release
ChEMBL 415 7 3 8 4.4 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)C)c2O)C(C)C)o1 10.1016/j.bmcl.2009.01.027
CHEMBL510437 189232 None 0 Human Binding pIC50 = 7.4 7.4 -158 2
Displacement of [125I]CXCL1 from CXCR2 receptor in human PMN assessed as myeloperoxidase releaseDisplacement of [125I]CXCL1 from CXCR2 receptor in human PMN assessed as myeloperoxidase release
ChEMBL 415 7 3 8 4.4 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)C)c2O)C(C)C)o1 10.1016/j.bmcl.2009.01.027
9880342 139569 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 325 4 3 7 2.2 O=c1c(O)c(Nc2ccc([N+](=O)[O-])cc2O)/c1=N/c1ccccc1 10.1016/j.bmcl.2006.04.082
CHEMBL379438 139569 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 325 4 3 7 2.2 O=c1c(O)c(Nc2ccc([N+](=O)[O-])cc2O)/c1=N/c1ccccc1 10.1016/j.bmcl.2006.04.082
9821417 90719 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 383 4 3 6 3.1 N#Cc1ccc(Nc2c(Nc3ccccc3Br)c(=O)c2=O)c(O)c1 10.1016/j.bmcl.2006.12.067
CHEMBL239136 90719 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 383 4 3 6 3.1 N#Cc1ccc(Nc2c(Nc3ccccc3Br)c(=O)c2=O)c(O)c1 10.1016/j.bmcl.2006.12.067
44432422 87999 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 385 1 3 5 2.9 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)cc(F)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL234178 87999 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 385 1 3 5 2.9 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)cc(F)cc21 10.1016/j.bmcl.2007.05.011
91937288 127315 None 0 Human Binding pIC50 = 5.4 5.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 504 7 1 4 7.4 CCc1cc2c(cc1C(=O)CSc1ccc(C(=O)Nc3ccc(F)cc3)cn1)C(C)(C)CCC2(C)C nan
CHEMBL3658296 127315 None 0 Human Binding pIC50 = 5.4 5.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 504 7 1 4 7.4 CCc1cc2c(cc1C(=O)CSc1ccc(C(=O)Nc3ccc(F)cc3)cn1)C(C)(C)CCC2(C)C nan
10179343 90982 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 403 5 3 7 3.1 O=c1c(Nc2ccc([N+](=O)[O-])cc2O)c(Nc2ccccc2Br)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL239348 90982 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 403 5 3 7 3.1 O=c1c(Nc2ccc([N+](=O)[O-])cc2O)c(Nc2ccccc2Br)c1=O 10.1016/j.bmcl.2006.12.067
71526068 145645 None 0 Human Binding pIC50 = 7.4 7.4 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 539 8 3 10 3.5 COC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
CHEMBL3915145 145645 None 0 Human Binding pIC50 = 7.4 7.4 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 539 8 3 10 3.5 COC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
71525884 132872 None 0 Human Binding pIC50 = 7.4 7.4 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 523 8 3 10 2.6 COC(=O)[C@H]1CCCN1C(=O)c1cccc(Nc2c(N[C@@H](c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c1O nan
CHEMBL3701188 132872 None 0 Human Binding pIC50 = 7.4 7.4 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 523 8 3 10 2.6 COC(=O)[C@H]1CCCN1C(=O)c1cccc(Nc2c(N[C@@H](c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c1O nan
59446410 127328 None 0 Human Binding pIC50 = 7.4 7.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 398 6 4 6 2.2 O=C(Nc1ccc(F)cc1O)c1ccc(SCc2ccccc2B(O)O)nc1 nan
CHEMBL3658338 127328 None 0 Human Binding pIC50 = 7.4 7.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 398 6 4 6 2.2 O=C(Nc1ccc(F)cc1O)c1ccc(SCc2ccccc2B(O)O)nc1 nan
71525975 133391 None 0 Human Binding pIC50 = 6.4 6.4 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 473 7 3 8 3.2 Cc1ccc([C@H](Nc2c(Nc3ccc(Cl)c(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3704572 133391 None 0 Human Binding pIC50 = 6.4 6.4 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 473 7 3 8 3.2 Cc1ccc([C@H](Nc2c(Nc3ccc(Cl)c(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
46897162 3716 None 15 Human Binding pIC50 = 7.4 7.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O nan
8501 3716 None 15 Human Binding pIC50 = 7.4 7.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O nan
CHEMBL3342269 3716 None 15 Human Binding pIC50 = 7.4 7.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O nan
46897254 119152 None 0 Human Binding pIC50 = 6.4 6.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 396 7 3 5 2.5 O=C(Nc1ccc(F)cc1)c1ccc(SCCc2ccccc2B(O)O)nc1 nan
CHEMBL3426951 119152 None 0 Human Binding pIC50 = 6.4 6.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 396 7 3 5 2.5 O=C(Nc1ccc(F)cc1)c1ccc(SCCc2ccccc2B(O)O)nc1 nan
100951623 156564 None 16 Human Binding pIC50 = 7.4 7.4 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4067429 156564 None 16 Human Binding pIC50 = 7.4 7.4 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
137646150 158117 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 386 4 3 4 3.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC23CC3)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4085657 158117 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 386 4 3 4 3.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC23CC3)c1O 10.1021/acs.jmedchem.7b01854
127051212 140945 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 434 3 3 4 5.1 CC(C)(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3819569 140945 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 434 3 3 4 5.1 CC(C)(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
44432396 87967 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 337 1 3 5 2.9 Cc1ccccc1NC1=NS(=O)(=O)c2cc(Cl)cc(O)c2N1 10.1016/j.bmcl.2007.05.011
CHEMBL233960 87967 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 337 1 3 5 2.9 Cc1ccccc1NC1=NS(=O)(=O)c2cc(Cl)cc(O)c2N1 10.1016/j.bmcl.2007.05.011
162663287 182072 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 417 5 2 5 5.2 CCOC(=O)c1c(NC(=S)Nc2ccc(N(C)C)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4780042 182072 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 417 5 2 5 5.2 CCOC(=O)c1c(NC(=S)Nc2ccc(N(C)C)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
44407551 141371 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 361 7 3 8 3.1 CC[C@@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
CHEMBL383235 141371 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 361 7 3 8 3.1 CC[C@@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
44432393 88093 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 419 1 3 5 3.5 O=S1(=O)N=C(Nc2cc(F)ccc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL234596 88093 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 419 1 3 5 3.5 O=S1(=O)N=C(Nc2cc(F)ccc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
59446412 114980 None 0 Human Binding pIC50 = 5.4 5.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 330 5 2 6 2.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2nn[nH]n2)nc1 nan
CHEMBL3342270 114980 None 0 Human Binding pIC50 = 5.4 5.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 330 5 2 6 2.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2nn[nH]n2)nc1 nan
44775716 114983 None 0 Human Binding pIC50 = 6.4 6.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 338 5 1 3 4.8 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2)nc1 nan
CHEMBL3342291 114983 None 0 Human Binding pIC50 = 6.4 6.4 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 338 5 1 3 4.8 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2)nc1 nan
71525422 132877 None 0 Human Binding pIC50 = 6.4 6.4 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 383 6 2 8 1.8 Cc1ccc(C(Nc2c(Nc3cccn(C)c3=O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701193 132877 None 0 Human Binding pIC50 = 6.4 6.4 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 383 6 2 8 1.8 Cc1ccc(C(Nc2c(Nc3cccn(C)c3=O)c(=O)c2=O)C2(C)COC2)o1 nan
136087076 115994 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 433 6 3 6 3.6 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(Cc3ccccc3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3354831 115994 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 433 6 3 6 3.6 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(Cc3ccccc3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
136087082 116046 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 383 5 3 6 2.9 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3CC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355236 116046 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 383 5 3 6 2.9 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3CC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
129316028 157406 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 442 5 3 5 4.0 CCC1(S(=O)(=O)c2c(Cl)ccc(NC(=O)N[C@@H]3CCC=C3C)c2O)CCOCC1 10.1021/acs.jmedchem.7b01854
CHEMBL4077201 157406 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 442 5 3 5 4.0 CCC1(S(=O)(=O)c2c(Cl)ccc(NC(=O)N[C@@H]3CCC=C3C)c2O)CCOCC1 10.1021/acs.jmedchem.7b01854
129315983 157981 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 402 6 3 5 3.1 COCC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4084077 157981 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 402 6 3 5 3.1 COCC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2C)c1O 10.1021/acs.jmedchem.7b01854
118554742 158343 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 456 5 3 5 4.3 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C2CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4088551 158343 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 456 5 3 5 4.3 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C2CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
118730035 118081 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 319 7 3 6 2.3 C[C@H](CO)Nc1cc(C(=O)O)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403828 118081 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 319 7 3 6 2.3 C[C@H](CO)Nc1cc(C(=O)O)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
57833197 118087 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 382 9 3 7 2.3 CC[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403833 118087 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 382 9 3 7 2.3 CC[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
44431196 150474 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 439 9 2 8 4.3 CCN(CC)c1nc2nc(SCc3cccc(F)c3F)nc(N[C@H](C)CO)c2s1 10.1016/j.bmcl.2007.02.080
CHEMBL395342 150474 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 439 9 2 8 4.3 CCN(CC)c1nc2nc(SCc3cccc(F)c3F)nc(N[C@H](C)CO)c2s1 10.1016/j.bmcl.2007.02.080
44419480 137571 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 455 4 3 5 2.9 CN(C)S(=O)(=O)c1c(F)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL375393 137571 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 455 4 3 5 2.9 CN(C)S(=O)(=O)c1c(F)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2006.08.042
11440492 152731 None 0 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL397237 152731 None 0 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
44446565 94757 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 411 8 3 7 3.2 CCc1ccc(C(CC)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)o1 10.1016/j.bmcl.2008.01.024
CHEMBL252852 94757 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 411 8 3 7 3.2 CCc1ccc(C(CC)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)o1 10.1016/j.bmcl.2008.01.024
12073809 155392 None 0 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 348 6 3 7 2.5 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
CHEMBL402986 155392 None 0 Human Binding pIC50 = 8.4 8.4 - 1
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 348 6 3 7 2.5 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
44446593 94863 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 417 7 3 7 3.2 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(Cl)co1 10.1016/j.bmcl.2008.01.024
CHEMBL253497 94863 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 417 7 3 7 3.2 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(Cl)co1 10.1016/j.bmcl.2008.01.024
44446650 97440 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2
ChEMBL 394 7 3 7 2.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccn1 10.1016/j.bmcl.2008.01.024
CHEMBL269707 97440 None 0 Human Binding pIC50 = 8.4 8.4 - 0
Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2
ChEMBL 394 7 3 7 2.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccn1 10.1016/j.bmcl.2008.01.024
44446639 155683 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 417 7 3 7 3.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(Cl)o1 10.1016/j.bmcl.2008.01.024
CHEMBL404490 155683 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 417 7 3 7 3.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(Cl)o1 10.1016/j.bmcl.2008.01.024
44446566 94786 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 461 7 3 7 3.4 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(Br)o1 10.1016/j.bmcl.2008.01.024
CHEMBL253050 94786 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 461 7 3 7 3.4 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(Br)o1 10.1016/j.bmcl.2008.01.024
44446567 94787 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 417 7 3 7 3.2 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(Cl)o1 10.1016/j.bmcl.2008.01.024
CHEMBL253051 94787 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 417 7 3 7 3.2 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(Cl)o1 10.1016/j.bmcl.2008.01.024
10201676 155113 None 0 Human Binding pIC50 = 8.3 8.3 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 411 7 3 6 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cccc(F)c1 10.1016/j.bmcl.2008.02.010
CHEMBL401512 155113 None 0 Human Binding pIC50 = 8.3 8.3 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 411 7 3 6 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cccc(F)c1 10.1016/j.bmcl.2008.02.010
10201676 155113 None 0 Human Binding pIC50 = 8.3 8.3 - 1
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 411 7 3 6 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cccc(F)c1 10.1021/jm0609622
CHEMBL401512 155113 None 0 Human Binding pIC50 = 8.3 8.3 - 1
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 411 7 3 6 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cccc(F)c1 10.1021/jm0609622
100951623 156564 None 16 Human Binding pIC50 = 7.4 7.4 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4067429 156564 None 16 Human Binding pIC50 = 7.4 7.4 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
135907764 113020 None 15 Human Binding pIC50 = 7.4 7.4 - 1
Displacement of [125I]-GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cell membranesDisplacement of [125I]-GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cell membranes
ChEMBL 319 4 1 5 3.5 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CC1 10.1016/j.bmcl.2014.06.011
CHEMBL3310783 113020 None 15 Human Binding pIC50 = 7.4 7.4 - 1
Displacement of [125I]-GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cell membranesDisplacement of [125I]-GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cell membranes
ChEMBL 319 4 1 5 3.5 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CC1 10.1016/j.bmcl.2014.06.011
44447947 155719 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 496 6 3 4 4.7 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCNC(=O)NS(=O)(=O)c3ccccc3Cl)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL404662 155719 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 496 6 3 4 4.7 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCNC(=O)NS(=O)(=O)c3ccccc3Cl)c2c1 10.1016/j.bmcl.2008.01.127
10268731 205154 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 338 4 1 4 1.9 CC(C)S(=O)(=O)c1ccc(C(=O)Nc2ccc(F)cc2)c[n+]1[O-] 10.1016/s0960-894x(01)00326-2
CHEMBL61655 205154 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 338 4 1 4 1.9 CC(C)S(=O)(=O)c1ccc(C(=O)Nc2ccc(F)cc2)c[n+]1[O-] 10.1016/s0960-894x(01)00326-2
44414248 79760 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 355 4 3 7 1.3 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/Cc2ccco2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL211609 79760 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 355 4 3 7 1.3 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/Cc2ccco2)c1O 10.1016/j.bmcl.2006.04.082
17903317 208573 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2ccc(Cl)cc2Cl)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL85820 208573 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2ccc(Cl)cc2Cl)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
162671722 183038 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 390 3 2 5 4.8 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1CCCO2 10.1016/j.ejmech.2020.112387
CHEMBL4792599 183038 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 390 3 2 5 4.8 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1CCCO2 10.1016/j.ejmech.2020.112387
10267982 168040 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Antagonist activity at CXCR2 in human neutrophils assessed as reduction in GRO-alpha mediated chemotaxisAntagonist activity at CXCR2 in human neutrophils assessed as reduction in GRO-alpha mediated chemotaxis
ChEMBL 320 5 1 5 2.7 COC(=O)CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.ejmech.2019.111853
CHEMBL431511 168040 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Antagonist activity at CXCR2 in human neutrophils assessed as reduction in GRO-alpha mediated chemotaxisAntagonist activity at CXCR2 in human neutrophils assessed as reduction in GRO-alpha mediated chemotaxis
ChEMBL 320 5 1 5 2.7 COC(=O)CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.ejmech.2019.111853
44318777 107045 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 365 4 1 5 4.6 COc1cccc(Cn2nc(-c3ccc(Cl)cc3Cl)nc2S)c1 10.1016/s0960-894x(03)00561-4
CHEMBL315206 107045 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 365 4 1 5 4.6 COc1cccc(Cn2nc(-c3ccc(Cl)cc3Cl)nc2S)c1 10.1016/s0960-894x(03)00561-4
9881570 208516 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 257 3 1 5 2.9 Sc1nc(-c2ccco2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL85390 208516 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 257 3 1 5 2.9 Sc1nc(-c2ccco2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
168269185 190114 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 367 6 2 6 4.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2sccc12 10.1016/j.ejmech.2022.114268
CHEMBL5171358 190114 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 367 6 2 6 4.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2sccc12 10.1016/j.ejmech.2022.114268
163322283 190918 None 3 Human Binding pIC50 = 6.4 6.4 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 362 6 2 6 3.4 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cnccc12 10.1016/j.ejmech.2022.114268
CHEMBL5183834 190918 None 3 Human Binding pIC50 = 6.4 6.4 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 362 6 2 6 3.4 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2cnccc12 10.1016/j.ejmech.2022.114268
135534060 113005 None 22 Human Binding pIC50 = 5.4 5.4 - 0
Displacement of [125I]-GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cell membranesDisplacement of [125I]-GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cell membranes
ChEMBL 387 4 1 5 5.3 N#Cc1c(O)nc(SCc2c(Cl)cccc2Cl)nc1-c1ccccc1 10.1016/j.bmcl.2014.06.011
CHEMBL3310768 113005 None 22 Human Binding pIC50 = 5.4 5.4 - 0
Displacement of [125I]-GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cell membranesDisplacement of [125I]-GRO-alpha from human recombinant CXCR2 receptor expressed in CHO cell membranes
ChEMBL 387 4 1 5 5.3 N#Cc1c(O)nc(SCc2c(Cl)cccc2Cl)nc1-c1ccccc1 10.1016/j.bmcl.2014.06.011
71525512 133375 None 0 Human Binding pIC50 = 6.4 6.4 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 465 8 3 8 2.6 COc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)cc1 nan
CHEMBL3704557 133375 None 0 Human Binding pIC50 = 6.4 6.4 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 465 8 3 8 2.6 COc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)cc1 nan
163322284 190266 None 3 Human Binding pIC50 = 7.4 7.4 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 352 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2022.114268
CHEMBL5173775 190266 None 3 Human Binding pIC50 = 7.4 7.4 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysisBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-binding incubated for 15 mins followed by addition of CXCL8 AF647 measured after 30 mins by flow cytometry analysis
ChEMBL 352 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2022.114268
44439728 11906 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 420 5 3 7 2.3 CN1CCCN(C(=O)c2cccc(Nc3c(Nc4ccccc4)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL1182492 11906 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 420 5 3 7 2.3 CN1CCCN(C(=O)c2cccc(Nc3c(Nc4ccccc4)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL240458 11906 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 420 5 3 7 2.3 CN1CCCN(C(=O)c2cccc(Nc3c(Nc4ccccc4)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
117627636 154352 None 0 Human Binding pIC50 = 7.4 7.4 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 401 6 3 8 2.3 Cc1ccc(C(Nc2c(NC3=CC=CN(C)C3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3986396 154352 None 0 Human Binding pIC50 = 7.4 7.4 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 401 6 3 8 2.3 Cc1ccc(C(Nc2c(NC3=CC=CN(C)C3O)c(=O)c2=O)C2CCCS2)o1 nan
162675312 183512 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 404 5 2 5 5.2 CCOC(=O)c1c(NC(=S)Nc2ccc(OC)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4798282 183512 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 404 5 2 5 5.2 CCOC(=O)c1c(NC(=S)Nc2ccc(OC)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
44318869 104791 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 283 3 2 5 3.0 Oc1cccc(Cn2nc(-c3ccccc3)nc2S)c1 10.1016/s0960-894x(03)00561-4
CHEMBL310634 104791 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 283 3 2 5 3.0 Oc1cccc(Cn2nc(-c3ccccc3)nc2S)c1 10.1016/s0960-894x(03)00561-4
44454986 155542 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 395 6 4 7 1.4 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)c(=O)[nH]c12 10.1016/j.bmcl.2007.11.039
CHEMBL403877 155542 None 0 Human Binding pIC50 = 7.4 7.4 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 395 6 4 7 1.4 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)c(=O)[nH]c12 10.1016/j.bmcl.2007.11.039
8497 2737 None 41 Human Binding pIC50 = 6.4 6.4 39 2
Antagonist activity at CXCR2 in human whole blood by CD11b assayAntagonist activity at CXCR2 in human whole blood by CD11b assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.bmcl.2014.10.003
9865554 2737 None 41 Human Binding pIC50 = 6.4 6.4 39 2
Antagonist activity at CXCR2 in human whole blood by CD11b assayAntagonist activity at CXCR2 in human whole blood by CD11b assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.bmcl.2014.10.003
CHEMBL216981 2737 None 41 Human Binding pIC50 = 6.4 6.4 39 2
Antagonist activity at CXCR2 in human whole blood by CD11b assayAntagonist activity at CXCR2 in human whole blood by CD11b assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.bmcl.2014.10.003
17903299 208482 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 301 3 1 4 3.9 Sc1nc(-c2ccccc2Cl)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL85045 208482 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 301 3 1 4 3.9 Sc1nc(-c2ccccc2Cl)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
17903311 208491 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 349 4 1 4 4.8 Sc1nc(-c2ccc(Cl)cc2Cl)nn1CCc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL85117 208491 None 0 Human Binding pIC50 = 6.4 6.4 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 349 4 1 4 4.8 Sc1nc(-c2ccc(Cl)cc2Cl)nn1CCc1ccccc1 10.1016/s0960-894x(03)00561-4
44432420 87971 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 365 2 3 6 2.8 CC(=O)c1ccccc1NC1=NS(=O)(=O)c2cc(Cl)cc(O)c2N1 10.1016/j.bmcl.2007.05.011
CHEMBL233973 87971 None 0 Human Binding pIC50 = 5.4 5.4 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 365 2 3 6 2.8 CC(=O)c1ccccc1NC1=NS(=O)(=O)c2cc(Cl)cc(O)c2N1 10.1016/j.bmcl.2007.05.011
21878309 205229 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 364 4 1 4 2.4 O=C(Nc1ccc(F)cc1)c1ccc(S(=O)(=O)C2CCCC2)[n+]([O-])c1 10.1016/s0960-894x(01)00326-2
CHEMBL62108 205229 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 364 4 1 4 2.4 O=C(Nc1ccc(F)cc1)c1ccc(S(=O)(=O)C2CCCC2)[n+]([O-])c1 10.1016/s0960-894x(01)00326-2
71526254 144905 None 0 Human Binding pIC50 = 7.3 7.3 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 523 8 3 8 4.3 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3909470 144905 None 0 Human Binding pIC50 = 7.3 7.3 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 523 8 3 8 4.3 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2CCCS2)o1 nan
71525511 133374 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 465 8 3 8 2.6 COc1cccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)c1 nan
CHEMBL3704556 133374 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 465 8 3 8 2.6 COc1cccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)c1 nan
21015140 165859 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 280 3 3 5 2.3 O=c1c(O)c(Nc2ccccc2)/c1=N/c1ccccc1O 10.1016/j.bmcl.2006.04.082
CHEMBL424694 165859 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 280 3 3 5 2.3 O=c1c(O)c(Nc2ccccc2)/c1=N/c1ccccc1O 10.1016/j.bmcl.2006.04.082
135673991 73766 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 382 5 2 8 4.5 Nc1nc2nc(SCc3cccc(Oc4ccccc4)c3)nc(O)c2s1 10.1016/j.bmcl.2005.10.091
CHEMBL201842 73766 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 382 5 2 8 4.5 Nc1nc2nc(SCc3cccc(Oc4ccccc4)c3)nc(O)c2s1 10.1016/j.bmcl.2005.10.091
44432437 86764 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 401 1 3 5 3.4 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)ccc(Cl)c21 10.1016/j.bmcl.2007.05.011
CHEMBL231922 86764 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 401 1 3 5 3.4 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)ccc(Cl)c21 10.1016/j.bmcl.2007.05.011
44446577 155384 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 493 8 3 7 4.9 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(-c2ccccc2Cl)o1 10.1016/j.bmcl.2008.01.024
CHEMBL402952 155384 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 493 8 3 7 4.9 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(-c2ccccc2Cl)o1 10.1016/j.bmcl.2008.01.024
9912703 83214 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 471 4 3 5 3.4 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL218387 83214 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 471 4 3 5 3.4 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2006.08.042
9968028 80326 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 345 5 3 6 1.7 CCC(CC)/N=c1\c(O)c(O)\c1=N/c1cccc(C(=O)N(C)C)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL214047 80326 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 345 5 3 6 1.7 CCC(CC)/N=c1\c(O)c(O)\c1=N/c1cccc(C(=O)N(C)C)c1O 10.1016/j.bmcl.2006.04.082
44455404 98028 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 338 6 3 8 2.1 C[C@H](CO)Nc1nc(SCc2ccco2)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL272705 98028 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 338 6 3 8 2.1 C[C@H](CO)Nc1nc(SCc2ccco2)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
12073809 155392 None 0 Human Binding pIC50 = 8.3 8.3 - 1
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 348 6 3 7 2.5 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL402986 155392 None 0 Human Binding pIC50 = 8.3 8.3 - 1
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 348 6 3 7 2.5 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
44455045 167518 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 461 8 3 9 2.8 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NS(C)(=O)=O)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL429682 167518 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 461 8 3 9 2.8 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NS(C)(=O)=O)sc12 10.1016/j.bmcl.2007.11.039
16098480 83518 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 437 7 3 8 2.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc2c(c1)OCO2 10.1021/jm0609622
CHEMBL220182 83518 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 437 7 3 8 2.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc2c(c1)OCO2 10.1021/jm0609622
10293321 94756 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 383 7 3 7 2.6 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccco1 10.1016/j.bmcl.2008.01.024
CHEMBL252851 94756 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 383 7 3 7 2.6 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccco1 10.1016/j.bmcl.2008.01.024
44446595 94864 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 461 7 3 7 3.4 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(Br)co1 10.1016/j.bmcl.2008.01.024
CHEMBL253498 94864 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 461 7 3 7 3.4 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(Br)co1 10.1016/j.bmcl.2008.01.024
10072431 118101 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 449 9 3 7 2.6 C[C@H](CO)Nc1cc(NS(=O)(=O)N(C)C)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403848 118101 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 449 9 3 7 2.6 C[C@H](CO)Nc1cc(NS(=O)(=O)N(C)C)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
57833185 118108 None 0 Human Binding pIC50 = 8.3 8.3 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 491 9 3 8 2.3 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCOCC2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403855 118108 None 0 Human Binding pIC50 = 8.3 8.3 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 491 9 3 8 2.3 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCOCC2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
10479502 1548 None 26 Human Binding pIC50 = 8.3 8.3 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
8499 1548 None 26 Human Binding pIC50 = 8.3 8.3 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
CHEMBL2178579 1548 None 26 Human Binding pIC50 = 8.3 8.3 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
DB12135 1548 None 26 Human Binding pIC50 = 8.3 8.3 - 0
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 462 4 4 5 3.1 O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl 10.1021/jm300682j
100951623 156564 None 16 Human Binding pIC50 = 8.3 8.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4067429 156564 None 16 Human Binding pIC50 = 8.3 8.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
16098486 162030 None 0 Human Binding pIC50 = 8.3 8.3 28 2
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 413 7 3 7 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)s1 10.1021/jm0609622
CHEMBL415446 162030 None 0 Human Binding pIC50 = 8.3 8.3 28 2
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 413 7 3 7 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)s1 10.1021/jm0609622
16098481 82143 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 383 6 3 7 2.5 Cc1ccc([C@@H](C)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)o1 10.1021/jm0609622
CHEMBL216602 82143 None 0 Human Binding pIC50 = 8.3 8.3 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 383 6 3 7 2.5 Cc1ccc([C@@H](C)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)o1 10.1021/jm0609622
21037713 155625 None 9 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 397 7 3 7 2.9 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.bmcl.2008.01.024
CHEMBL404249 155625 None 9 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 397 7 3 7 2.9 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.bmcl.2008.01.024
44446617 94762 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 399 7 3 7 3.1 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccsc1 10.1016/j.bmcl.2008.01.024
CHEMBL252898 94762 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 399 7 3 7 3.1 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccsc1 10.1016/j.bmcl.2008.01.024
100951623 156564 None 16 Mouse Binding pIC50 = 8.2 8.2 - 0
Antagonist activity at CXCR2 in C57 mouse whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 1 hr followed by GROalpha stimulation measured after 10 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in C57 mouse whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 1 hr followed by GROalpha stimulation measured after 10 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4067429 156564 None 16 Mouse Binding pIC50 = 8.2 8.2 - 0
Antagonist activity at CXCR2 in C57 mouse whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 1 hr followed by GROalpha stimulation measured after 10 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in C57 mouse whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 1 hr followed by GROalpha stimulation measured after 10 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
22648972 75590 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 453 8 3 9 4.9 CC(C)(CO)Nc1nc(SCc2cccc(Oc3ccccc3)c2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
CHEMBL204552 75590 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 453 8 3 9 4.9 CC(C)(CO)Nc1nc(SCc2cccc(Oc3ccccc3)c2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
24879232 155445 None 1 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 428 7 2 4 3.1 CN(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL403313 155445 None 1 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 428 7 2 4 3.1 CN(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
44446635 94869 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 394 7 3 7 2.4 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccncc1 10.1016/j.bmcl.2008.01.024
CHEMBL253506 94869 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 394 7 3 7 2.4 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccncc1 10.1016/j.bmcl.2008.01.024
136087094 116057 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 415 5 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c(F)c(C3CCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355248 116057 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 415 5 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c(F)c(C3CCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
137651658 157362 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 374 4 3 4 3.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4076769 157362 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 374 4 3 4 3.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCCC2)c1O 10.1021/acs.jmedchem.7b01854
57833164 118093 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 444 10 3 7 3.5 C[C@H](CO)Nc1cc(NS(=O)(=O)Cc2ccccc2)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403839 118093 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 444 10 3 7 3.5 C[C@H](CO)Nc1cc(NS(=O)(=O)Cc2ccccc2)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
136087069 115987 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 427 4 3 6 3.9 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c3cccc(Cl)c3[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3354823 115987 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 427 4 3 6 3.9 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c3cccc(Cl)c3[nH]2)c1O 10.1016/j.bmcl.2014.10.003
129316018 156832 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 467 5 3 5 4.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(C3CCC3)CC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4070506 156832 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 467 5 3 5 4.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(C3CCC3)CC2)c1O 10.1021/acs.jmedchem.7b01854
129316058 158105 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 422 5 4 5 3.0 CC(C)(CO)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@H]2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4085524 158105 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 422 5 4 5 3.0 CC(C)(CO)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@H]2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
71525701 133385 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 403 6 3 8 2.9 Cc1ccc(C(Nc2c(Nc3ccc(Cl)nc3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3704567 133385 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 403 6 3 8 2.9 Cc1ccc(C(Nc2c(Nc3ccc(Cl)nc3O)c(=O)c2=O)C2(C)COC2)o1 nan
9885174 145457 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 358 4 3 5 3.2 O=c1c(Nc2ccccc2O)c(Nc2ccccc2Br)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL391372 145457 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 358 4 3 5 3.2 O=c1c(Nc2ccccc2O)c(Nc2ccccc2Br)c1=O 10.1016/j.bmcl.2006.12.067
44432390 88048 None 0 Human Binding pIC50 = 5.3 5.3 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 401 1 3 5 3.4 O=S1(=O)N=C(Nc2ccc(Br)cc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL234395 88048 None 0 Human Binding pIC50 = 5.3 5.3 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 401 1 3 5 3.4 O=S1(=O)N=C(Nc2ccc(Br)cc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
44439677 90309 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 359 5 3 7 3.0 O=c1c(Nc2ccccc2)c(Nc2cc(Cl)c([N+](=O)[O-])cc2O)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL238511 90309 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 359 5 3 7 3.0 O=c1c(Nc2ccccc2)c(Nc2cc(Cl)c([N+](=O)[O-])cc2O)c1=O 10.1016/j.bmcl.2006.12.067
46896782 119151 None 0 Human Binding pIC50 = 7.3 7.3 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 400 6 3 5 2.6 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(F)ccc2B(O)O)nc1 nan
CHEMBL3426949 119151 None 0 Human Binding pIC50 = 7.3 7.3 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 400 6 3 5 2.6 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(F)ccc2B(O)O)nc1 nan
44447948 95048 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 480 6 3 4 4.2 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCNC(=O)NS(=O)(=O)c3ccc(F)cc3)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL254774 95048 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 480 6 3 4 4.2 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCNC(=O)NS(=O)(=O)c3ccc(F)cc3)c2c1 10.1016/j.bmcl.2008.01.127
91937330 114992 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 365 6 3 6 1.7 O=C(Nc1ccncc1)c1ccc(SCc2ccccc2B(O)O)nc1 nan
CHEMBL3342317 114992 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 365 6 3 6 1.7 O=C(Nc1ccncc1)c1ccc(SCc2ccccc2B(O)O)nc1 nan
11336278 87998 None 2 Human Binding pIC50 = 5.3 5.3 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 323 1 3 5 2.6 O=S1(=O)N=C(Nc2ccccc2Cl)Nc2c(O)cccc21 10.1016/j.bmcl.2007.05.011
CHEMBL234177 87998 None 2 Human Binding pIC50 = 5.3 5.3 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 323 1 3 5 2.6 O=S1(=O)N=C(Nc2ccccc2Cl)Nc2c(O)cccc21 10.1016/j.bmcl.2007.05.011
91937328 127326 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 486 6 1 5 5.1 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2cc(Br)cc3c2OCC3)nc1 nan
CHEMBL3658335 127326 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 486 6 1 5 5.1 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2cc(Br)cc3c2OCC3)nc1 nan
44414052 140168 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 338 3 3 7 1.9 COC(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL380052 140168 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 338 3 3 7 1.9 COC(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
71525976 153578 None 0 Human Binding pIC50 = 7.3 7.3 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 453 7 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCCO2)o1 nan
CHEMBL3979652 153578 None 0 Human Binding pIC50 = 7.3 7.3 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 453 7 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCCO2)o1 nan
44439680 90520 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 314 4 3 5 3.1 O=c1c(Nc2ccccc2)c(Nc2cc(Cl)ccc2O)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL238724 90520 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 314 4 3 5 3.1 O=c1c(Nc2ccccc2)c(Nc2cc(Cl)ccc2O)c1=O 10.1016/j.bmcl.2006.12.067
44432416 87422 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 415 3 3 6 4.4 O=S1(=O)N=C(Nc2ccccc2Oc2ccccc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL233346 87422 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 415 3 3 6 4.4 O=S1(=O)N=C(Nc2ccccc2Oc2ccccc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
11304851 154695 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 426 4 3 8 3.7 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Oc1ccccc1)N2 10.1016/j.bmcl.2007.05.011
CHEMBL399203 154695 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 426 4 3 8 3.7 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Oc1ccccc1)N2 10.1016/j.bmcl.2007.05.011
46896680 114981 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 332 5 1 4 3.7 O=C(Nc1ccc(F)cc1)c1ccc(SCC2CCCO2)nc1 nan
CHEMBL3342282 114981 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 332 5 1 4 3.7 O=C(Nc1ccc(F)cc1)c1ccc(SCC2CCCO2)nc1 nan
44414222 80127 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 391 3 3 6 2.2 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/[C@@H]2CCc3ccccc32)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL213147 80127 None 0 Human Binding pIC50 = 6.3 6.3 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 391 3 3 6 2.2 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/[C@@H]2CCc3ccccc32)c1O 10.1016/j.bmcl.2006.04.082
71525421 132873 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 412 7 4 8 2.9 Cc1ccc(C(Nc2c(Nc3cccc(C(C)O)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701189 132873 None 0 Human Binding pIC50 = 6.3 6.3 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 412 7 4 8 2.9 Cc1ccc(C(Nc2c(Nc3cccc(C(C)O)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
45485721 200953 None 0 Human Binding pIC50 = 5.3 5.3 - 0
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 318 6 4 7 0.4 CCNNc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2009.08.014
CHEMBL577738 200953 None 0 Human Binding pIC50 = 5.3 5.3 - 0
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 318 6 4 7 0.4 CCNNc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2009.08.014
44414294 78056 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 325 4 3 7 2.2 O=c1c(O)c(Nc2cc([N+](=O)[O-])ccc2O)/c1=N/c1ccccc1 10.1016/j.bmcl.2006.04.082
CHEMBL209858 78056 None 0 Human Binding pIC50 = 7.3 7.3 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 325 4 3 7 2.2 O=c1c(O)c(Nc2cc([N+](=O)[O-])ccc2O)/c1=N/c1ccccc1 10.1016/j.bmcl.2006.04.082
71525977 150292 None 0 Human Binding pIC50 = 7.3 7.3 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3951994 150292 None 0 Human Binding pIC50 = 7.3 7.3 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
44447942 95019 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 458 8 2 5 3.1 COc1cc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)N(C)C)c2cc1C#N 10.1016/j.bmcl.2008.01.127
CHEMBL254567 95019 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 458 8 2 5 3.1 COc1cc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)N(C)C)c2cc1C#N 10.1016/j.bmcl.2008.01.127
21184843 97241 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 365 2 3 3 4.3 N#Cc1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1021/jm034248l
CHEMBL26830 97241 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 365 2 3 3 4.3 N#Cc1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1021/jm034248l
162662426 182063 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 462 5 2 6 6.0 COc1ccc(NC(=S)Nc2sc3c(c2C(=O)OC(C)(C)C)C(C)CCC3)cc1OC 10.1016/j.ejmech.2020.112387
CHEMBL4779981 182063 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 462 5 2 6 6.0 COc1ccc(NC(=S)Nc2sc3c(c2C(=O)OC(C)(C)C)C(C)CCC3)cc1OC 10.1016/j.ejmech.2020.112387
44446580 95008 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 493 8 3 7 4.9 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(-c2cccc(Cl)c2)o1 10.1016/j.bmcl.2008.01.024
CHEMBL254516 95008 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 493 8 3 7 4.9 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(-c2cccc(Cl)c2)o1 10.1016/j.bmcl.2008.01.024
136087081 116045 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 in human whole blood by CD11b assayAntagonist activity at CXCR2 in human whole blood by CD11b assay
ChEMBL 399 4 3 6 3.4 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)C)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355235 116045 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 in human whole blood by CD11b assayAntagonist activity at CXCR2 in human whole blood by CD11b assay
ChEMBL 399 4 3 6 3.4 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)C)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
91937258 126888 None 0 Human Binding pIC50 = 7.2 7.2 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 516 6 1 5 5.7 CC1(C)C2CC3OB(c4ccccc4CSc4ccc(C(=O)Nc5ccc(F)cc5)cn4)OC3(C)C1C2 nan
CHEMBL3654444 126888 None 0 Human Binding pIC50 = 7.2 7.2 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 516 6 1 5 5.7 CC1(C)C2CC3OB(c4ccccc4CSc4ccc(C(=O)Nc5ccc(F)cc5)cn4)OC3(C)C1C2 nan
9953415 99068 None 10 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]IL-8 from CXCR2 (unknown origin) stably expressed in CHO cellsDisplacement of [125I]IL-8 from CXCR2 (unknown origin) stably expressed in CHO cells
ChEMBL 409 2 3 3 4.4 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c(O)c1Br 10.1016/j.ejmech.2019.111853
CHEMBL28009 99068 None 10 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]IL-8 from CXCR2 (unknown origin) stably expressed in CHO cellsDisplacement of [125I]IL-8 from CXCR2 (unknown origin) stably expressed in CHO cells
ChEMBL 409 2 3 3 4.4 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c(O)c1Br 10.1016/j.ejmech.2019.111853
44419479 84337 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 578 8 4 7 4.0 CCC(CC)(NS(=O)(=O)c1c(C)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCOCC1 10.1016/j.bmcl.2006.08.042
CHEMBL221481 84337 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 578 8 4 7 4.0 CCC(CC)(NS(=O)(=O)c1c(C)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCOCC1 10.1016/j.bmcl.2006.08.042
10272255 141802 None 0 Human Binding pIC50 = 8.2 8.2 41 2
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 399 7 3 7 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cccs1 10.1021/jm0609622
CHEMBL385715 141802 None 0 Human Binding pIC50 = 8.2 8.2 41 2
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 399 7 3 7 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cccs1 10.1021/jm0609622
9953415 99068 None 10 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 409 2 3 3 4.4 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c(O)c1Br 10.1021/jm034248l
CHEMBL28009 99068 None 10 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 409 2 3 3 4.4 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c(O)c1Br 10.1021/jm034248l
44446596 94865 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 459 8 3 7 4.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(-c2ccccc2)co1 10.1016/j.bmcl.2008.01.024
CHEMBL253499 94865 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 459 8 3 7 4.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(-c2ccccc2)co1 10.1016/j.bmcl.2008.01.024
16098482 141652 None 1 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 411 7 3 7 3.1 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)o1 10.1021/jm0609622
CHEMBL384889 141652 None 1 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 411 7 3 7 3.1 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)o1 10.1021/jm0609622
10294353 155574 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 399 7 3 7 3.1 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cccs1 10.1016/j.bmcl.2008.01.024
CHEMBL404059 155574 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 399 7 3 7 3.1 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cccs1 10.1016/j.bmcl.2008.01.024
44446621 155575 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 433 7 3 7 3.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(Cl)s1 10.1016/j.bmcl.2008.01.024
CHEMBL404060 155575 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 433 7 3 7 3.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(Cl)s1 10.1016/j.bmcl.2008.01.024
44446645 94925 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 398 7 3 8 2.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)on1 10.1016/j.bmcl.2008.01.024
CHEMBL253927 94925 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 398 7 3 8 2.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)on1 10.1016/j.bmcl.2008.01.024
136087081 116045 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 399 4 3 6 3.4 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)C)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355235 116045 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 399 4 3 6 3.4 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)C)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
129316022 158018 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 358 4 3 4 3.1 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2C=CCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4084412 158018 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 358 4 3 4 3.1 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2C=CCC2)c1O 10.1021/acs.jmedchem.7b01854
127050016 140888 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 478 4 3 5 4.9 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818820 140888 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 478 4 3 5 4.9 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
127050964 140918 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 425 3 3 3 5.1 O=C(Nc1ccc(Cl)c(C(=O)N2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3819221 140918 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 425 3 3 3 5.1 O=C(Nc1ccc(Cl)c(C(=O)N2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
10200589 94993 None 0 Human Binding pIC50 = 8.2 8.2 9 2
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2008.02.010
CHEMBL254370 94993 None 0 Human Binding pIC50 = 8.2 8.2 9 2
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2008.02.010
10200589 94993 None 0 Human Binding pIC50 = 8.2 8.2 9 2
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
CHEMBL254370 94993 None 0 Human Binding pIC50 = 8.2 8.2 9 2
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
44446569 94788 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 433 8 3 7 3.5 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(F)F)o1 10.1016/j.bmcl.2008.01.024
CHEMBL253052 94788 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 433 8 3 7 3.5 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(F)F)o1 10.1016/j.bmcl.2008.01.024
44455386 155330 None 1 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 369 6 3 9 2.2 Cc1nc(CSc2nc(N[C@H](C)CO)c3sc(=O)[nH]c3n2)cs1 10.1016/j.bmcl.2007.11.039
CHEMBL402728 155330 None 1 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 369 6 3 9 2.2 Cc1nc(CSc2nc(N[C@H](C)CO)c3sc(=O)[nH]c3n2)cs1 10.1016/j.bmcl.2007.11.039
71556114 124541 None 0 Human Binding pIC50 = 7.2 7.2 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 523 8 3 10 2.6 COC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(N[C@@H](c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c1O nan
CHEMBL3640000 124541 None 0 Human Binding pIC50 = 7.2 7.2 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 523 8 3 10 2.6 COC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(N[C@@H](c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c1O nan
3117 210300 None 60 Human Binding pIC50 = 5.2 5.2 -4 16
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)
ChEMBL 296 4 0 4 3.6 CCN(CC)C(=S)SSC(=S)N(CC)CC nan
CHEMBL964 210300 None 60 Human Binding pIC50 = 5.2 5.2 -4 16
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)
ChEMBL 296 4 0 4 3.6 CCN(CC)C(=S)SSC(=S)N(CC)CC nan
44432388 88047 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 401 1 3 5 3.4 O=S1(=O)N=C(Nc2cccc(Br)c2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL234393 88047 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 401 1 3 5 3.4 O=S1(=O)N=C(Nc2cccc(Br)c2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
46897351 126887 None 0 Human Binding pIC50 = 6.2 6.2 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 478 7 1 5 5.1 CC1(C)OB(c2ccccc2CCSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C nan
CHEMBL3654443 126887 None 0 Human Binding pIC50 = 6.2 6.2 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 478 7 1 5 5.1 CC1(C)OB(c2ccccc2CCSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C nan
71525345 132876 None 0 Human Binding pIC50 = 6.2 6.2 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 481 7 3 9 2.3 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCOCC4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701192 132876 None 0 Human Binding pIC50 = 6.2 6.2 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 481 7 3 9 2.3 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCOCC4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
9951571 66612 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 374 2 3 2 5.1 O=C(Nc1ccccc1Br)Nc1ccc(Cl)c(Cl)c1O 10.1016/j.bmcl.2004.06.097
CHEMBL185259 66612 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 374 2 3 2 5.1 O=C(Nc1ccccc1Br)Nc1ccc(Cl)c(Cl)c1O 10.1016/j.bmcl.2004.06.097
71525976 153578 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 453 7 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCCO2)o1 10.1021/acs.jmedchem.5b01337
CHEMBL3979652 153578 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 453 7 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCCO2)o1 10.1021/acs.jmedchem.5b01337
118554832 159325 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 432 4 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4098864 159325 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 432 4 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
137662215 159633 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 388 5 3 4 3.9 CCC1CCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4102423 159633 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 388 5 3 4 3.9 CCC1CCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
57833195 118098 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 397 9 3 7 1.8 C[C@H](CO)Nc1cc(NS(=O)(=O)N(C)C)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403845 118098 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 397 9 3 7 1.8 C[C@H](CO)Nc1cc(NS(=O)(=O)N(C)C)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
44431175 161959 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 383 6 3 8 3.0 C[C@@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL414894 161959 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 383 6 3 8 3.0 C[C@@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
44455191 97583 None 1 Human Binding pIC50 = 6.2 6.2 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 365 6 3 6 3.0 Cc1nc2c(N[C@H](C)CO)nc(SCc3cccc(F)c3F)nc2[nH]1 10.1016/j.bmcl.2007.11.039
CHEMBL270446 97583 None 1 Human Binding pIC50 = 6.2 6.2 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 365 6 3 6 3.0 Cc1nc2c(N[C@H](C)CO)nc(SCc3cccc(F)c3F)nc2[nH]1 10.1016/j.bmcl.2007.11.039
136087068 115986 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 393 4 3 6 3.2 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c3ccccc3[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3354822 115986 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 393 4 3 6 3.2 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)c3ccccc3[nH]2)c1O 10.1016/j.bmcl.2014.10.003
136087072 115990 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 419 5 3 6 3.7 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(-c3ccccc3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3354827 115990 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 419 5 3 6 3.7 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(-c3ccccc3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
136087073 115991 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 453 5 3 6 4.4 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(-c3ccccc3Cl)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3354828 115991 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 453 5 3 6 4.4 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(-c3ccccc3Cl)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
136087090 116054 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 433 5 3 6 3.6 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3CC(F)(F)C3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355244 116054 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 433 5 3 6 3.6 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3CC(F)(F)C3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
136087096 116060 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 425 5 3 6 4.0 Cc1c(C2CCCC2)[nH]c(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)nc1=O 10.1016/j.bmcl.2014.10.003
CHEMBL3355250 116060 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 425 5 3 6 4.0 Cc1c(C2CCCC2)[nH]c(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)nc1=O 10.1016/j.bmcl.2014.10.003
129316027 156977 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 437 6 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(F)(F)CN(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4072010 156977 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 437 6 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(F)(F)CN(C)C)c1O 10.1021/acs.jmedchem.7b01854
118540730 158215 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 394 4 3 4 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(F)F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4086957 158215 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 394 4 3 4 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(F)F)c1O 10.1021/acs.jmedchem.7b01854
137650877 157262 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 376 4 3 5 2.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4075487 157262 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 376 4 3 5 2.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
127051854 140911 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 487 4 3 5 4.4 CN1CC2(CC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)C2)C1 10.1021/acsmedchemlett.5b00489
CHEMBL3819163 140911 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 487 4 3 5 4.4 CN1CC2(CC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)C2)C1 10.1021/acsmedchemlett.5b00489
118730038 118091 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 434 10 3 8 2.1 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCCOc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403837 118091 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 434 10 3 8 2.1 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCCOc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
1316559 174902 None 22 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 in human U2OS cells assessed as effect on beta-arrestin2 recruitment by CCF4-AM staining based Tango assayAntagonist activity at CXCR2 in human U2OS cells assessed as effect on beta-arrestin2 recruitment by CCF4-AM staining based Tango assay
ChEMBL 364 5 2 3 4.9 CC1(C)CC(=O)C(C(=S)Nc2ccccc2)=C(NCc2ccccc2)C1 10.1016/j.ejmech.2019.111853
CHEMBL4562144 174902 None 22 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 in human U2OS cells assessed as effect on beta-arrestin2 recruitment by CCF4-AM staining based Tango assayAntagonist activity at CXCR2 in human U2OS cells assessed as effect on beta-arrestin2 recruitment by CCF4-AM staining based Tango assay
ChEMBL 364 5 2 3 4.9 CC1(C)CC(=O)C(C(=S)Nc2ccccc2)=C(NCc2ccccc2)C1 10.1016/j.ejmech.2019.111853
127049430 140925 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 422 4 3 4 4.8 CCS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3819295 140925 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 422 4 3 4 4.8 CCS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
44447918 95161 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 413 7 2 4 3.6 CCS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL255483 95161 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 413 7 2 4 3.6 CCS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
44432386 147583 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 401 1 3 5 3.4 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL393047 147583 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 401 1 3 5 3.4 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
44432391 147854 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 375 1 3 5 3.4 O=S1(=O)N=C(Nc2cccc(F)c2Cl)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL393253 147854 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 375 1 3 5 3.4 O=S1(=O)N=C(Nc2cccc(F)c2Cl)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
44447945 95021 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 400 5 3 4 2.6 CS(=O)(=O)NC(=O)NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL254569 95021 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 400 5 3 4 2.6 CS(=O)(=O)NC(=O)NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
3076852 182153 None 14 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 374 4 2 4 5.2 CCOC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4781097 182153 None 14 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 374 4 2 4 5.2 CCOC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
44414231 80305 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 351 4 4 6 1.9 CCNC(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL213943 80305 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 351 4 4 6 1.9 CCNC(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
44447929 95667 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 400 6 3 4 2.5 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(N)(=O)=O)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL257830 95667 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 400 6 3 4 2.5 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(N)(=O)=O)c2c1 10.1016/j.bmcl.2008.01.127
163322284 190266 None 3 Human Binding pIC50 = 6.2 6.2 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 352 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2022.114268
CHEMBL5173775 190266 None 3 Human Binding pIC50 = 6.2 6.2 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 352 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]nnc12 10.1016/j.ejmech.2022.114268
9884184 208274 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2cc(Cl)ccc2Cl)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL83292 208274 None 0 Human Binding pIC50 = 6.2 6.2 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2cc(Cl)ccc2Cl)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
162661251 181980 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 346 3 3 3 4.7 CC1CCCc2sc(NC(=S)Nc3ccccc3)c(C(=O)O)c21 10.1016/j.ejmech.2020.112387
CHEMBL4778886 181980 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 346 3 3 3 4.7 CC1CCCc2sc(NC(=S)Nc3ccccc3)c(C(=O)O)c21 10.1016/j.ejmech.2020.112387
162663300 182079 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 388 5 2 4 4.9 CCOC(=O)c1c(NC(=S)NCc2ccccc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4780140 182079 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 388 5 2 4 4.9 CCOC(=O)c1c(NC(=S)NCc2ccccc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
8497 2737 None 41 Human Binding pIC50 = 6.2 6.2 39 2
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.7b01854
9865554 2737 None 41 Human Binding pIC50 = 6.2 6.2 39 2
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.7b01854
CHEMBL216981 2737 None 41 Human Binding pIC50 = 6.2 6.2 39 2
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.7b01854
162669138 182741 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 474 4 2 5 7.1 CC1CCCc2sc(NC(=S)Nc3ccc(OC(C)(C)C)cc3)c(C(=O)OC(C)(C)C)c21 10.1016/j.ejmech.2020.112387
CHEMBL4788608 182741 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 474 4 2 5 7.1 CC1CCCc2sc(NC(=S)Nc3ccc(OC(C)(C)C)cc3)c(C(=O)OC(C)(C)C)c21 10.1016/j.ejmech.2020.112387
46897255 119149 None 0 Human Binding pIC50 = 6.2 6.2 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 348 8 3 5 2.8 O=C(Nc1ccc(F)cc1)c1ccc(SCCCCB(O)O)nc1 nan
CHEMBL3426947 119149 None 0 Human Binding pIC50 = 6.2 6.2 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 348 8 3 5 2.8 O=C(Nc1ccc(F)cc1)c1ccc(SCCCCB(O)O)nc1 nan
78098665 150868 None 0 Human Binding pIC50 = 7.2 7.2 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 489 7 3 8 4.0 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3956601 150868 None 0 Human Binding pIC50 = 7.2 7.2 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 489 7 3 8 4.0 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
9888410 122202 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 419 3 4 4 3.1 NS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
CHEMBL359670 122202 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 419 3 4 4 3.1 NS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
44419482 83267 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 505 4 3 5 3.8 CN(C)S(=O)(=O)c1c(C(F)(F)F)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL218665 83267 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 505 4 3 5 3.8 CN(C)S(=O)(=O)c1c(C(F)(F)F)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2006.08.042
44419477 138146 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 451 4 3 5 3.1 Cc1ccc(N/C(=N/C#N)Nc2ccccc2Br)c(O)c1S(=O)(=O)N(C)C 10.1016/j.bmcl.2006.08.042
CHEMBL376540 138146 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 451 4 3 5 3.1 Cc1ccc(N/C(=N/C#N)Nc2ccccc2Br)c(O)c1S(=O)(=O)N(C)C 10.1016/j.bmcl.2006.08.042
9842742 97817 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 378 6 3 8 2.4 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)cnc12 10.1016/j.bmcl.2007.11.039
CHEMBL271703 97817 None 0 Human Binding pIC50 = 8.2 8.2 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 378 6 3 8 2.4 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)cnc12 10.1016/j.bmcl.2007.11.039
44446613 155185 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 398 7 3 8 2.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)on1 10.1016/j.bmcl.2008.01.024
CHEMBL401894 155185 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 398 7 3 8 2.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)on1 10.1016/j.bmcl.2008.01.024
44446604 94892 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 478 8 3 9 3.9 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(-c2c(C)noc2C)co1 10.1016/j.bmcl.2008.01.024
CHEMBL253706 94892 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 478 8 3 9 3.9 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(-c2c(C)noc2C)co1 10.1016/j.bmcl.2008.01.024
127052174 140850 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 411 3 3 3 4.7 O=C(Nc1ccc(Cl)c(C(=O)N2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818323 140850 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 411 3 3 3 4.7 O=C(Nc1ccc(Cl)c(C(=O)N2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
127048710 140885 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 464 4 3 5 4.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818793 140885 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 464 4 3 5 4.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
57833094 118102 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 490 9 4 8 1.9 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCNCC2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403849 118102 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 490 9 4 8 1.9 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCNCC2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
10072910 118105 None 0 Human Binding pIC50 = 8.1 8.1 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 459 9 3 7 2.6 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403852 118105 None 0 Human Binding pIC50 = 8.1 8.1 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 459 9 3 7 2.6 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
10050534 118106 None 0 Human Binding pIC50 = 8.1 8.1 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 473 9 3 7 3.0 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCCCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403853 118106 None 0 Human Binding pIC50 = 8.1 8.1 - 1
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 473 9 3 7 3.0 C[C@H](CO)Nc1cc(NS(=O)(=O)N2CCCCC2)nc(SCc2cccc(F)c2F)n1 10.1016/j.bmcl.2015.01.067
44431195 93358 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 397 7 3 8 3.5 CNc1nc2nc(SCc3cccc(F)c3F)nc(N[C@H](C)CO)c2s1 10.1016/j.bmcl.2007.02.080
CHEMBL245180 93358 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 397 7 3 8 3.5 CNc1nc2nc(SCc3cccc(F)c3F)nc(N[C@H](C)CO)c2s1 10.1016/j.bmcl.2007.02.080
44432423 151767 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 445 1 3 5 3.5 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)cc(Br)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL396411 151767 None 0 Human Binding pIC50 = 7.2 7.2 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 445 1 3 5 3.5 O=S1(=O)N=C(Nc2ccccc2Br)Nc2c(O)cc(Br)cc21 10.1016/j.bmcl.2007.05.011
162674364 183284 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 430 4 2 4 6.5 CCOC(=O)c1c(NC(=S)Nc2ccc(C(C)(C)C)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4795585 183284 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 430 4 2 4 6.5 CCOC(=O)c1c(NC(=S)Nc2ccc(C(C)(C)C)cc2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
22648978 73926 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 313 8 3 8 2.4 CCCCCSc1nc(NCCO)c2sc(N)nc2n1 10.1016/j.bmcl.2005.10.091
CHEMBL201921 73926 None 0 Human Binding pIC50 = 5.2 5.2 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 313 8 3 8 2.4 CCCCCSc1nc(NCCO)c2sc(N)nc2n1 10.1016/j.bmcl.2005.10.091
91937327 127325 None 0 Human Binding pIC50 = 6.2 6.2 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 420 6 1 6 4.3 Cn1c(C(=O)CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)nc2ccccc21 nan
CHEMBL3658334 127325 None 0 Human Binding pIC50 = 6.2 6.2 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 420 6 1 6 4.3 Cn1c(C(=O)CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)nc2ccccc21 nan
71525607 133377 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 465 7 3 8 2.3 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCC(O)C4)c3)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3704559 133377 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 465 7 3 8 2.3 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCC(O)C4)c3)c(=O)c2=O)C2(C)COC2)o1 nan
44447915 169254 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 399 6 2 4 3.2 CS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL440405 169254 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 399 6 2 4 3.2 CS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
71525974 133389 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 439 7 3 8 2.5 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3704570 133389 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 439 7 3 8 2.5 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
117647858 133390 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 453 8 3 8 2.9 CCN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c1O nan
CHEMBL3704571 133390 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 453 8 3 8 2.9 CCN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c1O nan
46896784 126890 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 548 7 1 6 6.0 CC1(C)OB(c2ccc(OC(F)(F)F)cc2CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C nan
CHEMBL3654446 126890 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 548 7 1 6 6.0 CC1(C)OB(c2ccc(OC(F)(F)F)cc2CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C nan
44414261 81105 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 365 4 2 6 2.0 CN(C)C(=O)c1cccc(/N=c2/c(N(C)c3ccccc3)c(O)c2=O)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL215464 81105 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 365 4 2 6 2.0 CN(C)C(=O)c1cccc(/N=c2/c(N(C)c3ccccc3)c(O)c2=O)c1O 10.1016/j.bmcl.2006.04.082
91937339 127333 None 0 Human Binding pIC50 = 5.1 5.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 371 5 2 5 2.9 O=C(Nc1ccc(F)cn1)c1ccc([S+]([O-])Cc2ccccc2O)nc1 nan
CHEMBL3658346 127333 None 0 Human Binding pIC50 = 5.1 5.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 371 5 2 5 2.9 O=C(Nc1ccc(F)cn1)c1ccc([S+]([O-])Cc2ccccc2O)nc1 nan
46897162 3716 None 15 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assayInhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assay
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1016/j.bmcl.2015.04.041
8501 3716 None 15 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assayInhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assay
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1016/j.bmcl.2015.04.041
CHEMBL3342269 3716 None 15 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assayInhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assay
ChEMBL 382 6 3 5 2.4 Fc1ccc(cc1)NC(=O)c1ccc(nc1)SCc1ccccc1B(O)O 10.1016/j.bmcl.2015.04.041
44318669 106188 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 349 3 1 4 4.9 Cc1cccc(Cn2nc(-c3ccc(Cl)cc3Cl)nc2S)c1 10.1016/s0960-894x(03)00561-4
CHEMBL313465 106188 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 349 3 1 4 4.9 Cc1cccc(Cn2nc(-c3ccc(Cl)cc3Cl)nc2S)c1 10.1016/s0960-894x(03)00561-4
71525886 133393 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 439 7 3 8 2.5 Cc1ccc([C@@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3704574 133393 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 439 7 3 8 2.5 Cc1ccc([C@@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
44414295 139035 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 305 3 3 6 2.2 N#Cc1ccc(O)c(Nc2c(O)c(=O)/c2=N\c2ccccc2)c1 10.1016/j.bmcl.2006.04.082
CHEMBL378503 139035 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 305 3 3 6 2.2 N#Cc1ccc(O)c(Nc2c(O)c(=O)/c2=N\c2ccccc2)c1 10.1016/j.bmcl.2006.04.082
44432385 147580 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 341 1 3 5 2.8 O=S1(=O)N=C(Nc2ccccc2F)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL393046 147580 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 341 1 3 5 2.8 O=S1(=O)N=C(Nc2ccccc2F)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
162664334 182222 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 392 4 2 4 5.3 CCOC(=O)c1c(NC(=S)Nc2ccccc2F)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4782034 182222 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 392 4 2 4 5.3 CCOC(=O)c1c(NC(=S)Nc2ccccc2F)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
46897356 114987 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 396 6 1 5 4.6 COC(=O)c1ccccc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 nan
CHEMBL3342310 114987 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 396 6 1 5 4.6 COC(=O)c1ccccc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 nan
46896264 127304 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 396 5 1 5 4.4 O=C(Nc1ccc(F)cc1)c1ccc(SCC2COc3ccccc3O2)nc1 nan
CHEMBL3658246 127304 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 396 5 1 5 4.4 O=C(Nc1ccc(F)cc1)c1ccc(SCC2COc3ccccc3O2)nc1 nan
1105988 33212 None 12 Human Binding pIC50 = 5.1 5.1 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in human U2OS cells cp-expressing betaarrestin-2/TEV protease and beta lactamase assessed as effect on beta-arrestin2 recruitment preincubated for 30 mins followed by IL-8 addition and further incubated for 5 hrs subsequently adding CCF4-AM staining and measured after 2 hrs by Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in human U2OS cells cp-expressing betaarrestin-2/TEV protease and beta lactamase assessed as effect on beta-arrestin2 recruitment preincubated for 30 mins followed by IL-8 addition and further incubated for 5 hrs subsequently adding CCF4-AM staining and measured after 2 hrs by Tango assay
ChEMBL 435 4 1 4 6.2 CC(=O)c1c(C)oc2c1cc(NS(=O)(=O)c1ccc(C(C)(C)C)cc1)c1ccccc12 10.1016/j.ejmech.2019.111853
CHEMBL1417864 33212 None 12 Human Binding pIC50 = 5.1 5.1 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in human U2OS cells cp-expressing betaarrestin-2/TEV protease and beta lactamase assessed as effect on beta-arrestin2 recruitment preincubated for 30 mins followed by IL-8 addition and further incubated for 5 hrs subsequently adding CCF4-AM staining and measured after 2 hrs by Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in human U2OS cells cp-expressing betaarrestin-2/TEV protease and beta lactamase assessed as effect on beta-arrestin2 recruitment preincubated for 30 mins followed by IL-8 addition and further incubated for 5 hrs subsequently adding CCF4-AM staining and measured after 2 hrs by Tango assay
ChEMBL 435 4 1 4 6.2 CC(=O)c1c(C)oc2c1cc(NS(=O)(=O)c1ccc(C(C)(C)C)cc1)c1ccccc12 10.1016/j.ejmech.2019.111853
162662835 182051 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 434 6 2 6 5.2 CCOC(=O)c1c(NC(=S)Nc2ccc(OC)c(OC)c2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4779885 182051 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 434 6 2 6 5.2 CCOC(=O)c1c(NC(=S)Nc2ccc(OC)c(OC)c2)sc2c1C(C)CCC2 10.1016/j.ejmech.2020.112387
10221030 208476 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 268 3 1 5 2.7 Sc1nc(-c2ccncc2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL84988 208476 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 268 3 1 5 2.7 Sc1nc(-c2ccncc2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
168272758 190639 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]ccc12 10.1016/j.ejmech.2022.114268
CHEMBL5179622 190639 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 350 6 3 5 3.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]ccc12 10.1016/j.ejmech.2022.114268
59446384 114995 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 473 8 2 6 3.4 O=C(c1ccc(SCc2ccccc2B(O)O)nc1)N(Cc1ccccn1)c1ccc(F)cc1 nan
CHEMBL3342320 114995 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 473 8 2 6 3.4 O=C(c1ccc(SCc2ccccc2B(O)O)nc1)N(Cc1ccccn1)c1ccc(F)cc1 nan
91937308 127320 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 470 6 1 5 6.6 Cc1c(C(=O)CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)sc2ccc(Cl)cc12 nan
CHEMBL3658316 127320 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 470 6 1 5 6.6 Cc1c(C(=O)CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)sc2ccc(Cl)cc12 nan
11440492 152731 None 0 Human Binding pIC50 = 7.1 7.1 - 1
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.ejmech.2022.114268
CHEMBL397237 152731 None 0 Human Binding pIC50 = 7.1 7.1 - 1
Binding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system methodBinding affinity to human CXCR2 expressed in human U87 cells assessed as inhibition of CXCL8 AF647-induced calcium response incubated for 10 mins followed by addition of CXCL8 AF647 measured by FLIPR Tetra system method
ChEMBL 383 6 3 8 3.0 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.ejmech.2022.114268
46896783 119148 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 412 7 3 6 2.5 COc1ccc(B(O)O)c(CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)c1 nan
CHEMBL3426945 119148 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 412 7 3 6 2.5 COc1ccc(B(O)O)c(CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)c1 nan
129316023 155883 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 436 6 4 5 3.4 CC(C)(CCO)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@H]2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4059587 155883 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 436 6 4 5 3.4 CC(C)(CCO)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@H]2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
127049370 140845 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 461 4 3 5 4.0 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
CHEMBL3818277 140845 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 461 4 3 5 4.0 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
58180199 140937 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 460 4 3 4 5.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3819480 140937 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 460 4 3 4 5.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
57833159 118084 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 368 8 3 7 1.9 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403830 118084 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 368 8 3 7 1.9 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
57833099 118095 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 430 9 3 7 3.4 C[C@H](CO)Nc1cc(NS(=O)(=O)c2ccccc2)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403841 118095 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 430 9 3 7 3.4 C[C@H](CO)Nc1cc(NS(=O)(=O)c2ccccc2)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
22649035 143483 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 413 7 4 9 2.4 CC(CO)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL389792 143483 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 413 7 4 9 2.4 CC(CO)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
118730036 118082 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 396 8 3 8 1.3 C[C@H](CO)Nc1cc(C(=O)NS(C)(=O)=O)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403829 118082 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 396 8 3 8 1.3 C[C@H](CO)Nc1cc(C(=O)NS(C)(=O)=O)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
118730037 118085 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 368 8 3 7 1.9 C[C@H](O)CNc1cc(NS(C)(=O)=O)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403831 118085 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 368 8 3 7 1.9 C[C@H](O)CNc1cc(NS(C)(=O)=O)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
10268984 80345 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 343 3 3 6 1.5 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C2CCCC2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL214162 80345 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 343 3 3 6 1.5 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C2CCCC2)c1O 10.1016/j.bmcl.2006.04.082
44439706 11881 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 532 9 3 8 3.4 CCCc1ccccc1Nc1c(Nc2ccc(Cl)c(S(=O)(=O)N3CCN(CC)CC3)c2O)c(=O)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL1182441 11881 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 532 9 3 8 3.4 CCCc1ccccc1Nc1c(Nc2ccc(Cl)c(S(=O)(=O)N3CCN(CC)CC3)c2O)c(=O)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL238971 11881 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 532 9 3 8 3.4 CCCc1ccccc1Nc1c(Nc2ccc(Cl)c(S(=O)(=O)N3CCN(CC)CC3)c2O)c(=O)c1=O 10.1016/j.bmcl.2006.12.067
44439702 145582 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 451 9 4 8 2.1 COCCNS(=O)(=O)c1c(Cl)ccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c1O 10.1016/j.bmcl.2006.12.067
CHEMBL391465 145582 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 451 9 4 8 2.1 COCCNS(=O)(=O)c1c(Cl)ccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c1O 10.1016/j.bmcl.2006.12.067
44446616 94761 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 383 7 3 7 2.6 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccoc1 10.1016/j.bmcl.2008.01.024
CHEMBL252897 94761 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 383 7 3 7 2.6 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccoc1 10.1016/j.bmcl.2008.01.024
8497 2737 None 41 Mouse Binding pIC50 = 8.1 8.1 - 2
Antagonist activity at CXCR2 in C57 mouse whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 1 hr followed by GROalpha stimulation measured after 10 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in C57 mouse whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 1 hr followed by GROalpha stimulation measured after 10 mins by FITC-staining based FACS analysis
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.7b01854
9865554 2737 None 41 Mouse Binding pIC50 = 8.1 8.1 - 2
Antagonist activity at CXCR2 in C57 mouse whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 1 hr followed by GROalpha stimulation measured after 10 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in C57 mouse whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 1 hr followed by GROalpha stimulation measured after 10 mins by FITC-staining based FACS analysis
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.7b01854
CHEMBL216981 2737 None 41 Mouse Binding pIC50 = 8.1 8.1 - 2
Antagonist activity at CXCR2 in C57 mouse whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 1 hr followed by GROalpha stimulation measured after 10 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in C57 mouse whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 1 hr followed by GROalpha stimulation measured after 10 mins by FITC-staining based FACS analysis
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.7b01854
44446614 94760 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 399 7 3 9 1.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1nc(C)no1 10.1016/j.bmcl.2008.01.024
CHEMBL252896 94760 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 399 7 3 9 1.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1nc(C)no1 10.1016/j.bmcl.2008.01.024
44446602 94891 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 465 8 3 8 4.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(-c2ccsc2)co1 10.1016/j.bmcl.2008.01.024
CHEMBL253705 94891 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 465 8 3 8 4.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(-c2ccsc2)co1 10.1016/j.bmcl.2008.01.024
44446607 167712 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 384 7 3 8 2.0 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ncco1 10.1016/j.bmcl.2008.01.024
CHEMBL430116 167712 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 384 7 3 8 2.0 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ncco1 10.1016/j.bmcl.2008.01.024
134149652 148290 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 513 11 4 11 2.6 COC(=O)CNCC(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
CHEMBL3935902 148290 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 513 11 4 11 2.6 COC(=O)CNCC(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
17903304 208156 None 1 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2ccc(Cl)c(Cl)c2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL82328 208156 None 1 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 335 3 1 4 4.6 Sc1nc(-c2ccc(Cl)c(Cl)c2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
135950089 146854 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 337 2 3 5 2.3 O=S1(=O)N=C(NCc2ccccc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL392445 146854 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 337 2 3 5 2.3 O=S1(=O)N=C(NCc2ccccc2)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
11222420 86765 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 368 2 3 7 2.5 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Cl)N2 10.1016/j.bmcl.2007.05.011
CHEMBL231924 86765 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 368 2 3 7 2.5 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Cl)N2 10.1016/j.bmcl.2007.05.011
59446382 124487 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 401 7 2 7 3.1 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2cc(C(=O)O)no2)nc1 nan
CHEMBL3639571 124487 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 401 7 2 7 3.1 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2cc(C(=O)O)no2)nc1 nan
44446633 94868 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 396 7 3 7 2.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cccn1C 10.1016/j.bmcl.2008.01.024
CHEMBL253505 94868 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 396 7 3 7 2.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cccn1C 10.1016/j.bmcl.2008.01.024
71526161 148089 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 439 7 3 8 2.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@@H]2CCCO2)o1 nan
CHEMBL3934321 148089 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 439 7 3 8 2.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@@H]2CCCO2)o1 nan
44432417 152513 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 391 1 3 5 3.6 O=S1(=O)N=C(Nc2ccccc2C(F)(F)F)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL397068 152513 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 391 1 3 5 3.6 O=S1(=O)N=C(Nc2ccccc2C(F)(F)F)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
44318872 208626 None 1 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 301 3 1 4 3.9 Sc1nc(-c2ccc(Cl)cc2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL86284 208626 None 1 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 301 3 1 4 3.9 Sc1nc(-c2ccc(Cl)cc2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
10154731 95781 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 347 6 3 8 2.8 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2sc(N)nc12 10.1016/j.bmcl.2007.11.039
CHEMBL258334 95781 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 347 6 3 8 2.8 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2sc(N)nc12 10.1016/j.bmcl.2007.11.039
91937266 127308 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 444 6 1 4 5.2 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1cccc(Br)c1 nan
CHEMBL3658273 127308 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 444 6 1 4 5.2 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1cccc(Br)c1 nan
71526067 143987 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 539 8 3 10 3.5 COC(=O)[C@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
CHEMBL3901913 143987 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 539 8 3 10 3.5 COC(=O)[C@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
11414633 99623 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccccc1)Nc1cccc([N+](=O)[O-])c1O 10.1021/jm034248l
CHEMBL283736 99623 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccccc1)Nc1cccc([N+](=O)[O-])c1O 10.1021/jm034248l
44414095 78042 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 309 4 2 6 2.5 O=c1c(O)c(Nc2ccc([N+](=O)[O-])cc2)/c1=N/c1ccccc1 10.1016/j.bmcl.2006.04.082
CHEMBL209782 78042 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 309 4 2 6 2.5 O=c1c(O)c(Nc2ccc([N+](=O)[O-])cc2)/c1=N/c1ccccc1 10.1016/j.bmcl.2006.04.082
44447923 95520 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 453 6 2 4 4.1 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)C(F)(F)F)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL257178 95520 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 453 6 2 4 4.1 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)C(F)(F)F)c2c1 10.1016/j.bmcl.2008.01.127
44446583 94622 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 527 8 3 7 5.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(-c2cccc(C(F)(F)F)c2)o1 10.1016/j.bmcl.2008.01.024
CHEMBL251890 94622 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 527 8 3 7 5.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(-c2cccc(C(F)(F)F)c2)o1 10.1016/j.bmcl.2008.01.024
162674666 183358 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 389 3 3 5 4.2 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1CCNC2 10.1016/j.ejmech.2020.112387
CHEMBL4796430 183358 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 389 3 3 5 4.2 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccccc2)sc2c1CCNC2 10.1016/j.ejmech.2020.112387
162676130 183503 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 370 4 2 6 3.8 CCOC(=O)NC(=S)Nc1sc2c(c1C(=O)OCC)C(C)CCC2 10.1016/j.ejmech.2020.112387
CHEMBL4798148 183503 None 0 Human Binding pIC50 = 5.1 5.1 - 0
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 370 4 2 6 3.8 CCOC(=O)NC(=S)Nc1sc2c(c1C(=O)OCC)C(C)CCC2 10.1016/j.ejmech.2020.112387
44447933 155661 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 476 8 3 4 4.6 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)Nc3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL404395 155661 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 476 8 3 4 4.6 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)Nc3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
71525976 153578 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 453 7 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCCO2)o1 nan
CHEMBL3979652 153578 None 0 Human Binding pIC50 = 7.1 7.1 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 453 7 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCCO2)o1 nan
91937333 114996 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 473 8 2 6 3.4 O=C(c1ccc(SCc2ccccc2B(O)O)nc1)N(Cc1ccncc1)c1ccc(F)cc1 nan
CHEMBL3342321 114996 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 473 8 2 6 3.4 O=C(c1ccc(SCc2ccccc2B(O)O)nc1)N(Cc1ccncc1)c1ccc(F)cc1 nan
9882303 208529 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 285 3 1 4 3.4 Fc1ccccc1-c1nc(S)n(Cc2ccccc2)n1 10.1016/s0960-894x(03)00561-4
CHEMBL85497 208529 None 0 Human Binding pIC50 = 6.1 6.1 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 285 3 1 4 3.4 Fc1ccccc1-c1nc(S)n(Cc2ccccc2)n1 10.1016/s0960-894x(03)00561-4
46897165 119153 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 3 5 2.4 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc(B(O)O)cc2)nc1 nan
CHEMBL3426952 119153 None 0 Human Binding pIC50 = 6.1 6.1 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 3 5 2.4 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc(B(O)O)cc2)nc1 nan
44419473 83231 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 626 8 4 7 5.1 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1C[C@H](C)O[C@H](C)C1 10.1016/j.bmcl.2006.08.042
CHEMBL218486 83231 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 626 8 4 7 5.1 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1C[C@H](C)O[C@H](C)C1 10.1016/j.bmcl.2006.08.042
44419441 84168 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 411 4 3 5 2.8 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2F)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL220797 84168 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 411 4 3 5 2.8 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2F)c1O 10.1016/j.bmcl.2006.08.042
44419448 138209 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 499 7 3 6 4.2 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2OCc2ccccc2)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL376621 138209 None 0 Human Binding pIC50 = 8.1 8.1 - 0
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 499 7 3 6 4.2 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2OCc2ccccc2)c1O 10.1016/j.bmcl.2006.08.042
44407774 140432 None 0 Human Binding pIC50 = 8.0 8.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 397 7 3 8 3.4 CC[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
CHEMBL380732 140432 None 0 Human Binding pIC50 = 8.0 8.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 397 7 3 8 3.4 CC[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
44446598 155192 None 0 Human Binding pIC50 = 8.0 8.0 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 460 8 3 8 3.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(-c2ccncc2)co1 10.1016/j.bmcl.2008.01.024
CHEMBL401938 155192 None 0 Human Binding pIC50 = 8.0 8.0 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 460 8 3 8 3.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(-c2ccncc2)co1 10.1016/j.bmcl.2008.01.024
44446611 94734 None 0 Human Binding pIC50 = 8.0 8.0 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 384 7 3 8 2.0 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccno1 10.1016/j.bmcl.2008.01.024
CHEMBL252698 94734 None 0 Human Binding pIC50 = 8.0 8.0 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 384 7 3 8 2.0 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccno1 10.1016/j.bmcl.2008.01.024
44446610 155184 None 0 Human Binding pIC50 = 8.0 8.0 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 400 7 3 8 2.5 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1nccs1 10.1016/j.bmcl.2008.01.024
CHEMBL401893 155184 None 0 Human Binding pIC50 = 8.0 8.0 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 400 7 3 8 2.5 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1nccs1 10.1016/j.bmcl.2008.01.024
9969483 102028 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 372 4 1 4 2.5 O=C(Nc1ccc(F)cc1)c1ccc(S(=O)(=O)c2ccccc2)[n+]([O-])c1 10.1016/s0960-894x(01)00326-2
CHEMBL301424 102028 None 0 Human Binding pIC50 = 7.1 7.1 - 0
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 372 4 1 4 2.5 O=C(Nc1ccc(F)cc1)c1ccc(S(=O)(=O)c2ccccc2)[n+]([O-])c1 10.1016/s0960-894x(01)00326-2
44393573 66167 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 340 2 3 2 4.5 O=C(Nc1ccc(Cl)cc1O)Nc1ccccc1Br 10.1016/j.bmcl.2004.06.097
CHEMBL184147 66167 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 340 2 3 2 4.5 O=C(Nc1ccc(Cl)cc1O)Nc1ccccc1Br 10.1016/j.bmcl.2004.06.097
11371755 88005 None 0 Human Binding pIC50 = 7.0 7.0 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 357 1 3 5 3.3 O=S1(=O)N=C(Nc2ccccc2Cl)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL234186 88005 None 0 Human Binding pIC50 = 7.0 7.0 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 357 1 3 5 3.3 O=S1(=O)N=C(Nc2ccccc2Cl)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
44318765 208184 None 0 Human Binding pIC50 = 7.0 7.0 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 369 3 1 4 5.2 Sc1nc(-c2ccc(Cl)cc2Cl)nn1Cc1cccc(Cl)c1 10.1016/s0960-894x(03)00561-4
CHEMBL82566 208184 None 0 Human Binding pIC50 = 7.0 7.0 - 0
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 369 3 1 4 5.2 Sc1nc(-c2ccc(Cl)cc2Cl)nn1Cc1cccc(Cl)c1 10.1016/s0960-894x(03)00561-4
44414249 79359 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 379 5 3 6 1.8 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/CCc2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL211353 79359 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 379 5 3 6 1.8 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/CCc2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
44432418 153399 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 407 2 3 6 3.5 O=S1(=O)N=C(Nc2ccccc2OC(F)(F)F)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL397808 153399 None 0 Human Binding pIC50 = 6.0 6.0 - 0
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 407 2 3 6 3.5 O=S1(=O)N=C(Nc2ccccc2OC(F)(F)F)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
71525976 153578 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 453 7 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCCO2)o1 nan
CHEMBL3979652 153578 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 453 7 3 8 3.1 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCCO2)o1 nan
44446571 155627 None 0 Human Binding pIC50 = 7.0 7.0 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 440 9 3 8 2.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(CN(C)C)o1 10.1016/j.bmcl.2008.01.024
CHEMBL404251 155627 None 0 Human Binding pIC50 = 7.0 7.0 - 0
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 440 9 3 8 2.7 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(CN(C)C)o1 10.1016/j.bmcl.2008.01.024
3791448 167872 None 12 Human Binding pIC50 = 6.0 6.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 307 3 3 4 3.6 O=C(Nc1ccccc1)Nc1cc(Cl)c([N+](=O)[O-])cc1O 10.1016/j.bmcl.2006.12.067
CHEMBL430376 167872 None 12 Human Binding pIC50 = 6.0 6.0 - 0
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 307 3 3 4 3.6 O=C(Nc1ccccc1)Nc1cc(Cl)c([N+](=O)[O-])cc1O 10.1016/j.bmcl.2006.12.067
89534497 124547 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 445 7 3 9 2.6 Cc1ccc([C@H](Nc2c(Nc3csc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3640034 124547 None 0 Human Binding pIC50 = 7.0 7.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 445 7 3 9 2.6 Cc1ccc([C@H](Nc2c(Nc3csc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
71525608 133378 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 523 8 3 10 2.6 COC(=O)C1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c1O nan
CHEMBL3704560 133378 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 523 8 3 10 2.6 COC(=O)C1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c1O nan
91937295 127317 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 484 6 1 5 6.0 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2cc3ccc(Br)cc3o2)nc1 nan
CHEMBL3658303 127317 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 484 6 1 5 6.0 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2cc3ccc(Br)cc3o2)nc1 nan
134151106 152268 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 541 8 2 9 3.9 COC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(N[C@H](c3ccc(C)o3)[C@@H]3CCCS3)c(=O)c2=O)c1F nan
CHEMBL3968340 152268 None 0 Human Binding pIC50 = 6.0 6.0 - 0
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 541 8 2 9 3.9 COC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(N[C@H](c3ccc(C)o3)[C@@H]3CCCS3)c(=O)c2=O)c1F nan
10150526 82975 None 0 Human Binding pKd = 10.3 10.3 79 2
Binding affinity to human CXCR2 assessed as dissociation constant incubated for 6 to 24 hrs by radioligand binding assayBinding affinity to human CXCR2 assessed as dissociation constant incubated for 6 to 24 hrs by radioligand binding assay
ChEMBL 383 7 3 7 2.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccco1 10.1016/j.ejmech.2020.112872
CHEMBL218115 82975 None 0 Human Binding pKd = 10.3 10.3 79 2
Binding affinity to human CXCR2 assessed as dissociation constant incubated for 6 to 24 hrs by radioligand binding assayBinding affinity to human CXCR2 assessed as dissociation constant incubated for 6 to 24 hrs by radioligand binding assay
ChEMBL 383 7 3 7 2.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccco1 10.1016/j.ejmech.2020.112872
8497 2737 None 41 Human Binding pKd = 10.3 10.3 39 2
Displacement of [3H]Sch527123 from human CXCR2 assessed as dissociation constant measured every 30 secs for 48 hrs by radioligand binding assayDisplacement of [3H]Sch527123 from human CXCR2 assessed as dissociation constant measured every 30 secs for 48 hrs by radioligand binding assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
9865554 2737 None 41 Human Binding pKd = 10.3 10.3 39 2
Displacement of [3H]Sch527123 from human CXCR2 assessed as dissociation constant measured every 30 secs for 48 hrs by radioligand binding assayDisplacement of [3H]Sch527123 from human CXCR2 assessed as dissociation constant measured every 30 secs for 48 hrs by radioligand binding assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
CHEMBL216981 2737 None 41 Human Binding pKd = 10.3 10.3 39 2
Displacement of [3H]Sch527123 from human CXCR2 assessed as dissociation constant measured every 30 secs for 48 hrs by radioligand binding assayDisplacement of [3H]Sch527123 from human CXCR2 assessed as dissociation constant measured every 30 secs for 48 hrs by radioligand binding assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
8497 2737 None 41 Human Binding pKd = 10.3 10.3 39 2
Binding affinity to CXCL2 (unknown origin)Binding affinity to CXCL2 (unknown origin)
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
9865554 2737 None 41 Human Binding pKd = 10.3 10.3 39 2
Binding affinity to CXCL2 (unknown origin)Binding affinity to CXCL2 (unknown origin)
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
CHEMBL216981 2737 None 41 Human Binding pKd = 10.3 10.3 39 2
Binding affinity to CXCL2 (unknown origin)Binding affinity to CXCL2 (unknown origin)
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
11858154 155430 None 19 Human Binding pKd = 8.7 8.7 2691 2
Binding affinity to CXCR2 (unknown origin) expressed in HEK293 cellsBinding affinity to CXCR2 (unknown origin) expressed in HEK293 cells
ChEMBL 400 6 3 7 3.3 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2[nH]c(=O)sc12 10.1021/acs.jmedchem.3c00849
CHEMBL403225 155430 None 19 Human Binding pKd = 8.7 8.7 2691 2
Binding affinity to CXCR2 (unknown origin) expressed in HEK293 cellsBinding affinity to CXCR2 (unknown origin) expressed in HEK293 cells
ChEMBL 400 6 3 7 3.3 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2[nH]c(=O)sc12 10.1021/acs.jmedchem.3c00849
9841667 140836 None 41 Human Binding pKd = 7 7.0 1000 2
Binding affinity to wild type human CXCR2 assessed as dissociation constantBinding affinity to wild type human CXCR2 assessed as dissociation constant
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1021/acs.jmedchem.6b01309
CHEMBL38182 140836 None 41 Human Binding pKd = 7 7.0 1000 2
Binding affinity to wild type human CXCR2 assessed as dissociation constantBinding affinity to wild type human CXCR2 assessed as dissociation constant
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1021/acs.jmedchem.6b01309
44455014 95404 None 0 Human Binding pKd = 6 6.0 - 1
Binding affinity to wild type human CXCR2 assessed as dissociation constantBinding affinity to wild type human CXCR2 assessed as dissociation constant
ChEMBL 379 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)cnc12 10.1021/acs.jmedchem.6b01309
CHEMBL256668 95404 None 0 Human Binding pKd = 6 6.0 - 1
Binding affinity to wild type human CXCR2 assessed as dissociation constantBinding affinity to wild type human CXCR2 assessed as dissociation constant
ChEMBL 379 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)cnc12 10.1021/acs.jmedchem.6b01309
172460034 196278 None 0 Human Binding pKd = 6.9 6.9 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 957 22 6 12 7.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5420355 196278 None 0 Human Binding pKd = 6.9 6.9 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 957 22 6 12 7.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
172460034 196278 None 0 Human Binding pKd = 6.8 6.8 - 1
Binding affinity to CXCR2 (unknown origin) (28 to 99 residues) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to CXCR2 (unknown origin) (28 to 99 residues) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 957 22 6 12 7.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5420355 196278 None 0 Human Binding pKd = 6.8 6.8 - 1
Binding affinity to CXCR2 (unknown origin) (28 to 99 residues) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to CXCR2 (unknown origin) (28 to 99 residues) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 957 22 6 12 7.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
172448435 195874 None 0 Human Binding pKd = 7.6 7.6 7 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1042 25 6 13 7.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)CCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5412421 195874 None 0 Human Binding pKd = 7.6 7.6 7 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1042 25 6 13 7.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)CCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
9841667 140836 None 41 Human Binding pKd = 8.5 8.5 1000 2
Binding affinity to CXCL2 (unknown origin)Binding affinity to CXCL2 (unknown origin)
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1021/acs.jmedchem.3c00849
CHEMBL38182 140836 None 41 Human Binding pKd = 8.5 8.5 1000 2
Binding affinity to CXCL2 (unknown origin)Binding affinity to CXCL2 (unknown origin)
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1021/acs.jmedchem.3c00849
172455947 196389 None 0 Human Binding pKd = 6.5 6.5 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1014 24 7 13 6.8 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5422785 196389 None 0 Human Binding pKd = 6.5 6.5 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1014 24 7 13 6.8 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
172449372 195930 None 0 Human Binding pKd = 7.4 7.4 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1028 25 7 13 7.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5413545 195930 None 0 Human Binding pKd = 7.4 7.4 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1028 25 7 13 7.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
172460034 196278 None 0 Human Binding pKd = 7.3 7.3 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 957 22 6 12 7.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5420355 196278 None 0 Human Binding pKd = 7.3 7.3 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 957 22 6 12 7.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
172451170 195957 None 0 Human Binding pKd = 7.3 7.3 4 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1028 24 6 13 7.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)CNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5414239 195957 None 0 Human Binding pKd = 7.3 7.3 4 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1028 24 6 13 7.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)CNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
172460034 196278 None 0 Human Binding pKd = 6.3 6.3 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assay
ChEMBL 957 22 6 12 7.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5420355 196278 None 0 Human Binding pKd = 6.3 6.3 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assay
ChEMBL 957 22 6 12 7.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
24780598 1316 None 38 Human Binding pKd = 8.2 8.2 - 1
Binding affinity to CXCL2 (unknown origin)Binding affinity to CXCL2 (unknown origin)
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1021/acs.jmedchem.3c00849
8500 1316 None 38 Human Binding pKd = 8.2 8.2 - 1
Binding affinity to CXCL2 (unknown origin)Binding affinity to CXCL2 (unknown origin)
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1021/acs.jmedchem.3c00849
CHEMBL3039531 1316 None 38 Human Binding pKd = 8.2 8.2 - 1
Binding affinity to CXCL2 (unknown origin)Binding affinity to CXCL2 (unknown origin)
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1021/acs.jmedchem.3c00849
DB11922 1316 None 38 Human Binding pKd = 8.2 8.2 - 1
Binding affinity to CXCL2 (unknown origin)Binding affinity to CXCL2 (unknown origin)
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1021/acs.jmedchem.3c00849
172449372 195930 None 0 Human Binding pKd = 7.1 7.1 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1028 25 7 13 7.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5413545 195930 None 0 Human Binding pKd = 7.1 7.1 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1028 25 7 13 7.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
172448435 195874 None 0 Human Binding pKd = 7.1 7.1 7 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1042 25 6 13 7.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)CCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5412421 195874 None 0 Human Binding pKd = 7.1 7.1 7 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cells assessed as dissociation constant using furimazine as substrate preincubated for 1 hr followed by substrate addition for mins and measured every hour for 3 hrs by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1042 25 6 13 7.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)CCNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
172451170 195957 None 0 Human Binding pKd = 8.1 8.1 4 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1028 24 6 13 7.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)CNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5414239 195957 None 0 Human Binding pKd = 8.1 8.1 4 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as dissociation constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 1028 24 6 13 7.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)CNC(=O)CCCCCNC(=O)COc3ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
56645576 548 None 40 Human Binding pKi = 9.6 9.6 1 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 476 10 3 8 1.5 OC[C@@H]([C@H](Oc1nc(SCc2cccc(c2F)F)nc(c1)NS(=O)(=O)N1CCC1)C)O 10.1021/acs.jmedchem.3c00849
8948 548 None 40 Human Binding pKi = 9.6 9.6 1 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 476 10 3 8 1.5 OC[C@@H]([C@H](Oc1nc(SCc2cccc(c2F)F)nc(c1)NS(=O)(=O)N1CCC1)C)O 10.1021/acs.jmedchem.3c00849
CHEMBL4562140 548 None 40 Human Binding pKi = 9.6 9.6 1 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 476 10 3 8 1.5 OC[C@@H]([C@H](Oc1nc(SCc2cccc(c2F)F)nc(c1)NS(=O)(=O)N1CCC1)C)O 10.1021/acs.jmedchem.3c00849
44440865 151968 None 0 Human Binding pKi = 9.2 9.2 12 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 439 9 3 7 4.1 CCC(C)c1coc([C@@H](CC)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c1 10.1016/j.bmcl.2007.04.016
CHEMBL396573 151968 None 0 Human Binding pKi = 9.2 9.2 12 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 439 9 3 7 4.1 CCC(C)c1coc([C@@H](CC)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c1 10.1016/j.bmcl.2007.04.016
8497 2737 None 41 Human Binding pKi = 9.2 9.2 39 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
9865554 2737 None 41 Human Binding pKi = 9.2 9.2 39 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
CHEMBL216981 2737 None 41 Human Binding pKi = 9.2 9.2 39 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acs.jmedchem.3c00849
44440866 93575 None 0 Human Binding pKi = 9.1 9.1 38 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 453 10 3 7 4.5 CCC(CC)c1coc([C@@H](CC)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c1 10.1016/j.bmcl.2007.04.016
CHEMBL246318 93575 None 0 Human Binding pKi = 9.1 9.1 38 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 453 10 3 7 4.5 CCC(CC)c1coc([C@@H](CC)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c1 10.1016/j.bmcl.2007.04.016
44447966 94957 None 0 Human Binding pKi = 9 9.0 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 439 7 3 6 3.7 Cc1cc(F)cc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)c1 10.1016/j.bmcl.2008.02.010
CHEMBL254175 94957 None 0 Human Binding pKi = 9 9.0 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 439 7 3 6 3.7 Cc1cc(F)cc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)c1 10.1016/j.bmcl.2008.02.010
10237849 93441 None 0 Human Binding pKi = 9 9.0 7 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 411 8 3 7 3.2 CCc1coc([C@@H](CC)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c1 10.1016/j.bmcl.2007.04.016
CHEMBL245699 93441 None 0 Human Binding pKi = 9 9.0 7 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 411 8 3 7 3.2 CCc1coc([C@@H](CC)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c1 10.1016/j.bmcl.2007.04.016
10310100 93529 None 29 Human Binding pKi = 9 9.0 3 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 425 8 3 7 3.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C(C)C)co1 10.1016/j.bmcl.2007.04.016
CHEMBL246108 93529 None 29 Human Binding pKi = 9 9.0 3 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 425 8 3 7 3.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C(C)C)co1 10.1016/j.bmcl.2007.04.016
172458912 196325 None 0 Human Binding pKi = 8.9 8.9 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 526 10 4 9 3.8 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)OC(C)(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5421394 196325 None 0 Human Binding pKi = 8.9 8.9 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 526 10 4 9 3.8 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)CCNC(=O)OC(C)(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
44447952 155389 None 0 Human Binding pKi = 8.8 8.8 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 455 8 3 7 3.4 COc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)cc1F 10.1016/j.bmcl.2008.02.010
CHEMBL402965 155389 None 0 Human Binding pKi = 8.8 8.8 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 455 8 3 7 3.4 COc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)cc1F 10.1016/j.bmcl.2008.02.010
44447959 95049 None 0 Human Binding pKi = 8.8 8.8 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 429 7 3 6 3.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(F)cc(F)c1 10.1016/j.bmcl.2008.02.010
CHEMBL254775 95049 None 0 Human Binding pKi = 8.8 8.8 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 429 7 3 6 3.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(F)cc(F)c1 10.1016/j.bmcl.2008.02.010
44447968 155581 None 0 Human Binding pKi = 8.8 8.8 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 436 7 3 7 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(F)cc(C#N)c1 10.1016/j.bmcl.2008.02.010
CHEMBL404074 155581 None 0 Human Binding pKi = 8.8 8.8 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 436 7 3 7 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(F)cc(C#N)c1 10.1016/j.bmcl.2008.02.010
44447967 94958 None 0 Human Binding pKi = 8.7 8.7 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 432 7 3 7 3.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)cc(C#N)c1 10.1016/j.bmcl.2008.02.010
CHEMBL254176 94958 None 0 Human Binding pKi = 8.7 8.7 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 432 7 3 7 3.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)cc(C#N)c1 10.1016/j.bmcl.2008.02.010
44447960 155763 None 0 Human Binding pKi = 8.7 8.7 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 443 7 3 6 3.5 CC(C)[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(F)cc(F)c1 10.1016/j.bmcl.2008.02.010
CHEMBL404918 155763 None 0 Human Binding pKi = 8.7 8.7 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 443 7 3 6 3.5 CC(C)[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(F)cc(F)c1 10.1016/j.bmcl.2008.02.010
24780598 1316 None 38 Human Binding pKi = 8.7 8.7 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1021/acs.jmedchem.3c00849
8500 1316 None 38 Human Binding pKi = 8.7 8.7 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1021/acs.jmedchem.3c00849
CHEMBL3039531 1316 None 38 Human Binding pKi = 8.7 8.7 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1021/acs.jmedchem.3c00849
DB11922 1316 None 38 Human Binding pKi = 8.7 8.7 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 441 4 4 5 3.7 O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl 10.1021/acs.jmedchem.3c00849
10127252 187194 None 0 Human Binding pKi = 8 8.0 -1 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 433 7 3 7 3.1 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)(F)F)o1 10.1016/j.bmcl.2009.01.033
CHEMBL491330 187194 None 0 Human Binding pKi = 8 8.0 -1 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 433 7 3 7 3.1 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)(F)F)o1 10.1016/j.bmcl.2009.01.033
44440859 93411 None 0 Human Binding pKi = 8 8.0 12 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 413 7 3 7 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1sccc1C 10.1016/j.bmcl.2007.04.016
CHEMBL245500 93411 None 0 Human Binding pKi = 8 8.0 12 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 413 7 3 7 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1sccc1C 10.1016/j.bmcl.2007.04.016
10224935 199020 None 0 Human Binding pKi = 8 8.0 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 435 7 3 7 2.8 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCOCC3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL563855 199020 None 0 Human Binding pKi = 8 8.0 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 435 7 3 7 2.8 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCOCC3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
172445949 195207 None 0 Human Binding pKi = 8.0 8.0 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 691 14 6 10 4.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CNC(=O)OCC3c4ccccc4-c4ccccc43)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5398802 195207 None 0 Human Binding pKi = 8.0 8.0 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 691 14 6 10 4.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)CNC(=O)OCC3c4ccccc4-c4ccccc43)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
44410836 77061 None 0 Human Binding pKi = 7 7.0 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 492 15 2 7 5.0 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccccc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL207171 77061 None 0 Human Binding pKi = 7 7.0 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 492 15 2 7 5.0 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccccc3)c2)n1 10.1016/j.bmcl.2006.02.028
71624890 88389 None 0 Human Binding pKi = 7 7.0 1 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 422 8 3 8 2.2 CC(C)C[C@H](CO)Nc1nc(S(=O)(=O)Cc2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
CHEMBL2349184 88389 None 0 Human Binding pKi = 7 7.0 1 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 422 8 3 8 2.2 CC(C)C[C@H](CO)Nc1nc(S(=O)(=O)Cc2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
136036240 174582 None 0 Human Binding pKi = 5 5.0 -190 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 441 6 3 8 4.3 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)C)c2O)C(F)(F)F)o1 10.1016/j.bmcl.2009.01.027
CHEMBL455430 174582 None 0 Human Binding pKi = 5 5.0 -190 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 441 6 3 8 4.3 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)C)c2O)C(F)(F)F)o1 10.1016/j.bmcl.2009.01.027
136036253 177880 None 0 Human Binding pKi = 5 5.0 -234 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 363 5 3 7 3.5 C[C@H](Nc1nsnc1Nc1cccc(C(=O)N(C)C)c1O)C(C)(C)C 10.1016/j.bmcl.2009.01.027
CHEMBL464302 177880 None 0 Human Binding pKi = 5 5.0 -234 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 363 5 3 7 3.5 C[C@H](Nc1nsnc1Nc1cccc(C(=O)N(C)C)c1O)C(C)(C)C 10.1016/j.bmcl.2009.01.027
136036234 187110 None 0 Human Binding pKi = 5 5.0 -79 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 483 6 3 9 4.7 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccc3c(c2)OCCO3)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
CHEMBL490688 187110 None 0 Human Binding pKi = 5 5.0 -79 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 483 6 3 9 4.7 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccc3c(c2)OCCO3)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
136036257 190897 None 0 Human Binding pKi = 5 5.0 -229 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 465 6 3 7 5.4 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccc3c(c2)CCC3)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
CHEMBL518355 190897 None 0 Human Binding pKi = 5 5.0 -229 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 465 6 3 7 5.4 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccc3c(c2)CCC3)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
135539055 94923 None 0 Human Binding pKi = 8.0 8.0 5 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 447 4 3 7 2.5 CN(C)C(=O)c1cccc(NC2=NS(=O)(=O)N=C2N[C@@H](c2ccco2)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
CHEMBL253921 94923 None 0 Human Binding pKi = 8.0 8.0 5 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 447 4 3 7 2.5 CN(C)C(=O)c1cccc(NC2=NS(=O)(=O)N=C2N[C@@H](c2ccco2)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
136036519 155227 None 0 Human Binding pKi = 8.0 8.0 58 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 461 5 3 6 2.7 CC(C)[C@@H](NC1=NS(=O)(=O)N=C1Nc1cccc(C(=O)N(C)C)c1O)c1cccc(F)c1 10.1016/j.bmcl.2007.10.094
CHEMBL402076 155227 None 0 Human Binding pKi = 8.0 8.0 58 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 461 5 3 6 2.7 CC(C)[C@@H](NC1=NS(=O)(=O)N=C1Nc1cccc(C(=O)N(C)C)c1O)c1cccc(F)c1 10.1016/j.bmcl.2007.10.094
10180509 198711 None 0 Human Binding pKi = 8.0 8.0 11 2
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 421 8 3 6 3.8 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL561812 198711 None 0 Human Binding pKi = 8.0 8.0 11 2
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 421 8 3 6 3.8 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
44447964 155580 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 475 7 3 6 4.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)cc(C(F)(F)F)c1 10.1016/j.bmcl.2008.02.010
CHEMBL404073 155580 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 475 7 3 6 4.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)cc(C(F)(F)F)c1 10.1016/j.bmcl.2008.02.010
44447956 155762 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 441 8 3 7 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(F)c(OC)c1 10.1016/j.bmcl.2008.02.010
CHEMBL404917 155762 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 441 8 3 7 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(F)c(OC)c1 10.1016/j.bmcl.2008.02.010
45485757 199966 None 0 Human Binding pKi = 7.0 7.0 37 2
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 394 7 3 7 2.3 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.08.014
CHEMBL570042 199966 None 0 Human Binding pKi = 7.0 7.0 37 2
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 394 7 3 7 2.3 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.08.014
71716556 88384 None 0 Human Binding pKi = 6.0 6.0 -181 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 438 8 3 9 4.4 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2cc(Cl)ccn2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349179 88384 None 0 Human Binding pKi = 6.0 6.0 -181 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 438 8 3 9 4.4 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2cc(Cl)ccn2)nc2nc(N)sc12 10.1021/jm3012273
136036250 177044 None 0 Human Binding pKi = 6.9 6.9 -8 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 468 8 3 9 5.1 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)CCC#N)c2O)C(C)(C)C)o1 10.1016/j.bmcl.2009.01.027
CHEMBL462155 177044 None 0 Human Binding pKi = 6.9 6.9 -8 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 468 8 3 9 5.1 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)CCC#N)c2O)C(C)(C)C)o1 10.1016/j.bmcl.2009.01.027
136036531 94767 None 0 Human Binding pKi = 7.9 7.9 30 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 429 7 3 8 3.9 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2N[C@@H](c2ccco2)C2(C)CC2)c1O 10.1016/j.bmcl.2007.10.094
136104502 94767 None 0 Human Binding pKi = 7.9 7.9 30 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 429 7 3 8 3.9 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2N[C@@H](c2ccco2)C2(C)CC2)c1O 10.1016/j.bmcl.2007.10.094
CHEMBL252911 94767 None 0 Human Binding pKi = 7.9 7.9 30 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 429 7 3 8 3.9 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2N[C@@H](c2ccco2)C2(C)CC2)c1O 10.1016/j.bmcl.2007.10.094
44564998 187214 None 0 Human Binding pKi = 7.9 7.9 2 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 433 7 3 7 3.1 Cc1ccoc1[C@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(C)(F)F 10.1016/j.bmcl.2009.01.033
CHEMBL491506 187214 None 0 Human Binding pKi = 7.9 7.9 2 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 433 7 3 7 3.1 Cc1ccoc1[C@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(C)(F)F 10.1016/j.bmcl.2009.01.033
10225736 198774 None 0 Human Binding pKi = 7.9 7.9 3 2
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 448 7 3 7 2.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCN(C)CC3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL562286 198774 None 0 Human Binding pKi = 7.9 7.9 3 2
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 448 7 3 7 2.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCN(C)CC3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
45268603 198822 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 370 7 4 7 2.9 CC[C@@H](Nc1c(Nc2cccc(C(=O)O)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.bmcl.2009.05.049
CHEMBL562542 198822 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 370 7 4 7 2.9 CC[C@@H](Nc1c(Nc2cccc(C(=O)O)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.bmcl.2009.05.049
44410899 77301 None 0 Human Binding pKi = 6.9 6.9 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 472 18 2 7 4.9 CCCCCCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2ccnc2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL208065 77301 None 0 Human Binding pKi = 6.9 6.9 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 472 18 2 7 4.9 CCCCCCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2ccnc2)n1 10.1016/j.bmcl.2006.02.028
44626319 200877 None 0 Human Binding pKi = 6.9 6.9 81 2
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 346 7 3 7 1.1 CCN(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2009.08.014
CHEMBL577075 200877 None 0 Human Binding pKi = 6.9 6.9 81 2
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 346 7 3 7 1.1 CCN(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2009.08.014
CHEMBL5093947 217949 None 11 Human Binding pKi = 5.9 5.9 - 1
Displacement of [I-125]-interleukin-8 against human recombinant CXCR2 expressed in CHO-K1 cells incubated for 60 mins by radio ligand binding assayDisplacement of [I-125]-interleukin-8 against human recombinant CXCR2 expressed in CHO-K1 cells incubated for 60 mins by radio ligand binding assay
ChEMBL None None None Cc1c(F)cccc1NC(=O)Nc1ccc2c(c1O)S(=O)(=O)CCC2 10.1021/acs.jmedchem.1c01219
136036245 191139 None 0 Human Binding pKi = 5.9 5.9 -70 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 471 6 3 9 4.6 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N3CCOCC3)c2O)C(C)(C)C)o1 10.1016/j.bmcl.2009.01.027
CHEMBL518696 191139 None 0 Human Binding pKi = 5.9 5.9 -70 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 471 6 3 9 4.6 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N3CCOCC3)c2O)C(C)(C)C)o1 10.1016/j.bmcl.2009.01.027
44564941 189620 None 0 Human Binding pKi = 7.9 7.9 1 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 415 7 3 7 2.8 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@H](C)F)o1 10.1016/j.bmcl.2009.01.033
CHEMBL514001 189620 None 0 Human Binding pKi = 7.9 7.9 1 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 415 7 3 7 2.8 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@H](C)F)o1 10.1016/j.bmcl.2009.01.033
44447963 95076 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 493 7 3 6 4.4 CC(C)[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(F)cc(C(F)(F)F)c1 10.1016/j.bmcl.2008.02.010
CHEMBL254981 95076 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 493 7 3 6 4.4 CC(C)[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(F)cc(C(F)(F)F)c1 10.1016/j.bmcl.2008.02.010
44447954 94992 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 493 7 3 6 4.4 CC(C)[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(F)(F)F)c(F)c1 10.1016/j.bmcl.2008.02.010
CHEMBL254369 94992 None 0 Human Binding pKi = 7.9 7.9 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 493 7 3 6 4.4 CC(C)[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(F)(F)F)c(F)c1 10.1016/j.bmcl.2008.02.010
45485784 201494 None 0 Human Binding pKi = 6.9 6.9 40 2
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 395 7 3 8 1.7 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccn1 10.1016/j.bmcl.2009.08.014
CHEMBL585928 201494 None 0 Human Binding pKi = 6.9 6.9 40 2
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 395 7 3 8 1.7 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccn1 10.1016/j.bmcl.2009.08.014
136036244 177640 None 0 Human Binding pKi = 5.9 5.9 -91 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 431 7 3 8 4.9 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)C)c2O)C(C)C)s1 10.1016/j.bmcl.2009.01.027
CHEMBL464012 177640 None 0 Human Binding pKi = 5.9 5.9 -91 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 431 7 3 8 4.9 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)C)c2O)C(C)C)s1 10.1016/j.bmcl.2009.01.027
136036235 187111 None 0 Human Binding pKi = 5.9 5.9 -16 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 443 6 3 7 5.0 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2cccc(F)c2)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
CHEMBL490689 187111 None 0 Human Binding pKi = 5.9 5.9 -16 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 443 6 3 7 5.0 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2cccc(F)c2)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
71625625 88415 None 0 Human Binding pKi = 4.9 4.9 -309 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 414 8 3 9 4.0 CCC[C@H](CO)Nc1nc(S[C@@H](C)c2cccc(C#N)c2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349317 88415 None 0 Human Binding pKi = 4.9 4.9 -309 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 414 8 3 9 4.0 CCC[C@H](CO)Nc1nc(S[C@@H](C)c2cccc(C#N)c2)nc2nc(N)sc12 10.1021/jm3012273
11857486 88411 None 0 Human Binding pKi = 5.9 5.9 -169 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 404 8 3 7 4.1 CC(C)C[C@H](CO)Nc1nc(S[C@H](C)c2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
CHEMBL2349313 88411 None 0 Human Binding pKi = 5.9 5.9 -169 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 404 8 3 7 4.1 CC(C)C[C@H](CO)Nc1nc(S[C@H](C)c2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
44565148 177879 None 0 Human Binding pKi = 7.9 7.9 2 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 433 6 3 6 3.1 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3ccccc3)C(F)(F)F)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
CHEMBL464301 177879 None 0 Human Binding pKi = 7.9 7.9 2 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 433 6 3 6 3.1 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3ccccc3)C(F)(F)F)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
10194831 193390 None 0 Human Binding pKi = 7.9 7.9 -2 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 433 7 3 7 3.1 Cc1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)(F)F)c1 10.1016/j.bmcl.2009.01.033
CHEMBL523984 193390 None 0 Human Binding pKi = 7.9 7.9 -2 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 433 7 3 7 3.1 Cc1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)(F)F)c1 10.1016/j.bmcl.2009.01.033
44410952 77071 None 0 Human Binding pKi = 7.9 7.9 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 560 15 2 7 6.1 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(C(F)(F)F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL207199 77071 None 0 Human Binding pKi = 7.9 7.9 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 560 15 2 7 6.1 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(C(F)(F)F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
11964664 88414 None 0 Human Binding pKi = 5.9 5.9 -301 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 421 8 3 8 4.5 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2F)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349316 88414 None 0 Human Binding pKi = 5.9 5.9 -301 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 421 8 3 8 4.5 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2F)nc2nc(N)sc12 10.1021/jm3012273
136036524 94799 None 0 Human Binding pKi = 7.8 7.8 660 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 429 6 3 9 2.7 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2NCc2ccc3c(c2)OCO3)c1O 10.1016/j.bmcl.2007.10.094
136097523 94799 None 0 Human Binding pKi = 7.8 7.8 660 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 429 6 3 9 2.7 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2NCc2ccc3c(c2)OCO3)c1O 10.1016/j.bmcl.2007.10.094
CHEMBL253104 94799 None 0 Human Binding pKi = 7.8 7.8 660 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 429 6 3 9 2.7 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2NCc2ccc3c(c2)OCO3)c1O 10.1016/j.bmcl.2007.10.094
45272042 197588 None 0 Human Binding pKi = 7.8 7.8 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 470 8 3 7 4.1 CC[C@@H](Nc1c(Nc2ccc(-c3ccccn3)c(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL550130 197588 None 0 Human Binding pKi = 7.8 7.8 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 470 8 3 7 4.1 CC[C@@H](Nc1c(Nc2ccc(-c3ccccn3)c(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
71625144 88436 None 0 Human Binding pKi = 6.8 6.8 4 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 375 7 3 8 3.4 CC(C)[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349338 88436 None 0 Human Binding pKi = 6.8 6.8 4 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 375 7 3 8 3.4 CC(C)[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
71625273 88423 None 0 Human Binding pKi = 5.8 5.8 -21 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 403 8 3 8 4.1 Cc1ccccc1CSc1nc(N[C@@H](CO)CC(C)C)c2sc(N)nc2n1 10.1021/jm3012273
CHEMBL2349325 88423 None 0 Human Binding pKi = 5.8 5.8 -21 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 403 8 3 8 4.1 Cc1ccccc1CSc1nc(N[C@@H](CO)CC(C)C)c2sc(N)nc2n1 10.1021/jm3012273
136036521 94924 None 0 Human Binding pKi = 7.8 7.8 11 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 461 6 3 7 2.9 CCC(C)(C)[C@@H](NC1=NS(=O)(=O)N=C1Nc1cccc(C(=O)N(C)C)c1O)c1ccco1 10.1016/j.bmcl.2007.10.094
CHEMBL253922 94924 None 0 Human Binding pKi = 7.8 7.8 11 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 461 6 3 7 2.9 CCC(C)(C)[C@@H](NC1=NS(=O)(=O)N=C1Nc1cccc(C(=O)N(C)C)c1O)c1ccco1 10.1016/j.bmcl.2007.10.094
44447957 95023 None 0 Human Binding pKi = 7.8 7.8 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 455 8 3 7 3.4 COc1cc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)ccc1F 10.1016/j.bmcl.2008.02.010
CHEMBL254571 95023 None 0 Human Binding pKi = 7.8 7.8 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 455 8 3 7 3.4 COc1cc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)ccc1F 10.1016/j.bmcl.2008.02.010
44410839 77094 None 0 Human Binding pKi = 6.8 6.8 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 537 16 2 9 5.0 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc([N+](=O)[O-])cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL207309 77094 None 0 Human Binding pKi = 6.8 6.8 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 537 16 2 9 5.0 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc([N+](=O)[O-])cc3)c2)n1 10.1016/j.bmcl.2006.02.028
9885291 98340 None 0 Human Binding pKi = 6.8 6.8 4 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 361 7 3 8 3.1 CC[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL274737 98340 None 0 Human Binding pKi = 6.8 6.8 4 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 361 7 3 8 3.1 CC[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
71625389 88428 None 0 Human Binding pKi = 5.8 5.8 -33 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 467 8 3 8 4.5 CC(C)C[C@H](CO)Nc1nc(SCc2ccc(Br)cc2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349330 88428 None 0 Human Binding pKi = 5.8 5.8 -33 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 467 8 3 8 4.5 CC(C)C[C@H](CO)Nc1nc(SCc2ccc(Br)cc2)nc2nc(N)sc12 10.1021/jm3012273
136036249 191230 None 0 Human Binding pKi = 6.8 6.8 -4 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 497 6 3 8 5.8 Cc1ccc([C@H](Nc2nsnc2Nc2ccc(C(F)(F)F)c(C(=O)N(C)C)c2O)C(C)(C)C)o1 10.1016/j.bmcl.2009.01.027
CHEMBL518802 191230 None 0 Human Binding pKi = 6.8 6.8 -4 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 497 6 3 8 5.8 Cc1ccc([C@H](Nc2nsnc2Nc2ccc(C(F)(F)F)c(C(=O)N(C)C)c2O)C(C)(C)C)o1 10.1016/j.bmcl.2009.01.027
44410941 76947 None 0 Human Binding pKi = 7.8 7.8 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 576 16 2 8 5.9 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(OC(F)(F)F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL207024 76947 None 0 Human Binding pKi = 7.8 7.8 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 576 16 2 8 5.9 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(OC(F)(F)F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
45272863 198247 None 0 Human Binding pKi = 7.8 7.8 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 469 8 3 6 4.7 CC[C@@H](Nc1c(Nc2ccc(-c3ccccc3)c(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL557877 198247 None 0 Human Binding pKi = 7.8 7.8 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 469 8 3 6 4.7 CC[C@@H](Nc1c(Nc2ccc(-c3ccccc3)c(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
44410937 141415 None 0 Human Binding pKi = 5.8 5.8 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 416 14 2 7 3.4 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2ccnc2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL383487 141415 None 0 Human Binding pKi = 5.8 5.8 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 416 14 2 7 3.4 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2ccnc2)n1 10.1016/j.bmcl.2006.02.028
71625271 88420 None 0 Human Binding pKi = 5.8 5.8 -436 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 467 8 3 8 4.5 CC(C)C[C@H](CO)Nc1nc(SCc2ccccc2Br)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349322 88420 None 0 Human Binding pKi = 5.8 5.8 -436 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 467 8 3 8 4.5 CC(C)C[C@H](CO)Nc1nc(SCc2ccccc2Br)nc2nc(N)sc12 10.1021/jm3012273
58230407 88421 None 1 Human Binding pKi = 5.8 5.8 -34 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 423 8 3 8 4.4 CC(C)C[C@H](CO)Nc1nc(SCc2ccccc2Cl)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349323 88421 None 1 Human Binding pKi = 5.8 5.8 -34 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 423 8 3 8 4.4 CC(C)C[C@H](CO)Nc1nc(SCc2ccccc2Cl)nc2nc(N)sc12 10.1021/jm3012273
10224934 198135 None 0 Human Binding pKi = 7.8 7.8 1 2
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 435 7 4 7 2.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CC[C@H](O)C3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL556656 198135 None 0 Human Binding pKi = 7.8 7.8 1 2
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 435 7 4 7 2.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CC[C@H](O)C3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
45485775 200141 None 0 Human Binding pKi = 6.8 6.8 36 2
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 424 8 3 8 2.3 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(OC)cc1 10.1016/j.bmcl.2009.08.014
CHEMBL571141 200141 None 0 Human Binding pKi = 6.8 6.8 36 2
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 424 8 3 8 2.3 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(OC)cc1 10.1016/j.bmcl.2009.08.014
136036520 94890 None 0 Human Binding pKi = 6.7 6.7 6 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 459 5 3 7 2.6 Cc1ccc([C@H](NC2=NS(=O)(=O)N=C2Nc2cccc(C(=O)N(C)C)c2O)C2(C)CC2)o1 10.1016/j.bmcl.2007.10.094
CHEMBL253702 94890 None 0 Human Binding pKi = 6.7 6.7 6 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 459 5 3 7 2.6 Cc1ccc([C@H](NC2=NS(=O)(=O)N=C2Nc2cccc(C(=O)N(C)C)c2O)C2(C)CC2)o1 10.1016/j.bmcl.2007.10.094
44447953 94991 None 0 Human Binding pKi = 7.7 7.7 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 479 7 3 6 4.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(F)(F)F)c(F)c1 10.1016/j.bmcl.2008.02.010
CHEMBL254368 94991 None 0 Human Binding pKi = 7.7 7.7 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 479 7 3 6 4.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(F)(F)F)c(F)c1 10.1016/j.bmcl.2008.02.010
71625276 88426 None 0 Human Binding pKi = 6.7 6.7 -6 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 467 8 3 8 4.5 CC(C)C[C@H](CO)Nc1nc(SCc2cccc(Br)c2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349328 88426 None 0 Human Binding pKi = 6.7 6.7 -6 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 467 8 3 8 4.5 CC(C)C[C@H](CO)Nc1nc(SCc2cccc(Br)c2)nc2nc(N)sc12 10.1021/jm3012273
71625020 88400 None 0 Human Binding pKi = 5.7 5.7 -234 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 417 8 2 9 4.0 COC(=O)[C@@H](CC(C)C)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349303 88400 None 0 Human Binding pKi = 5.7 5.7 -234 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 417 8 2 9 4.0 COC(=O)[C@@H](CC(C)C)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
58230406 88427 None 0 Human Binding pKi = 5.7 5.7 -21 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 414 8 3 9 3.7 CC(C)C[C@H](CO)Nc1nc(SCc2cccc(C#N)c2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349329 88427 None 0 Human Binding pKi = 5.7 5.7 -21 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 414 8 3 9 3.7 CC(C)C[C@H](CO)Nc1nc(SCc2cccc(C#N)c2)nc2nc(N)sc12 10.1021/jm3012273
42642630 179492 None 0 Human Binding pKi = 8.7 8.7 3 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 423 6 3 7 2.7 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3ccco3)C(F)(F)F)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
CHEMBL473959 179492 None 0 Human Binding pKi = 8.7 8.7 3 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 423 6 3 7 2.7 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3ccco3)C(F)(F)F)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
44564999 193355 None 0 Human Binding pKi = 8.7 8.7 12 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 461 8 3 7 4.0 CC(C)c1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)(F)F)c1 10.1016/j.bmcl.2009.01.033
CHEMBL523769 193355 None 0 Human Binding pKi = 8.7 8.7 12 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 461 8 3 7 4.0 CC(C)c1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)(F)F)c1 10.1016/j.bmcl.2009.01.033
10478354 93527 None 0 Human Binding pKi = 8.7 8.7 16 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 439 10 3 7 3.9 CCCCc1coc([C@@H](CC)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c1 10.1016/j.bmcl.2007.04.016
CHEMBL246106 93527 None 0 Human Binding pKi = 8.7 8.7 16 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 439 10 3 7 3.9 CCCCc1coc([C@@H](CC)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c1 10.1016/j.bmcl.2007.04.016
9978981 93737 None 0 Human Binding pKi = 8.7 8.7 25 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 411 7 3 7 3.3 CC(C)c1coc([C@@H](C)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c1 10.1016/j.bmcl.2007.04.016
CHEMBL246941 93737 None 0 Human Binding pKi = 8.7 8.7 25 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 411 7 3 7 3.3 CC(C)c1coc([C@@H](C)Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c1 10.1016/j.bmcl.2007.04.016
9841667 140836 None 41 Human Binding pKi = 8.7 8.7 1000 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1021/acs.jmedchem.3c00849
CHEMBL38182 140836 None 41 Human Binding pKi = 8.7 8.7 1000 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1021/acs.jmedchem.3c00849
136036532 155482 None 0 Human Binding pKi = 8.6 8.6 9 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 431 6 3 8 4.1 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2N[C@@H](c2ccco2)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
136097489 155482 None 0 Human Binding pKi = 8.6 8.6 9 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 431 6 3 8 4.1 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2N[C@@H](c2ccco2)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
CHEMBL403547 155482 None 0 Human Binding pKi = 8.6 8.6 9 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 431 6 3 8 4.1 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2N[C@@H](c2ccco2)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
135457545 95066 None 0 Human Binding pKi = 8.6 8.6 18 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 445 7 3 8 4.4 Cc1cc([C@H](Nc2n[s+]([O-])nc2Nc2cccc(C(=O)N(C)C)c2O)C(C)C)oc1C 10.1016/j.bmcl.2007.10.094
136036530 95066 None 0 Human Binding pKi = 8.6 8.6 18 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 445 7 3 8 4.4 Cc1cc([C@H](Nc2n[s+]([O-])nc2Nc2cccc(C(=O)N(C)C)c2O)C(C)C)oc1C 10.1016/j.bmcl.2007.10.094
CHEMBL254943 95066 None 0 Human Binding pKi = 8.6 8.6 18 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 445 7 3 8 4.4 Cc1cc([C@H](Nc2n[s+]([O-])nc2Nc2cccc(C(=O)N(C)C)c2O)C(C)C)oc1C 10.1016/j.bmcl.2007.10.094
25022517 94956 None 0 Human Binding pKi = 8.6 8.6 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 425 7 3 6 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)cc(F)c1 10.1016/j.bmcl.2008.02.010
CHEMBL254174 94956 None 0 Human Binding pKi = 8.6 8.6 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 425 7 3 6 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)cc(F)c1 10.1016/j.bmcl.2008.02.010
10230576 197553 None 0 Human Binding pKi = 7.7 7.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 539 8 3 8 3.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCN(C(=O)c4ccccn4)CC3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL550006 197553 None 0 Human Binding pKi = 7.7 7.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 539 8 3 8 3.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCN(C(=O)c4ccccn4)CC3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
10161021 198149 None 0 Human Binding pKi = 7.7 7.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 449 8 4 7 2.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CC[C@H](CO)C3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL556861 198149 None 0 Human Binding pKi = 7.7 7.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 449 8 4 7 2.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CC[C@H](CO)C3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
10112905 198764 None 0 Human Binding pKi = 7.7 7.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 421 7 4 7 2.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CC(O)C3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL562207 198764 None 0 Human Binding pKi = 7.7 7.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 421 7 4 7 2.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CC(O)C3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
44410894 77294 None 0 Human Binding pKi = 6.7 6.7 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 520 13 2 8 4.6 CCOCCCNC(=O)[C@H](CC(C)C)Nc1ccnc(-n2cnc(-c3ccc(OC(F)(F)F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL208016 77294 None 0 Human Binding pKi = 6.7 6.7 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 520 13 2 8 4.6 CCOCCCNC(=O)[C@H](CC(C)C)Nc1ccnc(-n2cnc(-c3ccc(OC(F)(F)F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
45272856 198980 None 0 Human Binding pKi = 6.7 6.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 407 7 3 6 3.3 CC[C@@H](Nc1c(Nc2cc(C)cc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL563612 198980 None 0 Human Binding pKi = 6.7 6.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 407 7 3 6 3.3 CC[C@@H](Nc1c(Nc2cc(C)cc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
136036256 177034 None 0 Human Binding pKi = 5.7 5.7 -128 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 409 7 3 7 4.3 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccccc2)C2CC2)c1O 10.1016/j.bmcl.2009.01.027
CHEMBL462024 177034 None 0 Human Binding pKi = 5.7 5.7 -128 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 409 7 3 7 4.3 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccccc2)C2CC2)c1O 10.1016/j.bmcl.2009.01.027
11858153 88432 None 0 Human Binding pKi = 7.7 7.7 26 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 362 7 3 7 2.9 CC[C@H](CO)Nc1nc(SCc2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
CHEMBL2349334 88432 None 0 Human Binding pKi = 7.7 7.7 26 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 362 7 3 7 2.9 CC[C@H](CO)Nc1nc(SCc2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
11857488 88410 None 4 Human Binding pKi = 6.7 6.7 -26 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 404 8 3 7 4.1 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
CHEMBL2349312 88410 None 4 Human Binding pKi = 6.7 6.7 -26 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 404 8 3 7 4.1 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
11964663 88409 None 0 Human Binding pKi = 5.7 5.7 -117 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 403 8 3 8 4.3 CC(C)C[C@H](CO)Nc1nc(S[C@H](C)c2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349311 88409 None 0 Human Binding pKi = 5.7 5.7 -117 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 403 8 3 8 4.3 CC(C)C[C@H](CO)Nc1nc(S[C@H](C)c2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
45272839 198915 None 0 Human Binding pKi = 6.7 6.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 407 8 4 6 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)NC(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL563129 198915 None 0 Human Binding pKi = 6.7 6.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 407 8 4 6 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)NC(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
45272016 197798 None 0 Human Binding pKi = 7.7 7.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 326 6 3 6 3.2 CC[C@@H](Nc1c(Nc2ccccc2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.bmcl.2009.05.049
CHEMBL551747 197798 None 0 Human Binding pKi = 7.7 7.7 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 326 6 3 6 3.2 CC[C@@H](Nc1c(Nc2ccccc2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.bmcl.2009.05.049
71720196 88386 None 0 Human Binding pKi = 6.7 6.7 -10 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 425 8 3 8 3.9 CCC[C@H](CO)Nc1nc(S[C@@H](C)c2cnccc2Cl)nc2[nH]c(=O)sc12 10.1021/jm3012273
CHEMBL2349181 88386 None 0 Human Binding pKi = 6.7 6.7 -10 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 425 8 3 8 3.9 CCC[C@H](CO)Nc1nc(S[C@@H](C)c2cnccc2Cl)nc2[nH]c(=O)sc12 10.1021/jm3012273
71625272 88422 None 0 Human Binding pKi = 6.7 6.7 -9 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 407 8 3 8 3.9 CC(C)C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349324 88422 None 0 Human Binding pKi = 6.7 6.7 -9 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 407 8 3 8 3.9 CC(C)C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2nc(N)sc12 10.1021/jm3012273
136036238 174489 None 0 Human Binding pKi = 5.6 5.6 -66 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 401 7 3 8 4.2 CC[C@@H](Nc1nsnc1Nc1cccc(C(=O)N(C)C)c1O)c1cc(C)co1 10.1016/j.bmcl.2009.01.027
CHEMBL455209 174489 None 0 Human Binding pKi = 5.6 5.6 -66 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 401 7 3 8 4.2 CC[C@@H](Nc1nsnc1Nc1cccc(C(=O)N(C)C)c1O)c1cc(C)co1 10.1016/j.bmcl.2009.01.027
172455676 196431 None 0 Human Binding pKi = 7.6 7.6 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 634 12 5 9 5.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)OCC3c4ccccc4-c4ccccc43)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5423846 196431 None 0 Human Binding pKi = 7.6 7.6 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 634 12 5 9 5.5 CC[C@@H](Nc1c(Nc2cccc(C(=O)NCCNC(=O)OCC3c4ccccc4-c4ccccc43)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
136036243 190687 None 0 Human Binding pKi = 5.6 5.6 -30 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 465 6 3 8 5.6 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2cc3ccccc3o2)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
CHEMBL518030 190687 None 0 Human Binding pKi = 5.6 5.6 -30 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 465 6 3 8 5.6 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2cc3ccccc3o2)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
136036517 155660 None 0 Human Binding pKi = 7.6 7.6 83 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 515 4 3 8 2.7 CN(C)C(=O)c1cccc(NC2=NS(=O)(=O)N=C2N[C@@H](c2ccc3c(c2)OCCO3)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
CHEMBL404381 155660 None 0 Human Binding pKi = 7.6 7.6 83 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 515 4 3 8 2.7 CN(C)C(=O)c1cccc(NC2=NS(=O)(=O)N=C2N[C@@H](c2ccc3c(c2)OCCO3)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
136036241 189232 None 0 Human Binding pKi = 5.6 5.6 -158 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 415 7 3 8 4.4 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)C)c2O)C(C)C)o1 10.1016/j.bmcl.2009.01.027
CHEMBL510437 189232 None 0 Human Binding pKi = 5.6 5.6 -158 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 415 7 3 8 4.4 Cc1ccc([C@H](Nc2nsnc2Nc2cccc(C(=O)N(C)C)c2O)C(C)C)o1 10.1016/j.bmcl.2009.01.027
71625021 88401 None 0 Human Binding pKi = 5.6 5.6 -10 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 402 8 3 8 3.3 CC(C)C[C@@H](Nc1nc(SCc2ccccc2)nc2nc(N)sc12)C(N)=O 10.1021/jm3012273
CHEMBL2349304 88401 None 0 Human Binding pKi = 5.6 5.6 -10 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 402 8 3 8 3.3 CC(C)C[C@@H](Nc1nc(SCc2ccccc2)nc2nc(N)sc12)C(N)=O 10.1021/jm3012273
11635447 140783 None 0 Human Binding pKi = 7.6 7.6 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 562 15 2 8 5.6 CCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(OC(F)(F)F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL381597 140783 None 0 Human Binding pKi = 7.6 7.6 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 562 15 2 8 5.6 CCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(OC(F)(F)F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
44440860 93440 None 1 Human Binding pKi = 7.6 7.6 15 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 411 8 3 7 3.2 CCc1ccoc1[C@@H](CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2007.04.016
CHEMBL245697 93440 None 1 Human Binding pKi = 7.6 7.6 15 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 411 8 3 7 3.2 CCc1ccoc1[C@@H](CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2007.04.016
10155713 198351 None 0 Human Binding pKi = 7.6 7.6 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 365 7 4 6 2.4 CC[C@@H](Nc1c(Nc2cccc(C(N)=O)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL559031 198351 None 0 Human Binding pKi = 7.6 7.6 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 365 7 4 6 2.4 CC[C@@H](Nc1c(Nc2cccc(C(N)=O)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
71625390 88429 None 0 Human Binding pKi = 6.6 6.6 4 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 414 8 3 9 3.7 CC(C)C[C@H](CO)Nc1nc(SCc2ccc(C#N)cc2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349331 88429 None 0 Human Binding pKi = 6.6 6.6 4 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 414 8 3 9 3.7 CC(C)C[C@H](CO)Nc1nc(SCc2ccc(C#N)cc2)nc2nc(N)sc12 10.1021/jm3012273
45485798 201070 None 0 Human Binding pKi = 6.6 6.6 - 1
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 440 7 3 7 2.1 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(=O)c1ccc(F)cc1 10.1016/j.bmcl.2009.08.014
CHEMBL578807 201070 None 0 Human Binding pKi = 6.6 6.6 - 1
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 440 7 3 7 2.1 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(=O)c1ccc(F)cc1 10.1016/j.bmcl.2009.08.014
71625505 88412 None 0 Human Binding pKi = 5.6 5.6 -204 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 481 8 3 8 5.1 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2Br)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349314 88412 None 0 Human Binding pKi = 5.6 5.6 -204 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 481 8 3 8 5.1 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2Br)nc2nc(N)sc12 10.1021/jm3012273
44410945 77125 None 0 Human Binding pKi = 7.6 7.6 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 526 15 2 7 5.7 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(Cl)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL207497 77125 None 0 Human Binding pKi = 7.6 7.6 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 526 15 2 7 5.7 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(Cl)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
10299249 198842 None 0 Human Binding pKi = 7.6 7.6 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 476 7 3 7 2.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCN(C(C)=O)CC3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL562670 198842 None 0 Human Binding pKi = 7.6 7.6 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 476 7 3 7 2.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCN(C(C)=O)CC3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
44447950 94954 None 0 Human Binding pKi = 7.6 7.6 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 429 7 3 6 3.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(F)c(F)c1 10.1016/j.bmcl.2008.02.010
CHEMBL254172 94954 None 0 Human Binding pKi = 7.6 7.6 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 429 7 3 6 3.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(F)c(F)c1 10.1016/j.bmcl.2008.02.010
10293087 198961 None 0 Human Binding pKi = 7.6 7.6 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 379 7 4 6 2.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)NC)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL563467 198961 None 0 Human Binding pKi = 7.6 7.6 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 379 7 4 6 2.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)NC)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
11965767 88408 None 36 Human Binding pKi = 5.6 5.6 -724 3
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 403 8 3 8 4.3 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349310 88408 None 36 Human Binding pKi = 5.6 5.6 -724 3
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 403 8 3 8 4.3 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
44410901 139827 None 0 Human Binding pKi = 6.5 6.5 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 444 16 2 7 4.2 CCCCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2ccnc2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL379836 139827 None 0 Human Binding pKi = 6.5 6.5 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 444 16 2 7 4.2 CCCCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2ccnc2)n1 10.1016/j.bmcl.2006.02.028
136036528 94836 None 0 Human Binding pKi = 8.5 8.5 77 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 417 7 3 8 3.8 CC[C@@H](Nc1n[s+]([O-])nc1Nc1cccc(C(=O)N(C)C)c1O)c1ccc(C)o1 10.1016/j.bmcl.2007.10.094
136097219 94836 None 0 Human Binding pKi = 8.5 8.5 77 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 417 7 3 8 3.8 CC[C@@H](Nc1n[s+]([O-])nc1Nc1cccc(C(=O)N(C)C)c1O)c1ccc(C)o1 10.1016/j.bmcl.2007.10.094
CHEMBL253306 94836 None 0 Human Binding pKi = 8.5 8.5 77 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 417 7 3 8 3.8 CC[C@@H](Nc1n[s+]([O-])nc1Nc1cccc(C(=O)N(C)C)c1O)c1ccc(C)o1 10.1016/j.bmcl.2007.10.094
10411524 93686 None 0 Human Binding pKi = 8.5 8.5 17 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 451 8 3 7 4.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C2CCCC2)co1 10.1016/j.bmcl.2007.04.016
CHEMBL246731 93686 None 0 Human Binding pKi = 8.5 8.5 17 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 451 8 3 7 4.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C2CCCC2)co1 10.1016/j.bmcl.2007.04.016
10252538 93773 None 0 Human Binding pKi = 8.5 8.5 3 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 437 8 3 7 3.7 CC(C)c1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CC2)c1 10.1016/j.bmcl.2007.04.016
CHEMBL247150 93773 None 0 Human Binding pKi = 8.5 8.5 3 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 437 8 3 7 3.7 CC(C)c1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CC2)c1 10.1016/j.bmcl.2007.04.016
10237959 198468 None 0 Human Binding pKi = 8.5 8.5 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 418 7 3 7 2.9 CC[C@@H](Nc1c(Nc2cc(C#N)cc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL560089 198468 None 0 Human Binding pKi = 8.5 8.5 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 418 7 3 7 2.9 CC[C@@H](Nc1c(Nc2cc(C#N)cc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
9968028 83324 None 0 Human Binding pKi = 8.5 8.5 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 345 7 3 6 2.0 CCC(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1021/acs.jmedchem.3c00849
CHEMBL218964 83324 None 0 Human Binding pKi = 8.5 8.5 - 1
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 345 7 3 6 2.0 CCC(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1021/acs.jmedchem.3c00849
136036236 190801 None 0 Human Binding pKi = 5.5 5.5 -234 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 401 7 3 8 4.2 CC[C@@H](Nc1nsnc1Nc1cccc(C(=O)N(C)C)c1O)c1ccc(C)o1 10.1016/j.bmcl.2009.01.027
CHEMBL518201 190801 None 0 Human Binding pKi = 5.5 5.5 -234 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 401 7 3 8 4.2 CC[C@@H](Nc1nsnc1Nc1cccc(C(=O)N(C)C)c1O)c1ccc(C)o1 10.1016/j.bmcl.2009.01.027
44410909 141439 None 0 Human Binding pKi = 7.5 7.5 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 508 15 3 8 4.7 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(O)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL383633 141439 None 0 Human Binding pKi = 7.5 7.5 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 508 15 3 8 4.7 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(O)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
45485756 200857 None 0 Human Binding pKi = 6.5 6.5 - 1
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 360 6 3 7 0.6 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(C)=O 10.1016/j.bmcl.2009.08.014
CHEMBL576886 200857 None 0 Human Binding pKi = 6.5 6.5 - 1
Displacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation countingDisplacement of [125I]IL-8 from human CXCR2 expressed in mouse BaF3 cells by liquid scintillation counting
ChEMBL 360 6 3 7 0.6 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(C)=O 10.1016/j.bmcl.2009.08.014
135937901 193254 None 0 Human Binding pKi = 6.5 6.5 -6 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 469 6 3 9 4.6 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccc3c(c2)OCO3)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
CHEMBL522959 193254 None 0 Human Binding pKi = 6.5 6.5 -6 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 469 6 3 9 4.6 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccc3c(c2)OCO3)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
45272020 199057 None 0 Human Binding pKi = 7.5 7.5 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 405 8 4 6 3.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)NC3CC3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL564068 199057 None 0 Human Binding pKi = 7.5 7.5 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 405 8 4 6 3.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)NC3CC3)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
71625503 88387 None 0 Human Binding pKi = 6.5 6.5 -19 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 403 9 3 8 3.8 CC(C)C[C@H](CO)Nc1nc(SCCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349182 88387 None 0 Human Binding pKi = 6.5 6.5 -19 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 403 9 3 8 3.8 CC(C)C[C@H](CO)Nc1nc(SCCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
44410911 77189 None 0 Human Binding pKi = 7.5 7.5 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 562 15 2 8 5.6 CCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3cccc(OC(F)(F)F)c3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL207856 77189 None 0 Human Binding pKi = 7.5 7.5 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 562 15 2 8 5.6 CCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3cccc(OC(F)(F)F)c3)c2)n1 10.1016/j.bmcl.2006.02.028
44410946 77127 None 0 Human Binding pKi = 7.4 7.4 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 510 15 2 7 5.2 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL207498 77127 None 0 Human Binding pKi = 7.4 7.4 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 510 15 2 7 5.2 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
71625146 88418 None 0 Human Binding pKi = 6.4 6.4 -1 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 389 6 3 8 3.8 CC(C)(C)[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349320 88418 None 0 Human Binding pKi = 6.4 6.4 -1 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 389 6 3 8 3.8 CC(C)(C)[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
44447958 95024 None 0 Human Binding pKi = 7.4 7.4 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 479 7 3 6 4.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(F)c(C(F)(F)F)c1 10.1016/j.bmcl.2008.02.010
CHEMBL254572 95024 None 0 Human Binding pKi = 7.4 7.4 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 479 7 3 6 4.2 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(F)c(C(F)(F)F)c1 10.1016/j.bmcl.2008.02.010
136036242 189119 None 0 Human Binding pKi = 6.4 6.4 -25 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 415 6 3 8 4.5 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccco2)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
CHEMBL508938 189119 None 0 Human Binding pKi = 6.4 6.4 -25 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 415 6 3 8 4.5 CN(C)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccco2)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
8497 2737 None 41 Human Binding pKi = 8.4 8.4 39 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.bmcl.2009.01.033
9865554 2737 None 41 Human Binding pKi = 8.4 8.4 39 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.bmcl.2009.01.033
CHEMBL216981 2737 None 41 Human Binding pKi = 8.4 8.4 39 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.bmcl.2009.01.033
136036527 94835 None 0 Human Binding pKi = 8.4 8.4 32 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 441 6 3 7 4.6 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2N[C@@H](c2ccccc2)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
136097465 94835 None 0 Human Binding pKi = 8.4 8.4 32 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 441 6 3 7 4.6 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2N[C@@H](c2ccccc2)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
CHEMBL253305 94835 None 0 Human Binding pKi = 8.4 8.4 32 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 441 6 3 7 4.6 CN(C)C(=O)c1cccc(Nc2n[s+]([O-])nc2N[C@@H](c2ccccc2)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
10200589 94993 None 0 Human Binding pKi = 8.4 8.4 9 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.01.033
CHEMBL254370 94993 None 0 Human Binding pKi = 8.4 8.4 9 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.01.033
44564942 189898 None 0 Human Binding pKi = 8.4 8.4 1 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 415 7 3 7 2.8 Cc1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@H](C)F)c1 10.1016/j.bmcl.2009.01.033
CHEMBL516184 189898 None 0 Human Binding pKi = 8.4 8.4 1 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 415 7 3 7 2.8 Cc1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@H](C)F)c1 10.1016/j.bmcl.2009.01.033
44565052 193338 None 0 Human Binding pKi = 8.4 8.4 2 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 487 7 3 7 3.7 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(F)(F)C(F)(F)F)o1 10.1016/j.bmcl.2009.01.033
CHEMBL523645 193338 None 0 Human Binding pKi = 8.4 8.4 2 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 487 7 3 7 3.7 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(F)(F)C(F)(F)F)o1 10.1016/j.bmcl.2009.01.033
10150721 93412 None 0 Human Binding pKi = 8.4 8.4 2 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 397 7 3 7 2.9 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)co1 10.1016/j.bmcl.2007.04.016
CHEMBL245501 93412 None 0 Human Binding pKi = 8.4 8.4 2 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 397 7 3 7 2.9 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)co1 10.1016/j.bmcl.2007.04.016
10027494 93687 None 0 Human Binding pKi = 8.4 8.4 70 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 465 8 3 7 4.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C2CCCCC2)co1 10.1016/j.bmcl.2007.04.016
CHEMBL246733 93687 None 0 Human Binding pKi = 8.4 8.4 70 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 465 8 3 7 4.6 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C2CCCCC2)co1 10.1016/j.bmcl.2007.04.016
10252630 93772 None 0 Human Binding pKi = 8.4 8.4 2 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 439 8 3 7 4.0 CC(C)c1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)c1 10.1016/j.bmcl.2007.04.016
CHEMBL247149 93772 None 0 Human Binding pKi = 8.4 8.4 2 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 439 8 3 7 4.0 CC(C)c1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)c1 10.1016/j.bmcl.2007.04.016
44440873 93812 None 1 Human Binding pKi = 8.4 8.4 3 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 453 7 3 7 4.3 CC(C)c1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)(C)C)c1 10.1016/j.bmcl.2007.04.016
CHEMBL247356 93812 None 1 Human Binding pKi = 8.4 8.4 3 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 453 7 3 7 4.3 CC(C)c1coc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)(C)C)c1 10.1016/j.bmcl.2007.04.016
10343142 149939 None 0 Human Binding pKi = 8.4 8.4 2 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 439 7 3 7 3.9 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C(C)(C)C)co1 10.1016/j.bmcl.2007.04.016
CHEMBL394899 149939 None 0 Human Binding pKi = 8.4 8.4 2 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 439 7 3 7 3.9 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C(C)(C)C)co1 10.1016/j.bmcl.2007.04.016
44249793 198208 None 0 Human Binding pKi = 8.4 8.4 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 471 7 3 6 3.8 CC[C@@H](Nc1c(Nc2ccc(Br)c(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL557466 198208 None 0 Human Binding pKi = 8.4 8.4 - 1
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 471 7 3 6 3.8 CC[C@@H](Nc1c(Nc2ccc(Br)c(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
69440865 88403 None 0 Human Binding pKi = 8.4 8.4 2 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 426 8 3 7 3.8 CC(C)C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1021/jm3012273
CHEMBL2349306 88403 None 0 Human Binding pKi = 8.4 8.4 2 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 426 8 3 7 3.8 CC(C)C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1021/jm3012273
44447965 95077 None 0 Human Binding pKi = 8.4 8.4 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 489 7 3 6 4.6 Cc1cc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)cc(C(F)(F)F)c1 10.1016/j.bmcl.2008.02.010
CHEMBL254982 95077 None 0 Human Binding pKi = 8.4 8.4 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 489 7 3 6 4.6 Cc1cc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(C)C)cc(C(F)(F)F)c1 10.1016/j.bmcl.2008.02.010
10200589 94993 None 0 Human Binding pKi = 8.4 8.4 9 2
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL254370 94993 None 0 Human Binding pKi = 8.4 8.4 9 2
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
44447961 95050 None 0 Human Binding pKi = 8.4 8.4 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 441 7 3 6 3.3 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3cc(F)cc(F)c3)C3CC3)c(=O)c2=O)c1O 10.1016/j.bmcl.2008.02.010
CHEMBL254776 95050 None 0 Human Binding pKi = 8.4 8.4 - 1
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 441 7 3 6 3.3 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3cc(F)cc(F)c3)C3CC3)c(=O)c2=O)c1O 10.1016/j.bmcl.2008.02.010
44249825 198856 None 0 Human Binding pKi = 8.4 8.4 85 2
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 407 7 3 6 3.3 CC[C@@H](Nc1c(Nc2c(C)ccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
CHEMBL562781 198856 None 0 Human Binding pKi = 8.4 8.4 85 2
Displacement of human [125I]IL-8 from human CXCR2Displacement of human [125I]IL-8 from human CXCR2
ChEMBL 407 7 3 6 3.3 CC[C@@H](Nc1c(Nc2c(C)ccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2009.05.049
135405057 94861 None 0 Human Binding pKi = 8.3 8.3 9 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 501 4 3 8 2.7 CN(C)C(=O)c1cccc(NC2=NS(=O)(=O)N=C2N[C@@H](c2ccc3c(c2)OCO3)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
CHEMBL253495 94861 None 0 Human Binding pKi = 8.3 8.3 9 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 501 4 3 8 2.7 CN(C)C(=O)c1cccc(NC2=NS(=O)(=O)N=C2N[C@@H](c2ccc3c(c2)OCO3)C(C)(C)C)c1O 10.1016/j.bmcl.2007.10.094
10200589 94993 None 0 Human Binding pKi = 8.3 8.3 9 2
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2008.02.010
CHEMBL254370 94993 None 0 Human Binding pKi = 8.3 8.3 9 2
Displacement of [125I]IL8 from human CXCR2 by SPA assayDisplacement of [125I]IL8 from human CXCR2 by SPA assay
ChEMBL 393 7 3 6 3.0 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1016/j.bmcl.2008.02.010
11858154 155430 None 19 Human Binding pKi = 8.3 8.3 2691 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 400 6 3 7 3.3 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2[nH]c(=O)sc12 10.1021/acs.jmedchem.3c00849
CHEMBL403225 155430 None 19 Human Binding pKi = 8.3 8.3 2691 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 400 6 3 7 3.3 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2[nH]c(=O)sc12 10.1021/acs.jmedchem.3c00849
58735884 196446 None 0 Human Binding pKi = 8.3 8.3 524 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 397 7 3 7 2.9 CC[C@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
CHEMBL5424054 196446 None 0 Human Binding pKi = 8.3 8.3 524 2
Binding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assayBinding affinity to NanoLuc fused Snap CXCR2 (unknown origin) expressed in HEK293 cell membrane assessed as inhibition constant using furimazine as substrate incubated with substrate for 5 mins and measured every 15 secs for 60 mins by luminescence based NanoBRET fluorescent binding assay
ChEMBL 397 7 3 7 2.9 CC[C@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1021/acs.jmedchem.3c00849
44410842 140795 None 0 Human Binding pKi = 7.4 7.4 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 506 15 2 7 5.4 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(C)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL381705 140795 None 0 Human Binding pKi = 7.4 7.4 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 506 15 2 7 5.4 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(C)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
44564940 179445 None 0 Human Binding pKi = 6.4 6.4 - 1
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 451 8 3 7 3.5 CN(C)C(=O)c1cccc(Nc2c(N[C@H](CCC(F)(F)F)c3ccco3)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
CHEMBL473561 179445 None 0 Human Binding pKi = 6.4 6.4 - 1
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 451 8 3 7 3.5 CN(C)C(=O)c1cccc(Nc2c(N[C@H](CCC(F)(F)F)c3ccco3)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
136036255 177016 None 0 Human Binding pKi = 5.4 5.4 -204 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 433 7 3 7 4.5 CC[C@@H](Nc1nsnc1Nc1cccc(C(=O)N(C)C)c1O)c1cc(F)cc(F)c1 10.1016/j.bmcl.2009.01.027
CHEMBL461816 177016 None 0 Human Binding pKi = 5.4 5.4 -204 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 433 7 3 7 4.5 CC[C@@H](Nc1nsnc1Nc1cccc(C(=O)N(C)C)c1O)c1cc(F)cc(F)c1 10.1016/j.bmcl.2009.01.027
71625274 88424 None 0 Human Binding pKi = 5.4 5.4 -33 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 414 8 3 9 3.7 CC(C)C[C@H](CO)Nc1nc(SCc2ccccc2C#N)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349326 88424 None 0 Human Binding pKi = 5.4 5.4 -33 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 414 8 3 9 3.7 CC(C)C[C@H](CO)Nc1nc(SCc2ccccc2C#N)nc2nc(N)sc12 10.1021/jm3012273
44410903 77166 None 0 Human Binding pKi = 7.4 7.4 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 522 16 2 8 5.1 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(OC)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL207742 77166 None 0 Human Binding pKi = 7.4 7.4 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 522 16 2 8 5.1 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(OC)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
71625019 88399 None 0 Human Binding pKi = 5.4 5.4 -97 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 451 8 2 9 4.6 COC(=O)[C@@H](CC(C)C)Nc1nc(SCc2ccccc2Cl)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL2349302 88399 None 0 Human Binding pKi = 5.4 5.4 -97 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 451 8 2 9 4.6 COC(=O)[C@@H](CC(C)C)Nc1nc(SCc2ccccc2Cl)nc2nc(N)sc12 10.1021/jm3012273
3117 210300 None 60 Human Binding pKi = 5.4 5.4 -4 16
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)
ChEMBL 296 4 0 4 3.6 CCN(CC)C(=S)SSC(=S)N(CC)CC nan
CHEMBL964 210300 None 60 Human Binding pKi = 5.4 5.4 -4 16
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)
ChEMBL 296 4 0 4 3.6 CCN(CC)C(=S)SSC(=S)N(CC)CC nan
44410837 77101 None 0 Human Binding pKi = 7.4 7.4 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 517 15 2 8 4.9 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(C#N)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL207376 77101 None 0 Human Binding pKi = 7.4 7.4 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 517 15 2 8 4.9 CCCCc1cc(N[C@@H](CC(C)C)C(=O)NCCCOCC)nc(-n2cnc(-c3ccc(C#N)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
136036254 190301 None 0 Human Binding pKi = 5.4 5.4 -117 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 437 6 3 7 4.4 CN(C)C(=O)c1cccc(Nc2nsnc2NC(c2ccccc2)C(F)(F)F)c1O 10.1016/j.bmcl.2009.01.027
CHEMBL517430 190301 None 0 Human Binding pKi = 5.4 5.4 -117 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 437 6 3 7 4.4 CN(C)C(=O)c1cccc(Nc2nsnc2NC(c2ccccc2)C(F)(F)F)c1O 10.1016/j.bmcl.2009.01.027
11656697 140411 None 0 Human Binding pKi = 7.4 7.4 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 534 13 2 8 4.9 CCOCCCNC(=O)[C@H](CC(C)C)Nc1cc(C)nc(-n2cnc(-c3ccc(OC(F)(F)F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
CHEMBL380644 140411 None 0 Human Binding pKi = 7.4 7.4 - 1
Binding affinity to human CXCR2 receptor transfected in CHO cellBinding affinity to human CXCR2 receptor transfected in CHO cell
ChEMBL 534 13 2 8 4.9 CCOCCCNC(=O)[C@H](CC(C)C)Nc1cc(C)nc(-n2cnc(-c3ccc(OC(F)(F)F)cc3)c2)n1 10.1016/j.bmcl.2006.02.028
136036252 177064 None 0 Human Binding pKi = 7.4 7.4 -3 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 454 8 3 9 4.8 CN(CCC#N)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccco2)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
CHEMBL462331 177064 None 0 Human Binding pKi = 7.4 7.4 -3 2
Displacement of IL8 from CXCR2 receptorDisplacement of IL8 from CXCR2 receptor
ChEMBL 454 8 3 9 4.8 CN(CCC#N)C(=O)c1cccc(Nc2nsnc2N[C@@H](c2ccco2)C(C)(C)C)c1O 10.1016/j.bmcl.2009.01.027
CHEMBL5088269 217638 None 5 Human Binding pKi = 6.4 6.4 - 1
Displacement of [I-125]-interleukin-8 against human recombinant CXCR2 expressed in CHO-K1 cells incubated for 60 mins by radio ligand binding assayDisplacement of [I-125]-interleukin-8 against human recombinant CXCR2 expressed in CHO-K1 cells incubated for 60 mins by radio ligand binding assay
ChEMBL None None None Cc1c(F)cccc1NC(=O)Nc1ccc2c(c1O)S(=O)(=O)CC=C2 10.1021/acs.jmedchem.1c01219
69442228 88390 None 0 Human Binding pKi = 6.3 6.3 -1 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 406 8 3 7 2.5 CC(C)C[C@H](CO)Nc1nc([S+]([O-])Cc2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
CHEMBL2349185 88390 None 0 Human Binding pKi = 6.3 6.3 -1 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 406 8 3 7 2.5 CC(C)C[C@H](CO)Nc1nc([S+]([O-])Cc2ccccc2)nc2[nH]c(=O)sc12 10.1021/jm3012273
71718998 88385 None 0 Human Binding pKi = 6.3 6.3 -85 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 439 8 3 8 4.1 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2cc(Cl)ccn2)nc2[nH]c(=O)sc12 10.1021/jm3012273
CHEMBL2349180 88385 None 0 Human Binding pKi = 6.3 6.3 -85 2
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 439 8 3 8 4.1 CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2cc(Cl)ccn2)nc2[nH]c(=O)sc12 10.1021/jm3012273
135814569 94834 None 0 Human Binding pKi = 8.3 8.3 245 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 413 7 3 7 3.9 CC[C@@H](Nc1n[s+]([O-])nc1Nc1cccc(C(=O)N(C)C)c1O)c1ccccc1 10.1016/j.bmcl.2007.10.094
136036525 94834 None 0 Human Binding pKi = 8.3 8.3 245 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 413 7 3 7 3.9 CC[C@@H](Nc1n[s+]([O-])nc1Nc1cccc(C(=O)N(C)C)c1O)c1ccccc1 10.1016/j.bmcl.2007.10.094
CHEMBL253304 94834 None 0 Human Binding pKi = 8.3 8.3 245 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 413 7 3 7 3.9 CC[C@@H](Nc1n[s+]([O-])nc1Nc1cccc(C(=O)N(C)C)c1O)c1ccccc1 10.1016/j.bmcl.2007.10.094
135537605 155428 None 0 Human Binding pKi = 8.3 8.3 7 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 445 6 3 8 4.5 Cc1ccc([C@H](Nc2n[s+]([O-])nc2Nc2cccc(C(=O)N(C)C)c2O)C(C)(C)C)o1 10.1016/j.bmcl.2007.10.094
136036533 155428 None 0 Human Binding pKi = 8.3 8.3 7 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 445 6 3 8 4.5 Cc1ccc([C@H](Nc2n[s+]([O-])nc2Nc2cccc(C(=O)N(C)C)c2O)C(C)(C)C)o1 10.1016/j.bmcl.2007.10.094
CHEMBL403206 155428 None 0 Human Binding pKi = 8.3 8.3 7 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 445 6 3 8 4.5 Cc1ccc([C@H](Nc2n[s+]([O-])nc2Nc2cccc(C(=O)N(C)C)c2O)C(C)(C)C)o1 10.1016/j.bmcl.2007.10.094
44564898 179392 None 0 Human Binding pKi = 8.3 8.3 19 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 437 7 3 7 3.1 CN(C)C(=O)c1cccc(Nc2c(N[C@H](CC(F)(F)F)c3ccco3)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
CHEMBL473145 179392 None 0 Human Binding pKi = 8.3 8.3 19 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 437 7 3 7 3.1 CN(C)C(=O)c1cccc(Nc2c(N[C@H](CC(F)(F)F)c3ccco3)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
44565100 187163 None 0 Human Binding pKi = 8.3 8.3 3 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 457 6 3 7 3.4 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3cc(Cl)co3)C(F)(F)F)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
CHEMBL491135 187163 None 0 Human Binding pKi = 8.3 8.3 3 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 457 6 3 7 3.4 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3cc(Cl)co3)C(F)(F)F)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
10238257 189782 None 0 Human Binding pKi = 8.3 8.3 1 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 437 6 3 7 3.1 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(F)(F)F)o1 10.1016/j.bmcl.2009.01.033
CHEMBL515262 189782 None 0 Human Binding pKi = 8.3 8.3 1 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 437 6 3 7 3.1 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C(F)(F)F)o1 10.1016/j.bmcl.2009.01.033
44157035 191262 None 0 Human Binding pKi = 8.3 8.3 1 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 477 6 3 8 2.9 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3ccc4c(c3)OCO4)C(F)(F)F)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
CHEMBL518857 191262 None 0 Human Binding pKi = 8.3 8.3 1 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 477 6 3 8 2.9 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3ccc4c(c3)OCO4)C(F)(F)F)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
44565049 193316 None 0 Human Binding pKi = 8.3 8.3 4 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 447 8 3 7 3.5 CCC(F)(F)[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.bmcl.2009.01.033
CHEMBL523437 193316 None 0 Human Binding pKi = 8.3 8.3 4 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 447 8 3 7 3.5 CCC(F)(F)[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.bmcl.2009.01.033
44565099 193362 None 0 Human Binding pKi = 8.3 8.3 20 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 491 6 3 7 4.0 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3cc(Cl)c(Cl)o3)C(F)(F)F)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
CHEMBL523807 193362 None 0 Human Binding pKi = 8.3 8.3 20 2
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 491 6 3 7 4.0 CN(C)C(=O)c1cccc(Nc2c(N[C@@H](c3cc(Cl)c(Cl)o3)C(F)(F)F)c(=O)c2=O)c1O 10.1016/j.bmcl.2009.01.033
8497 2737 None 41 Human Binding pKi = 8.3 8.3 39 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.bmcl.2007.04.016
9865554 2737 None 41 Human Binding pKi = 8.3 8.3 39 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.bmcl.2007.04.016
CHEMBL216981 2737 None 41 Human Binding pKi = 8.3 8.3 39 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1016/j.bmcl.2007.04.016
44440858 148663 None 0 Human Binding pKi = 8.3 8.3 4 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 413 7 3 7 3.4 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)cs1 10.1016/j.bmcl.2007.04.016
CHEMBL393900 148663 None 0 Human Binding pKi = 8.3 8.3 4 2
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL